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Abstract 
 
The clinical success of assisted reproductive technology (ART) is measured by the 
clinical pregnancies (implantation success) and the live births rates. 
Following ART live birth rates vary from 20-40% and are dependent upon a 
variety of factors.  Various adjunct therapies are being used with ART to improve 
implantation and pregnancy outcomes. The effectiveness of these adjuvant 
therapies remains unclear and requires further evaluation. One group of medical 
adjuvant therapies widely used in clinical practice are thromboprophylactic 
agents, including heparin. Heparin can potentially modulate many of the 
mechanisms of implantation including successful apposition, adhesion and 
penetration of the developing embryo into the endometrium. This is 
independent of its anticoagulant function for which it is used routinely in clinical 
practice.   
Following completion of a literature review, it became evident that heparin could 
potentially improve decidualisation and implantation.  It improves function of 
various growth factors and cytokines in the endometrium promoting and 
facilitating implantation in laboratory models.  From this initial research, we 
postulated that heparin used as adjunct to ART should improve the clinical 
pregnancy and the live birth rates via these mechanisms described.   Bleeding is a 
known side effect of systemic heparin due to its effect on the coagulation 
cascade.   
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A systematic review and meta-analysis protocol was devised and peer-reviewed 
to assess the published data.  The aim of this was to establish whether using the 
currently available evidence, peri-implantation heparin improves pregnancy 
outcomes in women undergoing ART. A secondary aim was to determine if there 
were any significant side effects. The meta-analysis was performed in accordance 
with the protocol.   This demonstrated that peri-implantation systematic heparin 
does improve clinical pregnancy rates and live birth rates in these women.  
Nevertheless, there were only three randomised control trials (RCTs) included in 
the review that met the inclusion criteria and there was significant heterogeneity 
amongst the participants in the included studies. Systemic side effects of heparin 
including bleeding and bruising were also identified in this review.   
As the proposed mechanism of improving implantation by heparin is 
improvement of endometrial cytokines and growth factors. It was hypothesised 
that direct endometrial administration of heparin should improve decidualisation 
thus improving implantation.  To confirm or refute this hypothesis, initially a 
phase 1 study is required to be undertaken for direct endometrial administration 
of heparin as currently it is only licenced as a systemic injectable formulation. 
We developed a protocol to assess the feasibility of intrauterine flushing for 
direct endometrial administration of low molecular weight heparin (LMWH) with 
a prospective randomised placebo controlled pilot study. This novel study was 
approved by National Research Ethics Service (NRES), Medicine & Healthcare 
products Regulatory Authority (MHRA), UK. Sponsorship was obtained from the 
12 
 
University of Warwick and local Research & Development (R&D) approval was 
obtained.  The study was undertaken at University Hospitals Coventry and 
Warwickshire NHS Trust (UHCW).  It demonstrated the acceptability of 
intrauterine flushing of heparin to women. The concept of the trial was popular 
with patients making recruitment unproblematic.  Minimal side effects were 
reported, no serious adverse events occurred. Most women recruited underwent 
ART following the study, with many achieving a clinical pregnancy and live birth.   
Our hypothesis for primary outcome measure, uterine natural killer (uNK) cell 
density, as a marker of decidualisation was refuted.  
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1.0 Introduction: 
 
There were 698,512 births in England and Wales in 2013 providing joy to 
thousands of parents (Office for National Statistics, 2013).  Many couples are not 
so fortunate, one in seven couples experience subfertility (NICE, 2013).  Despite 
this, a large number of couples still fail to conceive following ART even with the 
transfer of good quality embryos (Polanski et al., 2014).   
ART has revolutionised the treatment of subfertility in last three decades. ART 
including in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) are 
now employed widely in significant numbers to help some subfertile couples to 
achieve a pregnancy. 45,264 women had IVF treatment in 2010 and there were 
12,714 babies born in 2009 as a result of IVF treatment (HEFA, 2010). 
ART has significant physical, social, psychological and financial implications. Its 
success is determined by a clinical pregnancy and the live birth of a child. Live 
birth rates with ART vary from 20% to 40%.  Thus, at present, more than 50% of 
women having ART will not achieve a successful implantation leading to 
pregnancy. These women are devastated by this outcome. 
Whilst significant improvements have been made in the preparation of embryos 
(with blastocyst culture and selection of embryos with time lapse microscopy), 
little progress has been made in improving the endometrial environment.   A 
successful pregnancy is dependent upon a favourable endometrial environment. 
Decidualisation is the process in which the endometrium prepares itself for an 
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implanting embryo. Failure of adequate decidualisation can lead to an abnormal 
maternal response to embryonic signals resulting in implantation failure and 
defective placentation (Salker et al., 2010, Teklenburg et al., 2010). 
Various medical adjuncts are used in conjunction with ART to improve the 
endometrial environment, implantation and therefore its overall success.  Some 
of the widely used medical adjuncts to improve the success of ART include low 
dose aspirin and heparin (particularly LMWH).  
In this chapter, I will summarise the current literature about the physiology of 
the menstrual cycle, the decidualisation process (before the presence of embryo 
to prepare for pregnancy and after the presence of embryo so to help in 
implantation), infertility and its management with ART, and heparin as a medical 
adjunct during ART. This chapter will conclude with a discussion about the gaps 
in the literature and provide an outline of my aims for this thesis. 
 
1.1 Menstrual Cycle: 
 
The menstrual cycle occurs as a consequence of the physiological changes in 
endometrium in women of reproductive age. The endometrium is under the 
influence of endocrine hormones (hypothalamic pituitary ovarian axis) and these 
changes transpire for the purposes of reproduction.  It is divided into two phases, 
the proliferative phase and the luteal phase. The proliferative phase starts from 
23 
 
first day of menstruation and ends with ovulation. Secretion of gonadotrophin 
releasing hormone (GnRH) from the hypothalamus acts upon anterior pituitary 
resulting in the release of follicle stimulating hormone (FSH).  FSH acts on the 
granulosa cells in the developing follicles within the ovaries leading to oestrogen 
secretion. This oestrogen causes endometrial proliferation. Ovulation is triggered 
following a surge in the release of luteinising hormone (LH) from the anterior 
pituitary which occurs as a consequence of high oestrogen levels. This happens 
once a dominant follicle is formed within the ovary.  
After ovulation, the dominant follicle on the ovary forms the corpus luteum 
which produces progesterone. The luteal phase starts after ovulation and ends 
with the start of menstruation. Progesterone from corpus luteum causes 
secretory changes within the endometrium in preparation for the possible 
implantation of an embryo. When implantation of an embryo does not occur, the 
corpus luteum involutes with a decline in circulating oestrogen and 
progesterone, leading to menstruation. The menstrual cycle is illustrated in 
Figure 1.1.  
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Figure 1.1: Human Female Menstrual Cycle (Aitken et al., 2008) 
 
1.1.1 Decidualisation (prior to embryo presence): 
 
Decidualisation is a post-ovulatory process within the endometrium under the 
influence of progesterone (Kuroda et al., 2013). During decidualisation, the 
endometrial stromal cells (ESCs) transform in preparation for an implanting 
embryo. This process involves glycogen accumulation in the ESC cytoplasm, the 
influx of leucocytes including uNK cells, and spiral artery angiogenesis.  
Consequently, this promotes an increase in stromal vascularity and oedema 
within the endometrium (Vontver, 2008). It involves endometrial stromal 
fibroblasts becoming specialised secretory decidual cells (Kuroda et al., 2013).  
The purpose of the process is to enable decidualising ESCs to regulate 
25 
 
trophoblast invasion and to resist both oxidative and inflammatory stresses. It is 
pivotal for successful implantation.   
Unlike many animal species, in humans, decidualisation begins in the mid-luteal 
phase of the menstrual cycle regardless of the presence of an implanting embryo 
(Gellersen, Brosens & Brosens, 2007, Salamonsen et al., 2003). A successful 
interaction between the implanting embryo and the endometrium can only take 
place in mid luteal phase described as the window of implantation (Gellersen, 
Brosens & Brosens, 2007). 
In the endometrium, progesterone acts with cyclic AMP (cAMP) regulated 
pathways causing decidualisation (Brosens, Hayashi & White, 1999, Brosens, 
Pijenborg & Brosens, 2002).  Various factors within the endometrium including 
metalloproteinases, cytokines and surface integrins are up and down regulated.  
ESCs become circular, showing structural similarities with epithelial cells and 
myofibroblasts (Oliver et al., 1999). They produce growth factors to aid 
decidualisation including prolactin (PRL), relaxin and insulin-like growth factor 
binding protein-1 (IGFBP-1) (Salamonsen et al., 2003, (Brosens, Hayashi & White, 
1999, Brosens, Pijenborg & Brosens, 2002, King, 2000).  In vitro studies have 
revealed that the decidualisation is associated with a change in sex steroid 
hormone receptor expression and the expression of growth factors, cytokines 
and chemokines. Remodelling of the extracellular matrix with induction of 
apoptosis modulators and transcription factors is also reported (Cooper et al., 
2001).  
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In the endometrium, various leukocytes are present. The most common 
leucocytes are uNK cells, macrophages and T cells. Uterine NK cells play an 
important role in embryo implantation as evidenced by their increase in number 
just after ovulation. Uterine NK cells are different to peripheral blood NK cells, 
both morphologically and functionally. Uterine NK cells have no cytolytic activity 
unlike peripheral blood NK cells (Cooper et al., 2001).  Human peripheral blood 
NK cells express various surface markers including CD16 and CD56.  In contrast, 
uNK express CD56 but not CD16 (Poli et al., 2009).  It has been reported that uNK 
cells are important in early pregnancy, as their numbers increase from  ovulation 
until the mid-luteal phase  and in early pregnancy but decrease in the second 
trimester and become non-existent in the decidua at delivery (Poli et al., 2009). 
Appropriate uNK cell recruitment depends upon presence of hormones including 
glucocorticoid and progesterone, but not on an implanting embryo (Ordi et al., 
2006). Glucorticoid steroid hormones decrease the number of uNK cells within 
the endometrium (Quenby & Farquharson, 2006). Maternal uNK cells directly 
interact with fetal trophoblast and this interaction is thought to influence 
migration and invasion of trophoblast thereby, regulating implantation (King, 
2000, Parham, 2004). 
In conclusion, decidualisation consists of many complex dynamic processes 
involving interactions among growth factors, cytokines and hormones in the 
endometrium and other many processes which are still not fully understood. The 
process of decidualisation continues under the influence of factors secreted by 
the embryo and endometrium.   
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1.1.2 Decidualisation (post embryo presence): 
 
Human embryo implantation involves the apposition of the embryo to the 
endometrium, adhesion, subsequent breaching of the luminal epithelium and 
finally invasion into endometrium (Quenby & Brosens, 2013).  Apposition is the 
initial contact between an embryo and the endometrium.  Adhesion involves a 
series of interactions between the embryo and the decidualised endometrium 
via chemokine and cytokine signalling which facilitate invasion and penetration 
of the embryo into the endometrium.  This is illustrated in Figure 1.2. 
 
 
Figure 1.2: Summary of various growth factors, cytokines, and hormones involved in 
implantation process (Singh, Chaudhry & Asselin, 2011). 
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With the exception of the mid-luteal phase of the menstrual cycle, the apical 
surface of the endometrial epithelium is covered by a thick glycocalyx composed 
of mucin.  Mucin is a transmembrane glycoprotein which prevents embryo 
attachment to the endometrium (Tathiah et al., 2004). Desmosomes are present 
on the lateral surface of the luminal epithelium with mucin the apical surface in a 
pre-receptive endometrium (Aplin & Kimber, 2004). The human embryo can 
attach to a receptive endometrium as the embryo induces cleavage of this mucin 
at the specific site where implantation will occur (Meseguer et al., 2001).   
Adhesion molecules which include selectins, cadherins and integrins are present 
on the endometrial epithelium and trophoblast. These adhesions molecules play 
a vital role in facilitating embryo attachment to the endometrial lining.  E-
cadherin expression is up-regulated by oestradiol in the proliferative phase of 
menstrual cycle (Wada-Hiraike et al., 2006) and down regulated by progesterone 
in the luteal phase of menstrual cycle facilitating trophoblast invasion resulting in 
successful implantation (Jha et al, 2006).  This adhesion interaction is 
strengthened further by the bridging ligands osteopontin and galectin-15. 
Endometrial glands produce these bridging ligands (Spencer et al., 2004). 
Invasion of endometrial stroma is further facilitated by reduction in desmosome 
density (Aplin & Kimber, 2004).  
An important growth factor involved in implantation is heparin-binding 
epidermal growth factor (HB-EGF). It is produced by leucocytes and chemotactic 
in nature (Iwamoto & Mekada, 2000). HB-EGF is vital to reduce apoptosis in ESCs 
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which is caused by transforming growth factor (TGF)-β or tumour necrosis factor 
(TNF)-α (Chobotova et al., 2005). HB-EGF expression within the endometrium is 
enhanced by sex steroid hormones particularly in the luteal phase of the 
endometrial cycle and continues to increase in early pregnancy (Leach et al., 
2004). Pinopodes are epithelial cellular protrusions on the endometrium where 
attachment of embryo takes place. HB-EGF is present on the surface of these 
pinopodes (Stavreus-Evers et al., 2002) suggesting the importance of role of HB-
EGF in embryo implantation. 
Insulin-like growth factors (IGF) type I and II are important for successful 
implantation (Fowden, 2003). In vitro studies found that IGF-I helps in the 
migration of the trophoblast aiding in implantation (Lacey et al., 2002). Increased 
expression of IGF-II is associated with trophoblastic invasion into the decidua 
(Hamilton et al., 1998). 
Transforming growth factors (TGF types β1-3) are present both in the 
endometrial and trophoblast cells. They are responsible for inhibition of 
proliferation and invasion of trophoblast leading to successful implantation 
(Lash et al., 2005).  
Cytokines, in particular interleukins (IL) I and II act as immune regulators and 
growth factors. They play a positive role in decidualisation (Dimitriadis et al., 
2005), trophoblast invasion (von Rango et al., 2004) leading to successful 
implantation (Dimitriadis et al., 2006). IL-I binding can lead to STAT-3 activation 
which is a transcription factor involved in trophoblast invasion (Corvinus et al., 
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2003; Poehlmann et al., 2005). Lower levels of IL-II were found in endometrium 
of infertile women when compared with fertile women (Dimitriadis et al., 2006). 
Similarly, low levels of IL-II levels were found in the glands of non-viable tubal 
pregnancies compared with viable tubal and intrauterine pregnancies (von 
Rango et al., 2004). Another member of IL-6 family required for successful 
implantation is leukemia inhibitory factor (LIF) (Kimber, 2005). 
Chemokines induce an inflammatory state in the endometrium by promoting 
leukocyte migration into the endometrium.  This is manifested by an interaction 
between non-polymorphic HLA class I antigens with uNK cells (Pijnenborg, 2002). 
Prostaglandins (PGs) promote cytokine production resulting in an improvement 
in vascular permeability, which is necessary for invasion and implantation.  
Chemokines interacting with G protein-coupled receptors in the endometrium 
cause a structural change in integrins, promoting implantation (Bokoch, 1995).  
This is illustrated in Figure 1.3.  
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Figure 1.3: Human embryo adhesion interactions (Aplin & Kimber, 2004-published by 
BioMed Central) 
 
Therefore embryo apposition, adhesion and invasion facilitating implantation is 
dependent upon ovarian steroid hormone, endometrial cell proliferation with 
glandular secretion, modulation of endometrial blood flow,  interaction of 
chemokines, cytokines and growth factors within the endometrium.   
Historically, implantation has been viewed as a passive process with regards to 
the endometrium requiring only receptivity and then an invading embryo. This 
required only an invading fetal trophoblast. However, more recent evidence 
indicates that human embryo implantation is more dynamically controlled by the 
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endometrium than was previously understood. The process involves the mutual 
attraction and interaction of maternal ESCs and the fetal trophoblast resulting in 
expansion of the trophoblast and ESC migration. This is a two way 
communication between the endometrium and the embryo dependent upon 
interactions between human ESCs and some of the growth factors discussed 
previously including HB-EGF, IGF and IL1 (Quenby & Brosens,  2013).  This is 
shown in Figure 1.4. 
  
 
 
Figure 1.4:  Models to explain human embryo implantation (Quenby & Brosens, 2013) 
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1.2 Subfertility: 
 
In the UK, subfertility is defined as failure to conceive after regular unprotected 
sexual intercourse for one year in the absence of known reproductive pathology 
(NICE, 2013).  It effects 15% of couples worldwide (Collins & Van Steirteghem, 
2004) and can be due to female and/or male factors, or it can be unexplained.  
Female causes of subfertility can be categorised as ovulation disorders 
(premature menopause, polycystic ovarian syndrome), hormonal disturbances 
(hypothalamic pituitary failure), genetic factors, tubal disorders (pelvic 
inflammatory disease), uterine disorders (adhesions, fibroids) and peritoneal 
disorders (endometriosis, previous pelvic surgery). Male causes of subfertility 
include defective sperm production, abnormal morphology and/or poor motility. 
These abnormalities can be genetic or acquired. In some couples no cause can be 
identified and this is categorised as unexplained subfertility. 
Management options are offered to couples depending upon the cause of their 
subfertility. Options include treatment with medications (clomiphene, aromatase 
inhibitors and gonadotrophins), surgical treatments (laparoscopy or 
hysteroscopy, surgical sperm retrieval) and ART (NICE, 2013).  
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1.2.1 Thrombophilia and Subfertility: 
 
Thrombophilias are associated with adverse pregnancy outcomes. It is thought 
that thrombophilias may also contribute to subfertility and recurrent 
implantation failure. This is because there is a higher prevalence of hereditary 
thrombophilias in women with recurrent implantation failure after ART 
(Grandone et al., 2001, Azem et al., 2004, Coulam et al., 2006).  
The presence of acquired thrombophilias is reported to be 5-10 times higher in 
infertile women (Gleicher et al., 1994, Sher et al., 1994, Fisch et al., 1995, Nip et 
al., 1995, Birdsall et al., 1996, Denis et al., 1997, Kowalik et al., 1997, Kutteh et 
al., 1997) when compared with the general obstetric population (Lockwood et 
al., 1989). Despite the higher prevalence of thrombophilias in the ART 
population, they were not associated with poor pregnancy outcomes after ART 
as reported in meta-analyses (Hornstein, 2000, Hornstein et al., 2000) and 
several reviews (Buckingham et al., 2006, Caccavo et al., 2007, Lee et al., 2007). 
 
1.3 Assisted Reproduction Technology (ART): 
 
ART involves all treatments or procedures or procedures requiring the in-vitro 
handling of human oocytes, sperm or embryos for the purpose of achieving a 
pregnancy as defined by World Health Organisation (WHO). ART includes IVF/ICSI 
but not intrauterine insemination (IUI) (Zegers-Hochschild et al., 2009).  
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ART has provided an effective treatment for some infertile couples (Collins & Van 
Steirteghem, 2004). 50% of infertile couples require ART as their management 
option for infertility.  2-3% of all births in Europe are as a result of ART treatment 
and around 5 million babies have been born from ART since July 1978 (Kupka et 
al., 2014).  Choosing the most appropriate infertility management option is 
linked to the underlying cause and decision of individual couple. Couples make 
ethical considerations according to their social, cultural and religious belief (egg 
or sperm donation, surrogacy) before deciding about the treatment (Kamel, 
2010).   
 
1.3.1 Complications of ART: 
 
Despite the benefits of ART, there are many reported complications experienced 
by women who have undergone ART in comparison to those who conceive 
spontaneously (Allen, Wilson & Cheung, 2006).  
During ART there is a risk of ovarian hyperstimulation syndrome (OHSS) which 
can be a life threatening condition. It is caused by the release of oestradiol in 
response to ovarian hyperstimulation and compounded by human chorionic 
gonadotrophin (hCG) which is given to trigger ovulation. The hCG causes an 
increase in vascular endothelial growth factor (VEGF) leading to an increase in 
vascular permeability (Agrawal et al., 1999).   This then can lead to extravasation 
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of the intravascular fluid resulting in ascites, pleural effusions, abnormal liver 
function and renal failure.  
Other complications of ART include the surgical risks which occur during oocyte 
retrieval (pelvic infection, haemorrhage and bowel, bladder and vascular injury). 
All fertility treatments can lead to multiple pregnancies including ART. The 
chances of a twin pregnancy occurring when a patient is taking clomiphene for 
ovulation induction is 10%, following IVF where two embryos are replaced is 20-
30% and following intrauterine insemination (IUI) treatment is 10-20% (Kennedy, 
2005).  
Multiple pregnancies are associated with an increased risk of miscarriage, 
preterm labour, pre-eclampsia, antepartum haemorrhage, stillbirth, operative 
delivery and caesarean section (Kennedy, 2005). Due to these increased risks, a 
single embryo transfer policy has been introduced in UK practice with the aim to 
try to reduce the risks of multiple pregnancies (Cutting et al., 2008).  
In addition, if ART is successful in achieving a singleton pregnancy, there is still 
increased risk of maternal and fetal complications. Maternal complications 
include pregnancy induced hypertension, pre-eclampsia, gestational diabetes, 
placenta praevia and antepartum haemorrhage   (Pinborg, 2005, Helmerhorst et 
al., 2004, Jackson et al., 2004). The pathophysiology of these conditions 
originates in early pregnancy and is thought to be due to abnormal trophoblastic 
invasion and implantation (Smith et al., 1998, Smith et al., 2002). Fetal 
complications include preterm delivery, fetal growth restriction and congenital 
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abnormalities. All of these cause an increase in perinatal mortality and morbidity 
(Katalinic, Rosch & Ludwig, 2004, Helmerhorst et al., 2004; Jackson et al., 2004).  
Unsuccessful ART treatment cycles which occur as a result of implantation failure 
have significant social, financial and psychological morbidity on couples (de Klerk 
et al., 2007). 
 
1.3.2 Progression in the Field of ART:  
 
Since the birth of the first IVF baby on 25 July 1978, there has been a constant 
improvement in the pregnancy rates following ART as a result of progress and 
development in this field. There have been innovations in laboratory 
technologies (including in-vitro oocyte maturation, cryopreservation techniques, 
blastocyst culture) (Glujovsky et al.,  2012), pre-genetic testing (Sengupta & 
Delhanty, 2012) and more recently time lapse embryo imaging (embryoscope) 
which provides a better selection of embryos to transfer (Freour et al., 2012). 
There has been improvement in surgical treatments (laparoscopy, hysteroscopy), 
ultrasonography and ovarian stimulation pathways particularly focusing on 
integrated individualised management approach.  
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1.3.3 Measuring Success of ART: 
 
As mentioned, the outcome of ART treatment is usually measured by clinical 
pregnancy and live birth rates. The European Society of Human Reproduction 
and Embryology (ESHRE) reported that the most important indicator of success 
of ART treatment is the birth of a single healthy child (Land & Evers, 2003). 
Offering an appropriate management plan for each infertile couple to improve 
the outcome of their ART treatment is dependent upon correct diagnosis for the 
cause of infertility, selection of the best ovarian stimulation protocol and transfer 
of the best quality embryo possible using a good transfer technique. Success 
should also take into consideration treatment complications including OHSS, 
treatment cycle failure and multiple pregnancy rates. This has encouraged 
clinicians to perform single embryo transfer, to consequently reduce some of the 
complications of assisted reproduction, primarily multiple pregnancies, thus 
reducing the cost and improving efficacy (Devroey, Fauser & Diedrich, 2009, 
Cutting et al., 2008).  An elective single embryo transfer (e-SET) policy will reduce 
the complications of ART particularly multiple pregnancies (Grady et al., 2012, 
ASRM, 2012).  
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1.3.4 Recurrent Implantation Failure: 
 
In reproductive medicine, implantation failure is defined as failure of the 
embryo(s) to implant into the endometrium following ART. There is no consensus 
for a standardised definition of recurrent implantation failure (El-Toukhy & 
Tarinissi, 2006). In the UK, a commonly used definition after a survey of IVF 
clinicians defined recurrent implantation failure as not achieving a pregnancy 
after more than three cycles of ART (Tan et al., 2005). Recently, a systematic 
review defined recurrent implantation failure as absence of implantation after 
two consecutive cycles of ART where at least two blastocysts or four cleavage 
stage embryos had been transferred (Polanski et al., 2014).  
Recurrent implantation failure could be a result of several factors including 
embryo quality, endometrial receptivity and embryo transfer techniques (Ola & 
Li, 2006). Other causes of implantation failure can be due to presence of 
endometriosis, hydrosalpnix, lesions within the endometrial cavity (tumours, 
polyps, fibroids, adhesions) and poor ovarian stimulation during ART resulting in 
immature oocytes (Margalioth et al., 2006).  
The quality of the transferred embryos could be affected by genetic disorders, 
difficult hatching (zona pellucida harding) and laboratory technical problems 
(poor cultural conditions). Assessment of the quality of the embryo relies upon 
morphological criteria and cleavage rates but is highly dependent on genetic 
composition. Many embryos are found to have genetic abnormalities despite 
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being morphologically normal. Pre-implantation genetic screening (PGS) and 
comparative genomic hybridisation (CGH) can be used to analyse the 
chromosomal or genetic abnormalities among the embryos before being 
transferred. Thus selecting a genetically normal embryo for embryo transfer 
during ART may improve implantation and pregnancy rates (Taranissi et al., 
2005).  Its routine usage remains controversial. Time lapse embryo imaging will 
help us in choosing the best embryos and improve the success of ART (Conaghan 
et al., 2013).  
A receptive endometrium in the presence of a good quality embryo is vital to 
achieve successful implantation (Ly et al., 2010).  Defective endometrial 
receptivity and inadequate preparation for pregnancy can cause disruption in the 
normal physiological processes of implantation (Achache & Revel, 2006).  
Endometrial proliferation during ART resulting in an endometrial thickness of 
<8mm on the day of embryo transfer has been shown to lead to reduced live 
birth rates (Noyes et al., 2001). A good embryo transfer technique has a positive 
impact on successful implantation (Schoolcraft, Surrey & Gardner, 2001, 
Frydman, 2004).  There is a decline in implantation rates and live birth rates, with 
increasing miscarriage rates in women aged >38 year (Navot et al., 1994).  
It is believed that the implantation failure is the main cause for low fecundity 
after ART (Macklon, Geraedts & Fauser, 2002).  
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1.3.5 Medical Adjuncts in ART: 
 
One of the many challenges for clinicians working in the field of reproductive 
medicine is to improve endometrial receptivity in preparation for pregnancy to 
increase clinical pregnancy and live birth rates. Various medical adjuncts have 
been used in ART to improve endometrial receptivity to increase embryo 
implantation and improve its success.   
Low dose aspirin and heparin are the two most commonly used medical adjuncts 
during ART to improve outcomes. Both are used during ART particularly in 
women with recurrent implantation failure due to their extensive usage in 
women with recurrent miscarriages.  
A Cochrane systematic review reported that use of low dose aspirin for women 
undergoing ART is not recommended as it does not improve the success of 
ART (Siristatidis, Dodd & Drakeley, 2011, Siristatidis, Dodd & Drakeley, 2012).  
Currently, some controversy exists in the literature surrounding the benefits of 
heparin use during ART. A small non-randomised study (Kutteh et al., 1997) 
showed that there was no difference in pregnancy outcomes with the use of 
heparin with low-dose aspirin in women with antiphospholipid positive 
antibodies undergoing ART.  Conversely,  a single centre non-randomised study 
(Sher et al.,1994) reported that heparin with low-dose aspirin during ART 
improved clinical pregnancy and live birth when given to women with positive 
antiphospholipid antibodies. Similar results were published by the same author 
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later in another non randomised study (Sher et al., 1998). The American Society 
for Reproductive Medicine (ASRM, 2008) advises that assessment of 
antiphospholipid antibodies was not indicated among couples undergoing ART, 
and heparin therapy was not justifiable on the basis of existing data to improve 
pregnancy and live birth rates. A prospective cohort study suggested that in 
women who found to have thrombophilia after repeated implantation failure, 
peri-implantation heparin during ART could improve clinical pregnancy. 
However, no precise data were published (Sharif & Ghunaim, 2010).  A review 
(Ricci et al., 2010) suggested that heparin should not be used in women 
undergoing ART until its efficacy is reported in well-designed RCTs. A 
retrospective observational study (Lodigiani et al., 2011) reported that heparin 
improved pregnancy rates when given to women with previous implantation 
failure during ART.  Due to this conflicting evidence that heparin may improve 
success of ART. I wanted to look at the scientific and clinical evidence of the use 
of heparin as a medical adjunct during ART.  
 
1.4 Heparin: 
 
1.4.1 Historical Background: 
 
Heparin as an anticoagulant was first identified by William Howell at John 
Hopkins University, USA in early 20th century shortly after the First World War.  
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The chemical structure of heparin was reported for the first time in the literature 
by Jorpes, 1935. Vitrum AB Sweden became the first manufacturer of this 
medication for intravenous (IV) use and the first ever study with use of IV 
heparin took place in 1935.  
 
1.4.2 Heparin Structure:  
 
Heparin is a glycosaminoglycan containing proteoglycans consisting of 
pyranosyluronic acid and glucosamine components (Comper, 1981).  This is 
shown in Figure 1.5. The pyranosyluronic acid component consists of 90% L-
iduronic acid and 10% D-glucuronic acid.  The glucosamine component consists 
of an amino acid group which can be sulphated, acetylated or un-substituted 
(Gallagher & Walker, 1985).   In practice, this is described as unfractionated 
heparin.  
 
Figure 1.5: Structure of heparin (Nelson & Greer, 2008) 
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1.4.2.1 Heparin Binding: 
 
Heparin binding sites contain positively charged proteins. Heparin contains 
negatively charged polysaccharide. Heparin binds with proteins via ionic bonding. 
This is strengthened by hydrogen bonding.  Heparin can bind with proteins 
including anti-thrombin, various growth factors and their receptors, (particularly 
HB-EGF), viral proteins and extracellular matrix proteins (Nelson & Greer, 2008).  
The glycosaminoglycans, containing proteoglycans, on the surface of heparin 
bind with extracellular ligands. This binding activates the receptor leading to 
activation of a signalling cascade. These heparin binding proteoglycans are found 
extensively throughout the reproductive tract an play an important role in the 
regulation of folliculogenesis during the menstrual cycle, (Rodgers et al.,  2003), 
endometrial cycling and remodelling (Potter & Morris,  1992, Kelly, Tawia & 
Rogers, 1995, Germeyer et al.,  2007, Lai et al.,  2007, Xu et al.,  2007).  
 
1.4.3 Heparin Types: 
  
Heparin can be either  
1. Unfractionated heparin (UFH) 
2. Fractionated (commonly called LMWH)    
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1.4.3.1 Unfractionated Heparin: 
 
UFH are short acting anticoagulants (plasma half-life 30 minutes) with a 
molecular weight of 10,000-15,000 Kilo Daltons (KDa). UFH is obtained from 
animal intestines or lungs (Warda et al., 2003).  It is less expensive than LMWH.  
Careful intense monitoring is required during its administration with activated 
partial thromboplastin time (APTT) (Bick et al., 2005).  UFH excretion is via the 
kidneys. It is safe to treat venous thromboembolism during pregnancy. However, 
it is not used routinely except in special circumstances as it requires intense 
monitoring.   
 
1.4.3.2 Low Molecular Weight Heparin:  
 
Fractionated or more commonly called, LMWHs are manufactured as they 
cannot be obtained from natural sources (Warda et al., 2003).  Various LMWHs 
(weight <10,000 KDa) are manufactured by pharmaceutical companies by 
depolymerisation of UFH (10.000-15,000 KDa). This process is either achieved 
with the use of enzymes, for example tinzaparin (molecular weight of 6500 KDa), 
or with the use of chemicals, for example dalteparin (molecular weight of 5000 
KDa) or enoxaparin (molecular weight of 4500 KDa). Careful intense monitoring 
of these medications is not required. Anti-Xa levels can be used to monitor the 
activity of LMWHs but this is not done routinely unless clinically indicated to 
ensure a patient is receiving an appropriate therapeutic dose. LMWHs are long 
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acting anticoagulants with a more predictable response when compared to UFH.  
This allows administration of fixed adjusted dosages for LMWH without 
requirement of routine anti-Xa level monitoring (Bick et al., 2005) The plasma 
half-life of LMWH  is around 3-6 hours (Nelson & Greer, 2008). LMWH clearance 
is by the kidneys.  LMWHs are safe and effective in preventing and treating 
venous thromboembolism during pregnancy. Due to its longer half-life and a 
more predictable antithrombotic response, it can be administered to patients in 
fixed-weight adjusted doses without the need for laboratory monitoring. It has a 
reduced risk of heparin induced thrombocytopenia (HIT) (Warkentin et al., 1995, 
Warkentin & Greinacher, 2004). 
 
1.4.4 Effects of Heparin on the Coagulation System:   
 
Heparin prophylactically is used to prevent clots and therapeutically to treat 
already formed clots (deep venous thrombosis, pulmonary embolism, myocardial 
infarction or cerebral infarcts). Its action is primarily on coagulation cascade. The 
effect of heparin on the coagulation cascade is illustrated in Figure 1.6.   
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Figure 1.6: The coagulation cascade (Hovanessian, 1999) 
“ *Site of action of unfractionated heparin (Xa/IIa inhibition 1:1). †Site of action of 
LMWH (Xa/IIa inhibition 2:1 to 4:1)”  
 
Heparin (UFH & LMWH) potentiates the anti-thrombin effect of anticoagulation 
in the coagulation cascade.  LMWHs exhibit lower anti-IIa activity when 
compared to UFH.  Due to their low molecular weight, they cannot attach 
simultaneously with thrombin and anti-thrombin to make complexes which are 
important for inhibition of thrombin by anti-thrombin. However, the interaction 
between anti-thrombin and factor Xa are not important for anti-Xa activity, thus 
the LMWH inactivates Xa with similar efficiency as UFH. Anti-Xa levels are 
therefore used to monitor LMWH activity (Bick et al., 2005). 
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1.4.5 Routes of Administration: 
 
UFH and LMWH are licenced to be administered either intravenously or 
subcutaneously. Practically UFH is commonly given by the intravenous route and 
LMWH by the subcutaneous route.  These routes of administrations result in a 
systemic effect of heparin.  
 
1.4.6 Adverse Effects of Heparin:  
 
Adverse effects of heparin treatment include bleeding, bruises, haematomas, 
injection site sensitivity reactions, skin necrosis, thrombocytopenia, abnormal 
liver function tests (LFTs),  osteoporosis (prolonged used) and HIT (prolonged 
use).   All of these adverse effects are more common with use of UFH compared 
to LMWHs, particularly HIT (Warkentin & Greinacher, 2004) and heparin induced 
osteoporosis (Murray et al., 1995).   Protamine sulphate reverses the effects of 
UFH and partially reverses the effects of LMWHs and could be used in life 
threatening haemorrhage (Nelson & Greer, 2008).  
 
1.4.7 Heparin in the Treatment of Miscarriages:  
 
Heparin has been given as medical adjunct to improve the outcomes of women 
with recurrent miscarriages.   
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Heparin and aspirin treatment in early pregnancy were found to be effective in 
preventing pregnancy loss in women with antiphospholipid syndrome (APS) by a 
Cochrane systematic review (Empson et al., 2005). However, another Cochrane 
systematic review reported that aspirin and heparin do not provide effective 
treatment for women suffering with idiopathic recurrent miscarriages (Kaandorp 
et al., 2009). 
 
1.4.8 Role of Heparin in Decidualisation and Implantation:  
 
As described previously, heparin can interact with various proteins in the 
endometrium which are involved in the physiological processes of 
decidualisation and implantation. Heparin may improve embryo apposition and 
adhesion to the endometrium. Therefore heparin could potentially have an 
important role in early pregnancy and ART. This is illustrated in Figure 1.7. 
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Figure 1.7: Potential actions of heparin on implantation (Nelson & Greer, 2008)  
 
Adhesion molecules, particularly selectins play an important role in promoting 
implantation.  Interestingly, certain heparins can block this selectin mediated 
embryo adhesion (Wang et al., 2002) but this is dependent upon the molecular 
weight of the heparin. Higher molecular weight heparins can block the selectin 
mediated ligand adhesion.   UFH and tinzaparin (which has the highest molecular 
weight in LMWH, 6500KDa) block this selectin mediated ligand binding of the 
embryo to the endometrium (Nelson & Greer, 2008). But all other LMWHs with a 
smaller molecular weights than tinzaparin, for example, dalteparin (molecular 
weight 5000 KDa) and enoxaparin (molecular weight 4500 KDa) do not block this 
selectin binding and do not impair adhesion of the embryo to the endometrium. 
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Consequently, all LMWH except tinzaparin should not be detrimental to 
implantation. 
E-cadherin expression is down regulated by progesterone in the luteal phase of 
menstrual cycle promoting implantation (Jha et al, 2006). It has been reported 
that UFH and LMWH (enoxaparin) down regulate endometrial E-cadherin 
expression (Erden et al., 2006), thus promoting implantation.  It has been 
reported that UFH and LMWH help in extravillous trophoblast differentiation 
(Quenby et al., 2004) further aiding in successful implantation. 
HB-EGF binding to epidermal growth factor (EGF) receptor is essential step for 
embryo adhesion.  This HB-EGF binding can only occur in the presence of heparin 
(Aviezer & Yayon, 1994).  
Matrix metalloproteinases (MMP) are capable of degrading extracellular matrix 
proteins. HB-EGF cleavage by these matrix metalloproteinases may be an 
important step in the prevention of trophoblast apoptosis prior to trophoblast 
invasion (Armant et al., 2006).  Laboratory studies have revealed that LMWH 
induces transcription of these trophoblastic MMPs (2 & 9) (Di Simone et al., 
2007). This results in HB-EGF up regulation and improves binding with EGF 
receptor.   
Heparin increases the presence of free IGF-I thus helping promote the 
trophoblastic migration (Arai et al., 1994, Møller et al., 2006).  
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As previously mentioned, TGF-β (1-3) modulates trophoblastic proliferation and 
invasion (Lash et al., 2005). LMWH inhibits expression of TGF-β1 (Weigert et al., 
2001) and decreases the TGF-β presence (Pecly et al., 2006) this further aids in 
promoting trophoblast invasion. 
Heparin synergistically interacts with IL-II signalling potentiating its effects 
resulting in activation of STAT3 transcription (Walton et al., 2002) which is also a 
beneficial signalling pathway for successful implantation. 
In conclusion, interaction of heparins with various factors involved in 
implantation and early pregnancy development include E-cadherin down 
regulation, HB-EGF and its binding, increase in IGF-I, interleukins (IL-1, IL-6), IL-
11-induced STAT3 activation and induction of MMP (2 & 9) (Arai et al., 1994, 
Aviezer & Yayon, 1994, Call & Remick, 1994, Di Simone et al., 2007, Erden et al., 
2006, Liang et al., 2006, Møller et al., 2006, Rajgopal  et al., 2006, Stavreus-Evers  
et al., 2002).  Heparin has been found to modulate decidualisation in in vitro 
studies (Fluhr et al., 2010, Fluhr et al., 2011a) and pro-inflammatory cytokine 
signalling (Fluhr et al., 2011b) in human ESC culture. UFH and LMWH are 
commonly known and used for their anticoagulant activity but their biological 
properties may also be vital for improvement of decidualisation and implantation 
(Fluhr et al., 2010. Fluhr et al., 2011a, Fluhr et al., 2011b).  Heparin can enhance 
the activity of several growth factors including IGF, ILs, EGF and HB-EGF . All of 
these properties of heparin may enhance embryo-endometrial interactions, 
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stimulate decidualisation and improve implantation (Bohlmann, 2011, Nelson & 
Greer, 2008).  
 
1.5 Intrauterine Flushing: 
 
Currently, medical adjuncts used in ART are not effective at improving the 
pregnancy and live birth rates (Nardo, Granne & Stewart, 2009). One possible 
explanation could be that all medical adjuncts used are administered 
systemically. Very few of these adjuncts have been given locally; there is a 
possibility that a novel technique of endometrial administration could be the 
future.  
It has been reported that uterine flushing is a safe and simple procedure (Li, 
Mackenna & Roberts, 1993). Uterine flushing was initially performed to recover 
sperm and analyse the endometrial secretions for assessment of cytokines 
(Williams et al., 1993). Endometrial flushing analysis prior to embryo transfer had 
been used in the past to study the role of cytokine profile within the 
endometrium with the aim of improving implantation (Boomsma et al., 2009a, 
Boomsma et al., 2009b). To improve the success of ART, endometrial secretions 
were aspirated prior to embryo transfer but this intervention did not improve 
outcomes (Van der Gaast et al., 2003). Uterine flushing at oocyte retrieval to 
detect LIF has been performed and it was not associated with adverse pregnancy 
rates (Olivennes et al., 2003). A RCT during which uterine flushing with embryo 
54 
 
culture media was done at embryo transfer, did not report any beneficial 
outcome (Berkkanoglu et al., 2006). More recently, a RCT reported that flushing 
of embryo culture media supernatant before blastocyst transfer could improve 
implantation and pregnancy rates (Goto et al., 2009). 
In the literature, there are few publications which report the use of a medication 
by the intrauterine route. Ogasawara & Aoki, 2000 (case report) reported 
intrauterine administration of prednisolone before ovulation in a woman with 
previous ten unexplained miscarriages and led to a successful pregnancy. A 
recent prospective randomised study reported that intrauterine injection of 
human gonadotrophic hormone (hCG) prior to embryo transfer improves 
implantation and clinical pregnancy rates (Santibañez et al., 2014). 
Flushing mice uteri with culture media from decidualising ESCs had a profound 
effect on the endometrium and the success rate of embryo transfer (Brosens et 
al., 2014).  
Thus, there is a body of evidence suggesting medications could be delivered by 
endometrial flushing to directly treat the endometrium and achieve improved 
pregnancy outcome.  
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1.6 Evidence Based Medicine: 
 
The medical profession needs to provide the most suitable care in light of 
available best evidence. Scientific and clinical evidence is formulated from 
studies. Clinical studies are categorised into two groups, descriptive or analytical. 
Descriptive studies can be cross-sectional or qualitative. Analytical studies can be 
observational (cohort, case control) or experimental (randomised or non-
randomised).  Results from individual studies of any type should be interpreted 
with caution due to the possibility of different biases. Bias can occur at any time 
during a study (planning, data collection, analysis and publication) (Pannucci & 
Wilkins, 2010). Results from multiple studies can be reviewed in a systematic 
review.  
Clinical reviews are of two types, narrative or systematic. Narrative reviews are 
descriptive in nature and do not include a systematic search of the available 
literature. Systematic reviews are based on a detailed search plan prior to the 
review. This aims to minimise bias. Results of a systematic review can be 
presented in meta-analysis which formulates a quantitative summary effect size 
from multiple studies data (Uman, 2011). In a systematic review, outcome 
measures are prespecified.  In this thesis the systematic review protocol (Chapter 
3) was peer-reviewed by the Cochrane Menstrual Disorder and Subfertility 
Group. 
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In the era of evidence based medicine and practice (Sackett et al., 1996, Straus & 
Sackett, 1998), levels of evidence had been defined in literature and level 1 
evidence (highest level) comprises of systematic reviews with meta-analysis of 
randomised controlled studies.  
 
1.7 Aims: 
 
 
1.7.1 Gaps in Our Knowledge:  
 
In this literature review I have identified that there is a clinical need to improve 
the ART success rates.  I have identified that there is a lack of effective 
interventions currently available to improve the endometrial environment, 
decidualisation, embryo-endometrial interactions and implantation.  I have 
provided evidence that heparin has the potential to improve the endometrial 
environment. I have also identified that intrauterine treatment may be a good 
alternative route of administration to directly treat the endometrium.   In this 
thesis I aim to explore the role of heparin (particularly LMWH) in improving ART 
success in a series of projects.   
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1.7.2 Specific Aims: 
 
1. I aim to assess the current clinical data available to assess the efficacy of 
peri-implantation heparin in ART.  A systematic review and meta-analysis 
was undertaken with the guidance of Cochrane Menstrual disorder and 
Subfertility group.  This included a protocol “Heparin for Assisted 
Reproduction” (Chapter 2) and the completed review with results 
“Heparin for Assisted Reproduction” (Chapter 3). 
2. I aim to assess the feasibility of intrauterine heparin administration to 
improve the peri-implantation endometrial environment. Initially a phase 
1 study is required for direct administration of heparin as currently only 
licensed as a systematic injectable formulation. The aim of this 
prospective phase 1 study is to demonstrate safety, acceptability, 
feasibility and the potential of this delivery method to effect 
implantation. We designed and carried out this single blinded, 
randomised, placebo control study of intrauterine LMWH flushing in non-
conception cycle.  This involved writing a protocol and obtaining ethical 
approval from NRES, MHRA and local R&D. Sponsorship was obtained 
from the University of Warwick. The study was undertaken at UHCW. 
Study protocol (Chapter 4) and results analysed and reported (Chapter 5).   
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Chapter 2 
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2.0 Heparin for Assisted Reproduction (Cochrane Review 
Protocol):  
 
2.1 Introduction: 
 
The systematic review and meta-analysis was performed under the well-
established “The Cochrane Collaboration”. Cochrane is an international, 
independent organisation which aids clinicians and the public with evidence-
based health decision-making.  It produces high-quality, relevant, accessible 
systematic reviews. The Cochrane Collaboration has more than 50 review groups 
which look at individual subspecialties of medicine and surgery one of which is 
the Menstrual Disorders and Subfertility Cochrane Review Group. This is led by 
Professor C Farquhar (Department of Obstetrics and Gynaecology, University of 
Auckland).  
Cochrane reviews are standardised. Each review addresses a specific well 
formulated question. Anybody who would like to undertake a review needs to 
submit a research question to the Chair of the Cochrane review group. Once 
accepted, a protocol for the systematic review and meta-analysis is submitted 
which is only approved by the Cochrane review group committee after careful 
discussion. The review can then be undertaken and submitted to the Cochrane 
review group.  It is carefully scrutinised, checked and cross referenced before 
acceptance.  Training to perform Cochrane reviews in UK is provided at the UK 
Cochrane Centre, Oxford.  
60 
 
Following completion of the systematic review protocol workshop at the UK 
Cochrane centre in May 2011, in collaboration with colleagues at the University 
of Warwick and University of Nottingham, I submitted a protocol to the 
Cochrane Menstrual Disorder and Subfertility Review Group to address the 
question “Does peri-implantation heparin improves clinical pregnancy and live 
birth rate in women undergoing ART?”  The published protocol is included in 
Other Appendices. 
  
2.2 Objectives: 
  
This review assessed the benefits and risks of peri-implantation heparin 
(unfractionated or low molecular weight) in subfertile women undergoing ART.  
 
2.3 Methods:  
 
2.3.1 Types of studies, Participants and Interventions to be Included 
in the Review: 
 
Only RCTs were included in the review. The method of randomisation was 
explained. No prospective or retrospective observational/case control/cohort 
studies were included. Quasi-randomised studies were excluded as per Cochrane 
recommendation. Participants were subfertile women having ART. WHO 
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definition of ART does not include intrauterine insemination (IUI) (Zegers-
Hochschild et al., 2009).  For this reason, women having IUI were excluded. 
Studies were included in which UFH or LMWH was compared to no treatment, 
placebo or aspirin during peri-implantation period at ART (from oocyte retrieval 
or embryo transfer until pregnancy test two weeks later).  
 
2.3.2 Outcomes to be assessed: 
  
The primary outcomes were the live birth rate per woman and the adverse 
effects of heparin. Secondary outcomes were the clinical pregnancy rate per 
woman, on-going pregnancy rate per woman and multiple pregnancy rates per 
woman. In addition, we reported any maternal or fetal pregnancy complications 
documented in the randomised control studies included in the review.  
 
Following outcomes were not pooled for statistical analysis (implantation rate, 
incidence of miscarriage and multiple pregnancies). However this data was 
reported into the ’table of comparisons’ in the review.  
 
2.3.3 Search Methodology: 
 
A thorough search was performed in conjunction with Trials Search Coordinator 
of the Cochrane Menstrual Disorders and Subfertility Group at University of 
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Auckland and according to  the Cochrane Handbook for Systematic Reviews of 
Interventions (Version 5.1.0) (Higgins & Green, 2011). 
These databases searched were The Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, The Cochrane library, Database 
of Abstracts of Reviews of Effects (DARE), Current Controlled Trials and The WHO 
International Trials Registry and Grey literature.  
 
2.3.4 Statistical Analysis: 
 
This was done according to the Cochrane Handbook for Systematic Reviews of 
Interventions version 5.1.0 (Higgins & Green, 2011). Revman software was used 
to input and analyse the data. Grade Pro software was used to make the 
summary of findings table in the systematic review. 
 
2.3.5 Study Selection and Data Collection: 
 
 
For all records identified which met the search criteria were further explored 
separately by two authors, any discrepancies between these two authors was 
resolved by consultation with a third author.  
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Study characteristics Patient data Intervention Outcome 
 Randomisation 
method 
 Allocation 
concealment 
 Study design 
 Screening log for 
eligibility, patients 
randomised, 
excluded, and 
finally analysed 
 Duration of study 
 Timing of study 
 Location of study 
 Source of funding 
 Age of patient 
 Fertility 
history 
 IVF or ICSI 
 
 
 Type 
 Dosage 
 Regimen 
 
 
 Definition 
 How it is 
measured 
 Timing 
 
 
Table 2.1:  Information collected for each included study. This will be reported in the 
table ’Characteristics of included studies’ in the published review  
(Akhtar et al., 2013) 
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 2.3.6 Bias Assessment: 
 
This was assessed by two authors autonomously according to modification of the 
quality criteria specified by the Cochrane Handbook for Systematic Reviews of 
Interventions 5.1.0. 
Any differences between two authors were resolved by consultation with a third 
author.  
Risk of bias assessment was performed for the following: 
 Selection bias- this refers to selection of population where adequate 
randomisation or allocation had not been achieved. So the population 
sample analysed is not representative of the intended population 
which needs to be analysed.  
 Performance bias- this involves non blinding of participants and 
researchers in a study which attributes to behavioural reactions and 
responses in view of which study group the subjects are.  
 Detection bias- refers to the systematic differences between groups 
and how the outcome had been assessed. Blinding of the outcome 
assessors reduces the risk of this bias. For example, ultrasound scan 
for clinical pregnancy to be performed by a radiologist or sonographer 
who are not part of the research team.  
 Attrition bias- refers to differences between groups in withdrawal 
from the study. This could result in incomplete outcome data.   
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 Reporting bias- refers to selective reporting where negative results, 
for example side effects, are not reported.   
 Any other bias 
 
When required, we used funnel plot to report potential publication bias, 
however it should be used with caution if there are fewer number of studies (less 
than 10) (Egger et al., 1997). Funnel plot looked at precision comparing the effect 
size against sample size. This helped identify any publication bias.  
 
2.3.7 Data Synthesis and Statistical Analysis:  
 
Meta-analyses were performed, as appropriate. A fixed-effect model was used in 
accordance with methods recommended in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins & Green, 2011). An increase in the 
odds of a positive or negative outcome was shown graphically.  
Odds ratios (OR) with 95% confidence intervals (CI) were calculated in both 
groups. Data per woman randomised was used for analysis. Data per cycle, per 
pregnancy or per embryo transfer (ET) were not appropriate for statistical 
pooling because of ’unit of analysis errors’. It meant that the use of multiple 
observations per woman leads to unpredictable bias in the estimate of treatment 
difference (Vail & Gardener, 2003). Multiple births were represented as one live 
birth event.  
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Authors were contacted to obtain any missing information or resolve any 
queries.  
We planned to perform subgroup analysis only if enough data is available 
(including heparin with different ART (fresh or frozen), regimen of heparin, age 
of women, previous implantation failure following ART, women with or without 
thrombophilias). 
 
2.3.7.1 Heterogeneity Assessment: 
 
The similarity of the studies with regards to participants, interventions and 
outcomes were assessed for suitability for pooling in the meta-analysis. Chi2 test 
was performed to ascertain statistical heterogeneity in the pooled data, with 
significance level of P < 0.1. The variation across the studies as a consequence of 
heterogeneity was assessed by I2 statistic (< 25% is low-level, 25-50% is 
moderate-level, and > 50% is high-level heterogeneity). Sensitivity analysis was 
performed if high levels of heterogeneity are noted. It was also done to evaluate 
study quality.  
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Chapter 3 
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3.0 Heparin for Assisted Reproduction (Cochrane Review 
with Results):  
 
3.1 Introduction: 
 
A literature search, data collection, analyses and assessment of risk of bias were 
performed by two authors autonomously in accordance with the protocol 
described in chapter 2.  
No open discussion or consultation with the third author was required to settle 
any differences between the two review authors. 
The published Cochrane review and the published summary of Cochrane review 
are included in the other appendices.  
 
3.2 Results of Literature Search: 
 
Seven studies met the pre-set criteria from the search performed. This is shown 
in Figure 3.1. 
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Figure 3.1: PRISMA flow chart  
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3.2.1 Included Studies: 
  
However, on further assessment only three of these studies were eligible for the 
review.  These three included studies in the review were Qublan et al., 2008; 
Urman et al., 2009; Noci et al., 2011. It is presented in the table ’Characteristics 
of included studies’ in the published review (Akhtar et al., 2013). 
 
3.2.2 Excluded Studies: 
 
Three studies identified failed to meet all of the inclusion criteria and this is 
summarised in Table 3.1. 
Study Reason for exclusion 
Berker et al., 2011 This was a quasi-randomised study.  
 
Colicchia et al., 2011 LMWH was used in addition to prednisolone 
 
Stern et al., 2003 Unfractionated heparin was used with low-dose aspirin 
 
Table 3.1: Excluded studies with reasons for exclusion 
 
Further information about these studies is available in the characteristics of 
excluded studies section in the published review (Akhtar et al., 2013). 
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3.2.3 Study completed but not published: 
 
We cannot include this study (Mashayekhy, 2011) as it has not yet been 
published. Only abstract published in Iranian Journal of Reproductive Medicine, 
spring 2011. Further information was sought from the authors of this study but 
no response received.  
 
3.3 Results (Included Studies): 
  
Results from these three included studies Qublan et al., 2008, Urman et al., 2009 
and Noci et al., 2011 were utilised for systematic review and meta-analysis.  
 
3.3.1 Participants: 
 
There were 386 trial participants in total.  Participants in the included studies 
were less than 40 years old.  
 
3.3.2 Interventions and Comparisons: 
 
All participants were undergoing single IVF/ICSI cycles only.  During the cycle 
LMWH was given to the participants either from oocyte retrieval or from embryo 
transfer.  The methods used in each study is summarised in Table 3.2. 
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Study Type of 
LMWH 
LMWH 
started 
LMWH stopped Control  
Noci  
et al., 2011 
Dalteparin  
2500 IU daily 
Day of 
oocyte 
retrieval 
At 9 weeks of 
pregnancy with 
a positive 
pregnancy test 
 
No LMWH 
Qublan  
et al., 2008 
Enoxaparin 
40 mg daily 
At embryo 
transfer (ET) 
If two weeks 
after ET β-hCG 
was less than 
425 IU/ml or if 
fetal demise or 
until delivery 
 
Placebo 
Urman 
et al., 2009 
Enoxaparin 
1mg/kg daily 
Day after 
oocyte 
retrieval 
At 12 weeks of 
pregnancy with 
a positive 
pregnancy test 
    No LMWH 
   
    
Table 3.2: Included studies with intervention used  
 
3.3.3 Outcomes: 
 
All three studies reported the primary outcome as the live birth rate. 
Other outcomes reported in all studies: 
 Adverse effects  
 Clinical pregnancy rate per woman 
 Multiple pregnancy rate per woman 
 Implantation rate per woman 
 Miscarriage rate per woman 
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3.3.3.1 Primary Outcomes: 
 
3.3.3.1.1 Live Birth Rate per Woman: 
 
Results pooled in meta-analysis (fixed-effect model) (Akhtar et al., 2013) showed 
that there was a statistically significant improvement in live birth rate with the 
use of LMWH (odds ratio (OR) 1.77, 95% confidence interval (CI) 1.07, 2.90 
P=0.03, I2 = 51%, three studies, 386 women) in comparison to placebo or no 
LMWH. See Figure 3.2.  
 
 
Figure 3.2 Forest plot of comparison:  Live Birth Rate per woman (Fixed effect model) 
(Akhtar et al., 2013) 
 
Sensitivity analysis performed with a random-effects model (Akhtar et al., 2014) 
showed that there was no statistically significant improvement in live birth rate 
with the use of LMWH (OR 1.85, 95% CI 0.80, 4.24 P=0.15, I2=51%, three studies, 
386 women) in comparison to placebo or no LMWH. See Figure 3.3. 
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Figure 3.3 Forest plot of comparison:  Live Birth Rate per woman (Random effect 
model) (Akhtar et al., 2014) 
This finding should be viewed with extreme caution due to high heterogeneity 
and sensitivity to choice of statistical model. The evidence was of very low 
quality as shown in summary of findings for the main comparison (Akhtar et al., 
2013). 
 
3.3.3.1.2 Adverse Effects: 
 
Table 3.3 summarises the reported side effects in each of the studies. 
Study Adverse effect Number of patients affected 
Noci et al.,2011 Minimal bruising around injection site Not quantified 
 
Qublan et al., 
2008 
Bleeding 3/42 (7.1%) 
Thrombocytopenia 2/42 (4.8%) 
Allergic reaction 1/42 (2.4%) 
 
Urman et al., 2009 Small ecchymosis around injection site Not quantified 
 
Table 3.3: Adverse effects of heparin reported in each study 
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When heparin was given over a longer duration, the reported side effects 
increased as shown in Qublan et al., 2008. 
 
3.3.3.2 Secondary Outcomes: 
 
3.3.3.2.1 Clinical Pregnancy Rates per Woman: 
 
This was reported in all included studies. Results pooled in meta-analysis (fixed-
effect model) (Akhtar et al., 2013) showed a statistically significant improvement 
in clinical pregnancy rate with the use of LMWH (OR 1.61 95% CI 1.03, 2.53 P = 
0.04, I2 = 29%, three studies, 368 women) in comparison to placebo or no LMWH. 
See Figure 3.4. 
 
 
 
Figure 3.4 Forest plot of comparison: Clinical Pregnancy Rate per woman (Fixed effect 
model) (Akhtar et al., 2013) 
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Sensitivity analysis performed with a random-effects model showed no 
statistically significant improvement in clinical pregnancy rate with the use of 
LMWH (OR 1.66, 95% CI 0.94, 2.90, I2 = 29%, three studies, 368 women) in 
comparison to placebo or no LMWH. See Figure 3.5. 
 
 
 
Figure 3.5 Forest plot of comparison: Clinical Pregnancy Rate per woman (Random 
effect model). 
 
3.3.3.2.2 Multiple Pregnancy Rates per Woman: 
 
‘Multiple pregnancy rates per woman’ were not reported in any of the included 
studies. “Multiple pregnancy rates per total number of pregnancies” was 
reported in all studies but cannot be pooled for meta-analysis due to unit of 
analysis errors as described in Chapter 2.  
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3.3.3.2.3 Maternal Pregnancy Complications: 
 
Study Complication Patient 
group 
Details 
Noci et al., 
2011 
No maternal 
complications 
reported  
 
 
 
 
 
Qublan et 
al., 2008 
Placental 
abruption 
LMWH One patient 
Pre-eclampsia Control Two patients 
 
Urman et 
al.,  2009 
Preterm delivery LMWH Nine patients 
- At 32 weeks gestation: 3 
patients, one singleton, 
one set of twins and one 
set of quadruplets 
- At 34 weeks gestation: 
two sets of twins 
- At 35 weeks gestation: 
three sets of twins 
- At 36 weeks gestation: 
one singleton 
Control Six patients 
- At 33 weeks gestations: 
one singleton 
- At 34 weeks gestation: 
two sets of twins 
- At 35 weeks gestation: 
one set of twins 
- At 36 weeks gestation: 
two sets of twins 
 
Table 3.4 Summary of maternal pregnancy complications described in the included 
studies 
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3.3.3.2.4 Fetal Complications during Pregnancy: 
  
Study Fetal complication 
Noci et al., 2011 No complications described 
 
Qublan et al., 2008 Two intrauterine deaths in LMWH group 
 
Urman et al., 2009 One baby with unilateral undescended testis in LMWH group. 
One baby who delivered at 32 weeks underwent surgery due 
to necrotising enterocolitis in LMWH group 
 
Table 3.5 Summary of fetal complications during pregnancy described in the included 
studies 
 
3.3.3.2.5 Other Analyses: 
 
We were unable to perform any subgroup analyses due to the small number of 
included studies. It was also not possible to create a funnel plot to assess 
publication bias. 
Implantation rate, incidence of miscarriage and multiple pregnancy data which 
was not appropriate for statistical pooling for meta-analysis is shown in Tables 
3.6-3.8.  
Study ID Heparin group Control group 
Noci et al., 2011 15% 12% 
Qublan et al., 2008 19.8% 6.1% 
Urman et al., 2009 24.5% 19.8% 
Table 3.6: Implantation rate per embryos transferred 
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Study ID Heparin group 
per pregnancy  
Control group 
per pregnancy 
Heparin group 
per woman 
Control group 
per woman 
Noci et al., 2011 4/19 3/16 4/73 3/80 
Qublan et al., 2008 1/13 
*IUFD 2/13 
2/4 
*IUFD 0/4 
1/42  
 
*IUFD 2/42 
2/41 
 
*IUFD 0/41 
Urman et al., 2009 n/a n/a n/a n/a 
*IUFD-intrauterine fetal death 
Table 3.7: Incidence of miscarriage per total number of pregnancies 
Study ID Heparin group Control group 
Noci et al.,  2011 (6/19) 31.5% (2/16) 12.5% 
Qublan et al., 2008 (3/13) 23.1% (1/4) 25% 
Urman et al.,  2009 (12/34) 35.3% (10/29) 34.5% 
 
Table 3.8: Incidence of multiple pregnancies per total number of pregnancies 
 
3.4 Bias Assessment: 
 
In accordance to the protocol, all included studies were assessed for bias. This is 
represented in the form of a graph (Figure 3.6) and summary (Figure 3.7)  
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Figure 3.6 Risk of bias graph presented as percentages across all included studies 
(Akhtar et al., 2013) 
 
Figure 3.7 Risk of bias summary for each risk of bias item for each included study 
(Akhtar et al., 2013) 
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3.4.1 Selection Bias: 
 
3.4.1.1 Random Sequence Generation: 
 
Noci et al., 2011 and Urman et al., 2009 randomised participants following an 
adequate computer generated randomisation method. Qublan et al., 2008 
randomised women from table of random numbers.  
 
3.4.1.2 Allocation Concealment: 
 
Noci et al., 2011 and Urman et al., 2009 reported allocation concealment. 
However, Qublan et al., 2008 did not describe allocation concealment so the bias 
risk is assessed as unclear. 
 
3.4.2 Performance Bias: 
 
Noci et al., 2011 and Urman et al., 2009 did not provide any information 
regarding blinding of participants and clinicians. However, Qublan et al., 2008 
reported blinding of participants but not clinicians. Thus, all were assessed as at 
high risk of performance bias.  
 
  
82 
 
3.4.3 Detection Bias: 
 
Outcome assessors were blinded in Noci et al., 2011. Blinding of outcome 
assessors was not performed in Qublan et al., 2008 and Urman et al., 2009 so 
categorised as high risk of detection bias.  
 
3.4.4 Attrition Bias: 
 
Incomplete outcome data is classified as attrition bias. Qublan et al., 2008 study 
reported all outcome data.  Urman et al., 2009 compensated for participant 
dropouts lost to follow up (five women) by using negative outcomes. Noci et al., 
2011 recruited 210 women.  Thirty eight were excluded on the day of oocyte 
retrieval. The remaining one hundred and seventy two women were divided into 
two groups (intervention and control). Thirteen women in the intervention group 
and six women in the control group were excluded as they did not have did not 
have any embryos to transfer. It was therefore rated as at unclear risk of attrition 
bias. 
 
3.4.5 Reporting Bias: 
  
Qublan et al., 2008 and Urman et al., 2009 were considered at low risk of 
reporting bias. As Noci et al., 2011 did not report any adverse events, so it was as 
at unclear risk of selective reporting.  
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3.4.6 Any Other Bias: 
 
No other obvious potential sources of bias were found in any of the included 
studies. But all of this was unclear.  
 
3.5 Overall Quality of Evidence:  
 
Overall quality of body of evidence for main outcomes are summarised in 
accordance with Cochrane review in a ’Summary of findings’ table (Akhtar et al., 
2013).  This was generated using GRADEPRO software. The criteria used for 
grading quality of evidence are based upon risks of bias, consistency and 
imprecision of effect.   
 
3.6 Conclusions:   
 
386 participants from only three studies were eligible to be included in the 
systematic review and meta-analysis. All the included studies characteristics 
were heterogeneous. One study was multi-centred (Noci et al., 2011), the other 
two were single centre studies (Qublan et al., 2008, Urman et al., 2009).  There 
was no regimen uniformity of LMWH among studies. Only one study was placebo 
controlled (Qublan et al., 2008). Performance bias was high amongst all studies 
due to the lack of blinding. 
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Statistical analysis of these studies revealed that the current evidence suggests 
that LMWH usage during peri-implantation period prior to ART may improve the 
clinical pregnancy rate and the live birth rate.  
However, this result should be interpreted with caution due to small number of 
heterogeneous studies with few participants. Most importantly, the result of this 
meta-analysis is sensitive to the choice of statistical model (fixed effect model or 
random effect model).  
 
Adverse effects (bruising, ecchymosis, bleeding, thrombocytopenia and allergic 
reactions) were associated with subcutaneous use of LMWH and as would be 
expected these adverse effects occurred more commonly with prolonged use of 
the drug.   
 
In conclusion, the current available evidence is not robust enough to justify the 
clinical use of peri-implantation LMWH in subfertile women undergoing ART. 
However, its efficacy should be further explored in good quality randomised 
controlled studies with no other medical adjuncts used additionally.  
Studies should be undertaken where local (uterine) heparin unlike systemic 
heparin is assessed for its efficacy and to ascertain its effect on decidualisation. 
As heparin does not have a medicinal licence to be given locally (intrauterine), a 
Phase 1 study will be required to establish its feasibility in the first instance.  
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Chapter 4 
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4.0 Study Protocol: Endometrial Flushing of Low Molecular 
Weight Heparin Improves Decidualisation- A Prospective 
Randomised Controlled Pilot Study 
 
Trial Registration: Current Controlled Trials ISRCTN78466363 
  
4.1 Background: 
 
Successful implantation is the result of a favourable embryo-endometrial 
interaction.  Recent advances in laboratory techniques in ART focussing on the 
embryo have led to improvements in pregnancy rates. However, currently there 
are few treatments to improve the endometrium in this critical interaction.  
Heparin has been used as an adjunct to ART and some studies suggest that it 
may improve implantation in women both with and without thrombophilias 
(Fiedler & Wurfel, 2004). In contrast, four recent high quality trials of heparin 
administration in early pregnancy failed to demonstrate efficacy in preventing 
miscarriage (RCOG, 2011).  Nevertheless, heparin given earlier, around the time 
of implantation may be beneficial to subfertile couples.  We performed a 
Cochrane meta-analysis of RCTs which suggests that subcutaneous LMWH may 
improve clinical pregnancy and live birth rates during ART (Akhtar et al., 2013).  
One problem with these RCTs was that they gave LMWH from the day of oocyte 
retrieval. Haemorrhage is a recognised risk during oocyte retrieval for ART. 
Administration of systemic LMWH at this time may increase the bleeding risk 
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further. Heparin has also been associated with other side effects including 
female genital tract bleeding, swelling and itching at the injection sites, 
osteopenia and potentially HIT (Bohlmann, 2011).  Hence, local administration of 
LMWH is likely to be safer and reduce these risks and side effects as systemic 
absorption should be less. Intrauterine LMWH could be equally or more 
beneficial for improving implantation.  Furthermore this pre-conception method 
of administration of heparin may prevent miscarriages when post conception 
method has not shown any benefit because it has the potential to influence 
decidualisation directly. 
 
4.1.1 Pharmacology of Enoxaparin: 
 
Enoxaparin (Clexane- Sanofi Aventis ATC code B01A B05) has a molecular weight 
of 4500 KDa. Compared to UFH it has a higher ratio of antithrombotic activity to 
anticoagulant activity. It does not influence platelet aggregation or their binding 
to fibrinogen and it also does not influence clotting tests (APTT and prothrombin 
time (PTT)). As shown in Figure 1.6, enoxaparin leads to the inhibition of 
coagulation factors IIa and Xa (Hovanessian, 1999). The maximum anti-Xa effect 
following subcutaneous injection of enoxaparin occurs 1 to 4 hours later.  This 
anti-Xa level can range from 0.16 IU/ml to 0.38 IU/ml after doses of 20 mg or 40 
mg respectively. The half-life of enoxaparin is 4 to 5 hours in a healthy non-
pregnant adult. Following a 40 mg dose, anti-Xa activity could be detected for up 
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to 24 hours. This is presented in the Other Appendices as the Summary of 
Product Characteristics (SmPC) of enoxaparin. 
 
4.1.2 Rationale for the Study: 
 
In humans, the endometrium is receptive to the embryo only during the 
implantation window. The implantation window occurs 5-7 days from ovulation. 
Ovulation can be detected by an ovulation kit testing for urinary LH surge.  The 
ability of the endometrium to support implantation depends upon adequate 
development of the endometrium prior to implantation, during the implantation 
and during early pregnancy. This process is known as decidualisation.  As 
discussed in Chapter 1, in-vitro studies have shown that that LMWH promotes 
decidualisation (Arai et al., 1994, Aviezer & Yayon, 1994, Call & Remick, 1994, Di 
Simone et al., 2007, Erden et al., 2006, Liang et al., 2006, McBride, Armstrong & 
McMurray, 1996, Møller et al., 2006, Rajgopal et al., 2006, Stavreus-Evers et al., 
2002). We postulate that LMWH promotes decidualisation in-vivo and that this 
explains the clinical improvement in implantation demonstrated by the meta-
analysis. We would like to assess a different route of administration of LMWH, 
endometrial flushing.  This will enable us to administer LMWH locally to the 
endometrium and then to assess acceptability and its influence if any upon 
endometrial decidualisation. Following this, improvement in decidualisation is 
anticipated to improve the quality of implantation and may assist in the future 
with treating patients who experience infertility or recurrent miscarriage. Local 
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application is expected to minimise the dose received systemically, while 
targeting the appropriate tissue for efficacy. In this study, we will obtain an 
endometrial biopsy 24 hours after LMWH or normal saline 0.9% application and 
test for markers of decidualisation. 
 
4.1.3 Markers of Decidualisation: 
 
As discussed in Chapter 1, Professor Brosens at the University of Warwick has 
established in-vitro models of stromal cell decidualisation (Teklenburg et al., 
2010, Salker et al., 2010, Salker et al., 2011). More recently this decidualisation 
model has been found to correlate well with uNK cell density established by 
Professor Quenby at the University of Warwick (Kuroda et al., 2013). 
 
4.2 Methods: 
 
Eligible  participants will be women aged 18-45 years old, who had previous one 
unsuccessful ART cycle or with history of recurrent miscarriages and able to 
provide informed consent.  
During a non-conception cycle, participants will be randomised to have 
endometrial flushing with either LMWH (treatment) or normal saline 0.9% 
(control) 5-7 days after ovulation (during the implantation window). All women 
will have serum anti-Xa levels performed four hours post endometrial flushing. 
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All participants will have an endometrial biopsy taken 24 hours post endometrial 
flushing. Full blood count (FBC) and liver function tests (LFTs) will be obtained at 
endometrial biopsy. Side effect diaries will be provided to all participants and a 
telephone follow up will be done two weeks after the endometrial biopsy. 
Participating women will then go ahead with fertility treatments including ART if 
they wish to after the study.  
An overview of the methods is shown in Figure 5.1.  Patient Information Sheet, 
Consent Form, Participant Invitation Letter and GP Letter are shown in the 
Appendices 1-4 respectively. 
 
4.2.1 Design: 
 
This will be a phase 1 prospective randomised, single-blind, placebo controlled 
trial of LMWH (enoxaparin) to assess feasibility of recruitment, integrity of trial 
procedures and to generate data to base future power calculations. This will 
enable us to obtain data about participant acceptability for this novel route of 
administration.   
The duration of the study will be 12 months from ethical approval to collect 
samples from patients. A further 12 months will be required to analyse the data. 
Recruitment will start upon approval of the study. Participants will be recruited 
from the implantation, reproductive medicine and recurrent miscarriage clinics, 
at Centre of Reproductive Medicine at UHCW. The Implantation clinic is already 
established and run by Professor Quenby and Professor Brosens.  
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This is a pilot study to assess efficacy and safety. Based upon the ART cycles at 
Centre of Reproductive Medicine and the availability of patients, we anticipate 
around 40 participants would be recruited over 12 months period (Expected to 
be from 1 January 2013 to 31 December 2013). 
 
4.2.2 Aims: 
 
We wish to develop a different method of administration of LMWH to improve 
decidualisation, hence reducing implantation failure and miscarriage. The aim of 
this phase 1 study is to demonstrate feasibility, safety, acceptability and the 
potential of this delivery method to effect decidualisation.  
 
4.2.3 Primary Outcome: 
  
Density of uNK cells as a surrogate marker of effective decidualisation will be 
looked as primary outcome. Previous work by Professor Quenby (Kuroda et al., 
2013) has shown that elevated uNK cell density corresponds to impaired 
induction of decidual markers (Prolactin, IGFBP1) in vitro.  Unfractionated 
heparin and LMWH has shown to improve markers of decidualisation (Prolactin, 
IGFB1) in in vitro studies (Fluhr et al., 2010).  So uNK cell density as a surrogate 
marker of decidualisation is appropriate. But this surrogate marker predicts 
improved decidualisation but not representative of clinical pregnancy and live 
birth.  
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Density of uNK cell is measured by immunohistochemistry as described 
previously by Professor Quenby (Quenby et al., 2009, Drury et al., 2011, Kuroda 
et al., 2013).  
4.2.4 NK Cell Density Count Method: 
 
The endometrial biopsy tissue obtained 24 hours post intrauterine flushing will 
be fixed in formalin at room temperature, processed and embedded in paraffin. 
Slides will be prepared for immunohistochemistry with the help of research 
histopathologist Mr S James at the University of Warwick. Slides will be stained 
for CD56 and subsequently photographed for analysis. Image J analysis (free java 
based software) (Schneider, Rasband & Eliceiri, 2012) with point picker tool 
(within image J software) was used for uNK cell counting. This highly 
reproducible method was first utilised to count uNK cells by Professor Quenby 
(Drury et al., 2011). CD56 cells were counted within the stroma closer to the 
epithelial edge in five high power fields. The formula for uNK cell density is below 
(Drury et al., 2011) 
 
%𝑢𝑁𝐾 =  
𝑢𝑁𝐾 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 × 100
𝑆𝑡𝑟𝑜𝑚𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
 
 
Uterine NK cell density is classified as normal if <5% and classified as high if >5% 
(Quenby et al., 2005, Tang et al., 2013, Kuroda et al., 2013).   
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4.2.5 Secondary Outcomes: 
 
 Side effects of endometrial administration of LMWH. For example, 
bleeding, pain, discomfort and infection. 
o Venous blood will be sampled after the flushing of the 
endometrium with LMWH or normal saline 0.9%. Anti-Xa level will 
be checked 4 hours after administration. FBC and LFTs will be 
checked 24 hours after intrauterine flushing at the time of 
endometrial biopsy.  
 Patient acceptability will be assessed with a questionnaire. Participants 
will undergo further fertility treatment if they wish to.  
 Endometrial samples will be divided into three (one frozen in liquid 
nitrogen (for future analysis), second into RNA later and the third is fixed 
in formalin for immunohistochemistry). These samples will be available 
for the laboratory team to ascertain which will be the most appropriate 
outcome measure for decidualisation in further studies. DNA, RNA and 
protein for PRL, L-selectin, HB-EGF, EGF and SGK1 will be assessed. These 
analyses are beyond the scope of this thesis and results will be published 
later. 
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4.2.6 Side Effect Monitoring: 
 
Women will be given a diary to record any side effects. They will also have a 
telephone consultation after enoxaparin or control administration when they will 
be asked about side effects and subsequent menstrual period.  
 
4.2.7 Inclusion Criteria: 
 
 Women attending the Centre for Reproductive Medicine, UHCW 
who have had one unsuccessful ART cycle, or women with 
recurrent miscarriages. 
 Women aged 18-45 years  
 Able to give informed consent. 
 
Women included in the study were heterogeneous as there were two distant 
groups, subfertile women, and women with recurrent miscarriages. This could 
have resulted in selection bias and confound the results. Both groups of women 
were included in the study to improve recruitment, there were fears that we 
may not be able to recruit women for this novel study in which there is no known 
direct beneficial effect upon patient outcomes.  
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4.2.8 Exclusion Criteria: 
 
 Currently pregnant 
 Currently breastfeeding 
 Women who have unprotected sexual intercourse  the within the month 
when endometrial flushing is planned 
 Women with body weight of < 45 kg (due to higher risk of bleeding) 
 Women with history of medical disorders (bleeding disorders, severe 
hypertension, known renal or liver disease, diabetes mellitus, peptic ulcer 
disease, recent stroke) 
 Women taking the following medications on a regular basis (warfarin, 
systemic steroids, acetylsalicylic acid, non-steroidal anti-inflammatory 
drugs (NSAIDS), dextran, clopidogrel or any immunosuppressant 
medications 
 Women with any known hypersensitivity to heparin, pork, beef or other 
animal products  
 Women having tubal patency testing, hysteroscopy or laparoscopy at the 
time when endometrial flushing is planned  
 Women being treated for a current genital tract infection (these women 
will be eligible for inclusion once treatment of the infection has been 
completed). 
Some of the exclusion criteria were to ensure that we do not cause harm to an 
on-going pregnancy or exacerbate genital tract infection. Other exclusion criteria 
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were developed for patient safety using summary of products characteristics of 
enoxaparin (see other appendices).   
4.2.9 Withdrawal Criteria: 
 
 Women may voluntarily withdraw from the study at any stage. 
 Women may be withdrawn if they should have been excluded from the 
study initially. 
 
4.2.10 Randomisation:  
 
Patients will be allocated study number on a sequential basis. Computer 
software will be used to generate random numbers which will allocate each 
study number to a treatment group. 
 
4.2.11 Allocation Concealment: 
 
This will be done with opaque numbered envelopes. This method will be used for 
allocation concealment in accordance to study numbers. 
 
4.2.12 Blinding: 
 
Patients and outcome assessors will be unaware of the treatment group.  
However, the clinicians will be aware of treatment allocation in the interests of 
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patient safety. The effects of LMWH can be partially reversed with protamine 
sulphate, hence the clinicians administrating the drug will be unblinded so that 
prompt action can be taken in the case of bleeding. Laboratory staff as the 
outcome assessors will be blinded to the intervention or control groups. 
 
4.2.13 Study Centre: 
 
The study will be conducted at University of Warwick. The patients will be seen 
in the outpatients department at Centre of Reproductive Medicine at UHCW, UK.  
 
4.2.14 Study Sponsor: 
 
University of Warwick (Sponsor Study ID: HEP001QUEN).  
 
4.2.15 Study Funder:  
 
Biomedical Research Unit (BRU), University of Warwick  
 
4.2.16 Interventions: 
 
All women were offered oral analgesia (paracetamol or codeine) 1 hour prior to 
interventions (endometrial flushing and endometrial biopsy).  
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4.2.17 Stability Data for Enoxaparin: 
 
Enoxaparin will be diluted with 4ml of sodium chloride 0.9% (normal saline) prior 
to administration for immediate use prior to administration. The supporting 
stability data from Sanofi-Aventis (manufacturer of Enoxaparin-Clexane) is 
provided. See Appendix 5. 
 
4.2.18 Administration Method of Treatment Arm: 
 
Pharmacy will supply enoxaparin (as per the sample drug label – see Appendix 6) 
as the 20mg/0.2ml undiluted pre-filled syringe.  
Using an aseptic technique the clinician will add the contents of an enoxaparin 
20mg pre-filled syringe to an empty sterile 5ml syringe and then dilute this by 
drawing up 4ml of sterile sodium chloride 0.9%. The prepared solution is for 
immediate use and will be administered into the endometrial cavity under 
ultrasound guidance with hysterosalpingo-contrast-sonograpghy (HyCoSy) 
catheter (Rocket Medical Ltd).   
 
4.2.19 Administration Method of Control Arm: 
 
Pharmacy will supply sodium chloride 0.9% (as per the sample drug label – see 
Appendix 6), which is commercially available as 10ml plastic ampoules.  Using an 
aseptic technique the clinician will draw 4ml of sterile sodium chloride 0.9% into 
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an empty sterile 5ml syringe. The prepared solution is for immediate use and will 
be administered into the endometrial cavity under ultrasound guidance with 
HyCoSy catheter (Rocket Medical Ltd).   
 
4.2.20 Treatment for Heparin Toxicity: 
 
If any adverse events or serious adverse events occur, these will be reported to 
the chief investigator, see Appendix 7.  
Specifically, if haemorrhage occurs, the anticoagulant effects of enoxaparin can 
be largely reversed by intravenous protamine sulphate. The available data 
suggest that in the first 8 hours after enoxaparin administration 1 mg of 
protamine sulphate should neutralise the effects of 1mg of enoxaparin. The 
clinicians will consider that in a non-pregnant woman the amount of enoxaparin 
in the body is reduced to 50% after 8 hours and 33% or less after 12 hours. The 
dose of protamine sulphate should be adjusted depending upon the length of 
time since the enoxaparin was administered. If protamine sulphate is required, 
all treatments will be discussed with the Consultant Haematologist at UHCW. 
 
4.2.21 Dispensing and Accountability: 
 
Dispensing will be done using a trial specific prescription (see Appendix 8). For 
this study enoxaparin and sodium chloride 0.9% as placebo are both being used 
as an investigational medicinal product (IMP) (see Appendix 6). 
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Dispensing of enoxaparin 20 mg and sodium chloride 0.9% will be done by 
pharmacy department of UHCW. Both enoxaparin and sodium chloride 0.9% will 
be taken from commercially available stock. The pharmacy department will 
maintain accountability logs for enoxaparin and sodium chloride 0.9% used in the 
trial. Accountability logs will record the manufacturer, batch number, expiry date 
and the patient’s trial number, to allow traceability of the stock issued within the 
trial. Pharmacy will be responsible for the labelling of the IMP. 
The labelling of IMP will be in accordance with Volume 4 of Good Manufacturing 
Practices, Annex 13 (Manufacture of investigational medicinal products) 
(Eudralex, 2003). 
All records will be maintained in accordance with current Good Clinical Practice 
(GCP) and in line with the Medicines for Human Use (Clinical Trials) Regulations 
2004.  
 
4.3 Assessment and Follow Up: 
 
All participants will be assessed 4 hours and 24 hours after endometrial flushing 
of LMWH or normal saline 0.9%. Anti-Xa levels will be checked at 4 hours. FBC 
and LFTs will be checked 24 hours after endometrial flushing. Participants in both 
groups will have an endometrial biopsy obtained 24 hours after the endometrial 
flushing procedure.  All endometrial biopsies will be performed by study 
clinicians. Participants will have a telephone follow up 14 days after obtaining 
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endometrial biopsy and asked to complete a non-validated participant 
questionnaire (see Appendix 9). The participants can contact the research study 
team 24 hours a day 7 days a week by telephone. We will seek information from 
the participants regarding any future treatment outcomes once participated in 
the study. 
 
4.3.1 Loss to Follow Up: 
 
If participants do not arrive for their follow up, letters will be sent and telephone 
calls will be made. If we are still unable to contact them, we will contact their 
General Practitioner (GP) by telephone and letter. Participants’ GPs will already 
be aware about their patients’ participation in the study as per the GP letter (See 
Appendix 4).  
 
4.4 Trial Closure: 
 
Trial will be closed after the recruitment of 40 participants in total. The trial will 
be closed early if there is any mortality or significant morbidity due to the 
treatment. 
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4.5 Safety Considerations: 
 
1. Patients will be able to contact the hospital 24 hours a day 7 days a week. 
A member of the team will be available. Protamine sulphate will be 
available 24 hours 7 days a week. 
2. Anti-Xa level, FBC and LFTs will be reviewed by the study team and 
appropriate action will be taken if any abnormalities are detected. Dr 
Chapman, Consultant Haematologist at UHCW will review these results if 
there are any concerns.  
3. The administration and sampling techniques which will be performed in 
the study are used regularly by investigators at the Centre of 
Reproductive Medicine with minimal complications. These comprise of 
ultrasonography, endometrial flushing with the use of HyCoSy catheter 
and performing an endometrial biopsy. 
4. We are using a thromboprophylactic (enoxaparin 20 mg- 2000IU) rather 
than therapeutic dose of LMWH, even if it is systemically absorbed 
completely, it is unlikely to cause bleeding. 
5. Endometrial flushing will be performed in non-pregnant women in a cycle 
when they are not trying to conceive. All patients will be advised to use 
non spermicidal barrier contraception and a pregnancy test will be 
performed prior to any procedure. 
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4.6 Sample Size Calculation: 
 
For this pilot study the sample size was determined following discussion with the 
statistician Professor N Stallard (Professor and Head of Statistics and 
Epidemiology Department, University of Warwick). He calculated that 
95% Confidence interval widths for two-arm randomised study in subgroup with 
20 patients per arm 
Endpoint                         95% Confidence interval width                                      
Uterine NK cells                        9.642 
IGFBP1                                  0.05960 
PRL                                          0.01525 
  
In terms of power for a statistical test, for the two arm comparative study, a test 
will have 90% power to detect a difference between the two groups of one half 
of the confidence interval width. Thus we will have 90% power to detect a 
difference between the two groups of 4.82% in the uNK cell density test. 
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4.7 Data Analysis: 
 
Analysis will proceed in the following steps: 
1. Summary statistics for demographic information relating to the allocation 
groups will be tabulated. The data will be examined to determine the 
extent to which the treatment and placebo groups are similar. 
2. The primary outcome will be assessed in each group. This will be 
expressed in a table and graph format. It will include the median and 
range of each group. 
3.  All adverse events will be reported according to allocation group. 
4. Secondary outcomes including anti-Xa level, blood haematology and 
biochemistry and side effect reporting (telephone follow up and side 
effect diaries) will be presented in a tabulated form.   
Data and all appropriate documentation will be stored for a minimum of ten 
years after the completion of the study, including the follow up period. Graph 
pad and Microsoft Excel software will be used to interpret results when required.  
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4.8 Reporting Procedure: 
 
All adverse events (AEs) will be reported to the chief investigator. She will then 
forward these to the MHRA, Trust R&D Office, and the Research Ethics and 
Governance Manager within Warwick Medical School, University of Warwick. See 
Appendix 7. 
 
4.9 Ethical and Regulatory Issues: 
 
Approval to conduct the trial has been granted from the West Midlands Research 
Ethics Committee (NRES Reference: 12/WM/0347) and MHRA (24637/0004/001-
0001). See Other Appendices.  The trial is registered with European and 
international Clinical trials database (EUDRACT No: 2012-003682-18). The study 
will be conducted in accordance with the recommendations for physicians 
involved in research on human subjects adopted by the 18th World Medical 
Assembly, Helsinki 1964 and later revisions. 
 
4.10 Patient Acceptability and Consent 
 
Women who meet the inclusion criteria will be informed about the study 
objectives and they will be given a written patient information sheet (Appendix 
1-3). All participants will have voluntarily consented prior to enrolment. Consent 
to participate in the study will be sought from each participant after a full 
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explanation has been given, an information leaflet offered and sufficient time 
allowed for consideration (minimum 24 hours). Signed participant consent will 
be obtained by the trial investigators prior to participation in the study. The right 
of the participant to refuse to participate without giving reasons must be 
respected. All participants are free to withdraw at any time from the protocol 
treatment without giving reasons and without prejudicing further treatment. 
Potential participants will be made aware by the research team and the 
information sheet that participation is entirely voluntary and that their decision 
whether or not to participate in the research has no bearing upon their 
treatment or care.  
 
4.11 Data Monitoring: 
 
The chief investigator will be responsible for adhering to the protocol. As this is a 
single site trial, direct supervision by the chief investigator will ensure a high 
standard of care for the participants. 
The day to day management of the trial will be coordinated by the investigators 
based at the Clinical Sciences Research Laboratories, University of Warwick 
including review of AEs, serious adverse events (SAE) and serious unexpected 
serious adverse reactions (SUSAR). They will also look at the safety data (side 
effect diaries, anti- Xa levels, FBCs, LFTs).  
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4.12 Trial Status: 
 
The study started in January 2013 and recruitment of all 42 participants was 
completed in July 2013. A flow diagram of the study is illustrated in Figure 4.1. 
This explains the process each study participant will undertake if they consent to 
participate in the trial. 
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Figure 4.1: Flow Diagram of the study 
 
  
Inform patient about the study in Implantation , reproductive medicine and 
recurrent miscarriage  clinics. Patient provided with patient information sheet and 
consent form in the clinic. Vaginal swabs will be done if no results available before. 
Patient will inform chief investigator/study team by telephone or email 
when she ovulates as determined by the use of a urinary LH Kit at home 
during the study month. This will confirm her participation in the study. 
Appointment at implantation clinic 5-7 days later after ovulation. 
She will provide the signed consent form. We will perform a 
pregnancy test. Study number will be generated. She will be given a 
study number and randomised accordingly to either treatment or 
placebo group. Endometrial flushing will be performed. Side effect 
diary will be provided. 
Anti-Xa level blood test will be done 4 hours after enometrial 
flushing. 
Appointment at implantation clinic 24 hours later for endometrial 
biopsy. Blood test to check FBC and LFTs will be done at the same 
time. Participant questionairre provided. 
Telephone follow up 14 days later 
Patient questionaire and side effect diaries to be returned by post in prepaid 
envelopes after the telephonic follow up. 
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Chapter 5 
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5.0 Results of Endometrial Flushing of Low Molecular 
Weight Heparin to Improve Decidualisation- A Prospective 
Randomised Controlled Pilot Study: 
 
5.1 Introduction: 
 
As discussed in Chapter 3, a Cochrane systematic review (Akhtar et al., 2013) 
reported that the administration of LMWH during ART may improve clinical 
pregnancy and live birth rates. The suggested biological mechanism for this 
improvement is modulation and optimisation of embryo apposition, adherence 
and implantation, and trophoblast differentiation and invasion (Nelson & Greer, 
2008). Daily LMWH administration is associated with side effects that include 
patient dissatisfaction with injecting for long periods of time, genital tract 
bleeding, and swelling, bruising and itching at the injection site (Bohlmann, 
2011). There is one case reported in the literature about a patient who died 
following cerebral haemorrhage who was taking aspirin and heparin in order to 
improve pregnancy outcome (Bohlmann, 2011). 
In view of this, it would be desirable to develop a treatment in which the positive 
effects on endometrial receptivity of LMWH could be utilised without the 
deleterious effects of daily systemic injections. Therefore, our group decided to 
investigate an alternative mode of administration of LMWH. The mode of 
administration was based upon the already well-defined HyCoSy technique. The 
HyCoSy technique is performed to help to determine the patency of the fallopian 
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tubes (NICE, 2013).  A radio-opaque solution is injected into the uterine cavity at 
high pressure while visualising the uterus and fallopian tubes using transvaginal 
ultrasonography (TVS) (see Figure 5.1 & 5.2). If the fallopian tubes are patent, 
the fluid is seen to pass through them into the peritoneal cavity. HyCoSy is well 
tolerated by patients (Marci et al., 2013). 
For our study, we hypothesised that we could improve decidualisation by 
administering a single dose of LMWH directly into the uterine cavity.  Figure 5.1 
shows the HyCoSy catheter used and Figure 6.2 illustrates the HyCoSy technique.  
We successfully developed a method for human intrauterine flushing, allowing 
targeted treatment to the endometrium during the implantation window, whilst 
reducing the potential for side effects seen with systemic administration.  This 
method was assessed in terms of patient acceptability of the technique, 
including any reported side-effects.  Endometrial samples were collected and the 
primary outcomes measure of NK cell density assessed.  
 
Figure 5.1: Hycosy Catheter (Rocket Medical plc. used with permission) 
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Figure 5.2: Hycosy Technique Illustration (Rocket Medical plc. used with permission) 
 
5.2 Methods: 
 
Forty two participants with either, one or more unsuccessful ART cycles, or a 
history of recurrent miscarriage were recruited from the UHCW implantation, 
reproductive medicine and recurrent miscarriage clinics, between January 2013 
and July 2013. Written information in the form of patient information sheets 
were provided to all patients (see Appendix 1).  Those who wanted to take part 
and thought that they met the eligibility criteria then had high vaginal and 
endocervical swabs to exclude asymptomatic pelvic infections and completed an 
eligibility questionnaire.  
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Eligible women were randomly allocated to the control or treatment group and 
followed the protocol described in chapter 4.   
Participants were asked to monitor their LH levels daily with an ovulation kit and 
to contact us by telephone or email when the test became positive. The flushing 
procedure was scheduled 5-7 days after the LH surge in order to occur within the 
implantation window. All women signed a written consent form (see Appendix 2) 
to participate in the study. 
As mentioned, our technique was based on the already established HyCoSy 
procedure (Figure 5.1 & 5.2). An important difference was that the fluid 
(enoxaparin or placebo) was administered into the uterus slowly by an assistant 
with minimal force so that the flush did not enter the fallopian tubes but 
remained within the uterine cavity for 4 minutes. Each intrauterine flushing 
procedure was monitored using TVS.  
A clinician and an assistant were present for each intrauterine flushing. Each 
flush was 4ml, drawn up in a 5ml syringe as discussed in Chapter 4.2.18 and 
4.2.19. The participant was positioned in the lithotomy position, sedation was 
not required. TVS was performed prior to the flushing for several reasons. Firstly, 
to determine the flexion, size and shape of the uterus, secondly to measure the 
endometrial thickness and thirdly to rule out any obvious uterine pathology such 
as endometrial polyp, submucosal fibroid and adenomyosis. The cervix was 
visualised using a Cusco’s vaginal speculum and cleaned with 0.9% sodium 
chloride using a cotton wool ball or gauze swab mounted on a Rampleys sponge 
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holding forceps. A Hycosy catheter (Rocket Medical Ltd- see Figure 5.1) was 
passed through the cervix to the 5cm mark, using a sterile Rampleys sponge 
holding forceps to gently guide its passage if required. The catheter balloon of 
the HyCoSy catheter was inflated with 1ml of 0.9% normal saline and the Cusco’s 
speculum carefully removed. A TVS was used to confirm the correct position of 
the catheter and to monitor administration of the flush to ensure it did not pass 
through the fallopian tubes and remained in the uterine cavity. The flush was 
then slowly and gently injected into the uterine cavity over 2 minutes (rate of 
2mls/minute). Using this direct visualisation technique, the fluid was seen to be 
absorbed from the uterine cavity but not to enter the pelvis via fallopian tubes. 
Figures 5.3-5.6 illustrate two participants’ images prior and during the 
intrauterine flushing procedure.  
 
Figure 5.3: Endometrium prior to flushing procedure (participant 1) 
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Figure 5.4: Endometrium showing presence of hycosy catheter balloon and flushing 
fluid (participant 1) 
 
Figure 5.5: Endometrium prior to flushing procedure (participant 2) 
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Figure 5.6: Endometrium showing presence of flushing fluid after removal of Hycosy 
catheter (participant 2) 
 
Following intrauterine flushing, the TVS probe was removed, the catheter 
balloon deflated and the HyCoSy catheter removed.    
Participants remained in the Centre for Reproductive Medicine, UHCW for 5-20 
minutes following the procedure and left once comfortable. Side effects diaries 
and questionnaires with pre-paid envelopes were provided to all participants on 
the day of intrauterine flushing. As mentioned in Chapter 2, all women had an 
anti-Xa level blood test four hours after the endometrial flushing. Participants 
attended 24 hours later for endometrial biopsy which was obtained in presence 
of chaperone by Wallace catheter. FBC and LFTs were checked at that visit. A 
follow up telephone consultation occurred two weeks later to collect information 
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about period heaviness, duration and pain, any other side effects noted and 
patient acceptability. Participant questionnaire (see Appendix 9) and side effects 
diaries were sent back to the study team in the prepaid envelope provided. 
Participating women then underwent fertility treatments including ART if they 
wish to after the study.  
 
5.3 Results: 
 
We screened 66 women to participate in the study. Forty two women were 
eligible to participate. Forty two participating women were randomised. Two 
women were excluded. It was not possible to pass the HyCoSy catheter through 
the cervix due to cervical stenosis in one participant. The other excluded 
participant had adenomyosis within uterus so decided not to proceed due to risk 
of bleeding after intrauterine flushing of heparin.   
 
5.3.1 Participant’s Demography: 
 
Participants’ age, parity, BMI and reproductive history in both control and the 
treatment groups are shown in Table 5.1. A student t test was undertaken for 
statistical analysis.  All groups were similar for other demographic data except 
women with recurrent miscarriages in both groups. Women in control group had 
a higher number of miscarriages compared to the treatment group. However, 
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the total number of women in both groups was five (3 in control and 2 in 
treatment group). BMI was also raised in women with recurrent miscarriages 
compared to women with subfertility.  
 Control group  
(normal saline 0.9%) 
(n=20) 
Treatment group  
(enoxaparin) 
(n=20) 
Previous unsuccessful IVF/ICSI 17 18 
Recurrent miscarriage 3 2 
Age (years): mean+- SD (range) 33.7 +- 5.80 (24-43) 33.5+-4.88 (25-42)      p<0.96 
Parity: mean+- SD (range) 0.25 +- 0.71 (0 – 3) 0.2 +- 0.41 (0 - 1)         p<0.78 
BMI (Kg/m2): mean +- SD 
(range all patients) 
(range for IVF patients) 
26.74 +- 5.96 
(17-43) 
(17-36) 
25.74 +-5.87                 p<0.59 
(20-45)  
(20-33)      
Duration of subfertility (years): 
mean +- SD (range) 
 
2.91+- 1.54 (1-7) 
 
3.47 +- 1.73 (2-8)        p<0.38 
Previous number of IVF/ICSI 
attempts: mean+- SD (range) 
 
2+- 1.45 (1-6) 
 
1.58 +- 1.06 (1-4)        p<0.35          
Embryos transferred per cycle: 
mean +- SD (range) 
 
1.82 +- 0.39 (1-2) 
 
1.65 +- 0.58 (1-2)        p<0.30 
Number of miscarriages in 
IVF/ICSI patients :  
Mean +- SD (range) 
 
 
0.35 +- 0.60 (0-2) 
 
 
0.27 +- 0.46 (0-1)        p<0.68 
Number of miscarriages 
recurrent miscarriage patients: 
mean +- SD (range) 
 
 
7 +- 1 (6-8) 
 
 
3.5 +- 0.70 (3-4)           p<0.02 
Endometrial flushing day (LH+): 
mean +- SD (range) 
 
5.85 +- 0.74 (5-7) 
 
6.2 +- 0.95 (4-7)           p<0.20 
Endometrial biopsy timing 
(hours after flushing):  
mean +- SD (range)   
 
 
24.17 +-  1.54 (20.27) 
 
 
24.05 +- 2.08 (20-30)  p<0.83 
 
Table 5.1: Participants demographic Table 
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5.3.2 Primary Outcome: 
  
The uNK cell density obtained after the intrauterine flushing in both groups is 
shown in Table 5.2 with a graph. There was no difference in uNK cell density 
count density in both groups.  
 Control group 
(normal saline 
0.9%) (n=20) 
Treatment group 
(enoxaparin)  
(n=20) 
Uterine Natural Killer cells (%) median  
(range) 
5.34  
(2.13-19.73) 
4.61 
(1.17-16.33) 
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Table 5.2 with graph: showing Uterine NK cell levels in control and intervention group 
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5.3.3 Secondary Outcomes: 
5.3.3.1 Adverse Events 
 
There were no AEs reported during or after the study by participants. 
 
5.3.3.2 Anti-Xa Assay Level Results: 
Anti-Xa assay levels obtained 4 hours after the intrauterine flushing in both 
groups are shown in Table 6.3 with the graph below. 
 Control group (normal 
saline 0.9%)  
(n=20) 
Treatment group 
(enoxaparin)  
(n=20) 
Anti-Xa level (IU/ml) median (range) 
Mean  
0.10 (0.02-0.014) 0.14 (0.03-0.33) 
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 Table 5.3 with graph: showing anti-Xa levels in control and intervention group 
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Anti-Xa levels were significantly higher in the treatment group when compared 
to control group.  
 
5.3.3.3 Blood Haematology and Biochemistry Results: 
 
Blood haematology and biochemistry results including FBC and LFTs obtained 24 
hours after intrauterine flushing for safety of LMWH administration are shown in 
Table 5.4. 
Test Control group  
(normal saline 0.9%)  
(n=20) 
Treatment group 
(enoxaparin)  
(n=20) 
Haemoglobin (g/dL): median 
(range) 
13.25 (9.8-14.7) 13.65 (12.3-14.8) 
White cell count (x 109/L): median 
(range) 
7.71 (5.61-12.14) 7.45 (4.83-12.94) 
Platelet count(x 109/L): median 
(range) 
277 (206-420) 265.5 (123-345) 
Bilirubin (μmol/L): median (range) 8 (5-24) 8.5 (3-18) 
Albumin (g/L): median (range) 47 (42-49) 46 (43-52) 
Alkaline phosphatase (ALP) (U/L): 
median (range) 
58 (42-109) 62 (39-98) 
Alanine aminotransferase (ALT) 
(U/L): median (range) 
17 (8-35) 15 (8-27) 
 
Table 5.4: Blood biochemistry results in the study groups. 
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There were no differences in blood platelet count or liver function tests after 
single intrauterine flushing with a dose of 20 mg enoxaparin. 
 
5.3.3.4 Participant Questionnaire and Side Effect Diary Outcome: 
 
Participant reporting of pain, vaginal spotting, effect on next period and other 
side-effects were collected at the two-week telephone review, from the side 
effect diaries and the patient questionnaire.  A summary of these are shown in 
Tables 5.5 and 5.6. 
 Control group  
(normal saline 0.9%) 
(n=20) 
Treatment group 
(enoxaparin)  
(n=20) 
Diaries/questionnaires returned n=15 n=11 
Pain following flushing? 
Yes (mild, significant) 
No 
 
6 (4,2) 
9 
 
4 (2,2) 
7 
Pain following biopsy? 
Yes (mild, significant) 
No 
 
13 (6,7) 
2 
 
9 (5,4) 
2 
Spotting? 
Yes 
No 
 
11 
4 
 
7 
4 
 
Table 5.5: Table showing patient recorded outcomes from side-effect diaries and 
participant questionnaire 
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 Control group 
 (normal saline 0.9%)  
(n=20) 
Treatment group 
(enoxaparin)  
(n=20) 
Telephone follow-up (two weeks 
post endometrial biopsy) 
n=20 n=20 
Bruising or bleeding other than 
vaginal 
Nil Nil 
Pain 
Yes 
No 
 
13 
7 
 
7 
13 
Median pain score (range) 0 (0-5) 0 (0-6) 
Analgesia required 
Yes 
No 
 
6 
14 
 
6 
14 
Period length 
Shorter  
Normal 
Longer 
 
4 
14 
2 
 
1 
8 
11 
Period strength 
Lighter  
Normal 
Heavier 
 
2 
14 
4 
 
0 
4 
16 
 
Table 5.6: Table showing patient recorded outcomes from telephone follow-up (two 
weeks after intrauterine flushing and endometrial biopsy) 
 
All patients had a two week telephone follow-up interview, during which they 
were asked about spotting, pain and the length and heaviness of their period 
following the procedures. From these interviews, the majority of participants in 
both the treatment and the control groups reported no pain following the 
124 
 
flushing procedure. Most of the treatment group and most of the control group 
reported spotting following the procedures. There was no significant difference 
between the reported pain scores or vaginal spotting between the control and 
treatment groups.  
As shown in Table 5.5 and 5.6, participants recorded greater levels of pain in 
their side effect diaries when compared with the telephone consultation. 
However, the side effect diaries were returned by a smaller number of 
participants, but from these diaries we were better able to distinguish between 
pain following flushing and pain related to the endometrial biopsy.  The majority 
of pain reported was associated with the endometrial biopsy rather that the 
intrauterine flushing. No significant side effects were reported and no AEs 
occurred. Comments in the side effects diaries included: "was made to feel very 
special" "no negative comments" "no pain" "mild spotting for a few days after" 
“flushing: slight stomach cramps” Spotting after biopsy” "only pain during 
biopsy" "straight forward and easy". 
35/40 endometrial flushing procedures were technically easy (one attempt), 
4/40 difficult (two attempts) and 1/40 was very difficult with more than two 
attempts.  
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5.3.3.5 Decidualisation Markers: 
 
Further work which is beyond the scope of this thesis will be performed on the 
stored samples for DNA, RNA and protein studies examining PRL, L-selectin, HB-
EGF, EGF, IGFBP1 and SGK1. Endometrial stromal cell cultures are required to 
test for majority of these markers. 
 
5.3.4 Outcome of Participants after Study Participation: 
 
Figures 5.7 and 5.8 show the outcomes collected for both the control and 
treatment groups within one year of participating in the study.   
 
 
Control group 
- 20  
Recurrent 
miscarriage - 3 
Positive - 1 Live birth -1 
Negative - 2 
Subfertility - 
17 
ART - 11 
Positive - 4 
Live birth - 3 
Miscarriage -1  
Negative - 7 
IUI - 1 Negative 1 
No ART - 3 
No 
information - 2 
PT 
PT 
PT 
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Figure 5.7: Control group: Outcome of study participants within 1 year of taking part in 
study. 20 patients in total, 3 patients with recurrent miscarriages and 17 with 
subfertility.  PT: pregnancy test 
 
 
Figure 5.8: Heparin group: Outcome of study participants within 1 year of taking part 
in study. 20 patients in total, 2 patients with recurrent miscarriage and 18 with 
subfertility.  PT: pregnancy test 
 
5.4 Discussion:  
 
Overall, the intrauterine flushing procedure was well tolerated by participants. 
This is highlighted by the positive comments recorded in the side effects diaries. 
Where pain was reported, it was mainly associated with the endometrial biopsy 
which is known to be uncomfortable and would not necessarily be performed if 
intrauterine flushing was used as a treatment. Therefore, the procedure itself 
Heparin group - 
20  
Recurrent 
miscarriage - 2 
Positive - 2 
Live birth - 1 
Miscarriage - 1 
Subfertility - 18 
ART - 12 
Positive - 7 
Live birth - 4 
Miscarriage -3  
Negative - 5 
IUI - 1 Negative 1 
No ART - 3 
No information 
- 2 
PT 
PT 
PT 
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could be said to be well tolerated. The difference in reporting of side effects 
when comparing the two week telephone consultation with the side effect 
diaries may be due to recall bias or the participants not feeling comfortable 
making negative comments to the research team. This highlights the importance 
of the side effect diaries. 
Importantly, those in the treatment group had higher anti-Xa levels 4 hours post 
intrauterine flushing compared to the control group, indicating that the 
enoxaparin was absorbed via the endometrium which was surprising.  
There is a clear biological effect seen, significantly more of the participants in the 
treatment group reported a longer and heavier period than normal following the 
intrauterine flushing. This again supports the suggestion that the enoxaparin had 
a direct effect on the endometrium. It also suggests that the LMWH was 
absorbed by the endometrium even though exposure to the drug was only 4 
minutes. This suggests that during the implantation window, the endometrium 
has the ability to absorbed drugs very rapidly and is thus a sensible therapeutic 
target. 
There was no difference observed in the primary outcome measure of uNK cell 
density between the two groups. The uNK cell density count was performed as 
described by Professor Quenby (Kuroda et al., 2013). There are several possible 
reasons for this; enoxaparin may not effect decidualisation, selection bias, the 
included study population with extremes of BMI could have influenced the 
result, the study was not adequately powered to detect subtle differences, there 
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was only 24 hours between intrauterine flushing and obtaining the endometrial 
biopsy and this may not have been a sufficient time to measure any effect.   
Endometrial flushing has been used in the past to assess improvement in 
implantation and pregnancy rates. Li, Mackenna & Roberts, 1993 reported a case 
series of 90 patients suggesting that uterine flushing is a safe, simple procedure 
and causes less discomfort than endometrial biopsy. Lédée-Bataille et al., 2002 
analysed uterine flushing for LIF and TNF to predict pregnancy outcomes. 
Olivennes et al., 2003 reported in a prospective study that uterine flushing at the 
time of egg collection is not associated with adverse pregnancy rates.  A 
prospective randomised study Berkkanoglu et al., 2006 reported that direct 
flushing of endometrial cavity with culture media just after cervical irrigation at 
the time of embryo transfer had no beneficial effects on implantation and 
pregnancy rates. During this study 0.4 mls of embryo culture media was flushed 
into the endometrial cavity with an embryo transfer catheter under ultrasound 
guidance. Embryo transfer was performed soon afterwards. There was no 
improvement in outcome with this intervention. A case report Ogasawara & 
Aoki, 2000 reported uterine steroid therapy before ovulation for a woman with 
previous ten unexplained miscarriages led to a successful pregnancy. Thus 
suggesting medications could be delivered by endometrial flushing to achieve 
improved pregnancy outcomes. Mostly published studies focussing upon uterine 
flushing are used to analyse cytokine presence in the uterine cavity to predict 
pregnancy outcomes. 
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It is becoming increasingly clear that successful implantation is dependent upon 
a favourable embryo-endometrial interaction. However, there are few 
interventions available to improve the endometrial part of this critical interaction 
with the exception of the increasing utilised endometrial biopsy prior to ART 
(Nastri et al., 2011).  We have described the potential for a novel way to 
administer drugs directly to the endometrium. This method does result in 
biological and clinical effects, allowing for potential administration of a single 
dose of a drug, prior to ART. This is distinct from systemic drug administration 
which has the potential to reduce side effects of the drug. 
 
5.5 Conclusion: 
 
This is one of the few RCTs to evaluate intrauterine flushing of a medicinal 
product.  Our study findings show that endometrial flushing is a safe, simple 
feasible, well tolerated technique which can be used to deliver medications 
directly to the endometrium. The procedure is well tolerated by patients. There 
were no adverse events in the study. Minimal side effects were reported.  
The primary outcome measure (uNK cell density) was observed to be no different 
in both groups, however a larger sample size study (Phase 2) is needed to 
confirm or refute this. There could be various possible reasons for this result 
mainly relating to the methodology.  
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Firstly, included women in the study were heterogeneous as it included two 
distant groups, subfertile women, and women with recurrent miscarriages. This 
could have led to selection bias may have attributed to a negative result. Both of 
these groups of women were included in the study to improve recruitment for 
the study, there were concerns that we may not be able to recruit women for 
this novel method in which there is no direct beneficial effects upon patient 
outcomes. However, the study recruitment was completed within six months. 
Secondly, uNK cell density was counted as described by Professor Quenby 
previously (Kuroda et al., 2013).  UNK cell density assessment by Professor 
Quenby’s method did correlate with laboratory markers of decidualisation 
(Kuroda et al., 2013). There are other methods of counting NK cell density and 
there is no consensus about the best method of counting uNK cell density (in 
numbers or percentages) as described in this systematic review and meta-
analysis (Sheshadri et al., 2014).  This also suggested that there is not a 
significant difference in live birth rates in women with increased NK cells 
compared with women without increased NK cells but the test should be offered 
in context of the research settings (Sheshadri et al., 2014). However, Professor 
Quenby’s method of uNK density assessment did appear to predict pregnancy 
outcomes (Tang et al., 2013). But the use of a surrogate marker for 
decidualistaion (uNK cell count) cannot replace the clinical outcomes of 
implantation, clinical pregnancy and live birth.  
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Thirdly, the endometrial biopsy was obtained 24 hours after intrauterine flushing 
suggesting that there may not been enough time to see an effect in the uNK cell 
density or stromal cell decidualisation. Endometrial biopsy for uNK cell density 
was done 5-8 days after ovulation (around day 19-22). It has been established 
that uNK cell count increases from 5% in early secretory phase of the menstrual 
cycle to more than 35% in the premenstrual endometrium. So the optimal time 
to count uNK cell density is before 23 of the menstrual cycle as from day 23 uNK 
density continue to increase (Russell et al., 2011). Endometrial biopsy was taken 
at the appropriate time but there was only a 24 hours interval from intrauterine 
flushing to endometrial biopsy, this may have contributed to the result of no 
difference in the primary outcome.  
Fourthly, in this pilot study we compared intrauterine flushing of LMWH with 
intrauterine flushing of normal saline 0.9%. Both interventions caused a 
mechanical disruption of the endometrium regardless of any pharmacological 
effect. This mechanical disruption might have attributed to this negative result in 
the primary outcome. On further consideration, there should have been three 
groups compared. The third group of participants would have no intervention of 
intrauterine flushing prior to endometrial biopsy. The result from those 
participants in the third group would have informed us if any mechanical 
disruption of the endometrium with intrauterine flushing was influencing the 
primary outcome.   
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The recruitment for the study was achieved with in six months. Women were 
willing to participate and there were no major adverse events during the study. 
Intrauterine flushing of LMWH has a pharmacological and biological effect. The 
majority of participants underwent ART after taking part in the study and of 
those, there have been nine live births.   
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   Chapter 6 
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6.0 Conclusion: 
 
Worldwide, most couples can achieve pregnancy naturally but some are unable 
to do so.  In the UK it is estimated that one in seven couples experience 
subfertility at some point in their reproductive life. This causes a great deal of 
stress, anxiety and unhappiness. Human fecundity is poor; at best natural 
conception per cycle is 25 %.  This reduces further with increasing female age.  
Additionally, 20-25 % of pregnancies end with miscarriage. In the UK, the number 
of children born per family has decreased over the recent few decades. The 
number of live births in the UK decreased by 4.3% from 2012 to 2013 with 729 
674 live births in 2012 and only 698 512 in 2013 (Office of National Statistics, 
2013). Society is adapting with changes in life styles.  As we all are working for 
more years and living longer. Life has become more sedentary with use of 
technology,  more focus on our careers and changing eating and exercise habits.   
This has led to increase in male and female subfertility in the developed world 
including the UK. All women will lose the ability to have their own biological child 
as they reach the menopause.  Currently, there are no tests to confirm fertility 
and fertility treatments fail more often than they succeed. 
Since the birth of the first IVF baby in 1978, ART has revolutionised the 
management of the subfertile couple. Many innovations in the field of 
reproductive medicine have led to improvements in embryo culture, selection of 
good quality embryos (usage of time-lapse microscopy) and blastocyst transfer.  
This has led to improvements in the success rates of ART. There have been 
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improvements in the diagnosis and management of conditions associated with 
male and female subfertility. Improving controlled ovarian stimulation during 
ART by individualising each treatment cycle has led to a better yield of oocytes. 
ICSI treatment has enhanced the fertilisation rate in couples where the male 
partner has poor quality sperm.  Surgical interventions in women (salpingectomy 
for hydrosalpinx, removal of submucosal fibroid or endometrial polyp) and men 
(surgical sperm retrieval) prior to ART has contributed to the continued 
improvement in outcomes.   
However, despite these innovations, the success rates of ART are around 20-40% 
although this depends upon the couple’s clinical situation. This means that ART 
fails more often than it is successful. One of the most important factors which 
remains a challenge in improving ART outcomes is to improve endometrial 
receptivity.  
The endometrium is one of the most fascinating tissues in the human body as it 
regenerates each month. The sole purpose of the endometrium is to implant and 
support an early embryo during a small window of implantation (Revel, 2012).  
Implantation is steered by physical, physiological and biochemical contact 
between an embryo and the endometrium. The process of implantation involves 
complex signalling between the embryo and endometrium leading to the 
processes of apposition, adhesion, attachment and penetration. Successful 
implantation involves a harmony in these interactions in the presence of a 
competent embryo and a receptive endometrium. An appropriately receptive 
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and selective endometrium will pave the way for the successful embryo intrusion 
within the endometrial stroma. This is achieved by the interaction between 
trophoblast cells and the endometrium, allowing penetration through the 
luminal epithelium and basal lamina into the stroma. Embryo attachment to the 
luminal epithelium is followed by continued decidualisation of the endometrial 
stroma. So a functional harmonious communication involving embryo, 
endometrial epithelial and stromal cells is necessary for decidualisation, thus 
paving way for successful implantation (Cha, Sun & Dey., 2012).  
Implantation involves various cytokines, chemokines and ovarian steroids. One 
important signalling pathway is HB-EGF mediated, this pathway known to be 
important in the process of decidualisation (Das, 2009). HB-EGF is expressed in 
increasing amounts in the secretory phase endometrium on the surface of the 
pinopodes. The expression of HB-EGF in luminal and glandular epithelium is 
highest when fully developed pinopodes are present. These findings suggest that 
HB-EGF may play a role in both the attachment and penetration steps in the 
human implantation process (Stavreus-Evers et al., 2002).  
Much of the current focus is on improving endometrial receptivity so as to 
improve pregnancy outcomes (Revel, 2012). Medical adjuncts including low dose 
aspirin, LMWH, corticosteroids, immunoglobulins and intralipids have been used 
with the aim of improving endometrial receptivity (Fatemi & Popovic-Todorovic, 
2013). Heparin is the second most commonly used medical adjunct in ART. It is 
believed that heparin improves implantation rates leading to a positive 
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pregnancy test, not by its anticoagulant effect but with by its effect upon 
endometrial decidualisation and embryo apposition, adhesion, attachment and 
penetration. 
A systematic review and meta-analysis of randomised controlled studies was 
undertaken to find the best currently available evidence with the use of LMWH 
in ART. This level 1 evidence (systematic review and meta-analysis) “Heparin for 
Assisted Reproduction” was carried out following the pre-specified, published 
methodology by Cochrane Review Group (Akhtar et al., 2013). We reported that 
peri-implantation LMWH used in ART cycles may improve the clinical pregnancy 
and the live birth rates. However, with only a small number of studies (three 
studies with 386 participants), extrapolation of these findings is difficult. In the 
included studies there was no uniformity of dose and timing or duration of the 
intervention. There was heterogeneity among included studies. Only one study 
used a placebo control. There was performance bias in all studies and detection 
bias in two studies. There were reported side effects of systematic usage of 
heparin with bleeding. The use of heparin in this patient group needs to be 
further investigated with adequately powered, large scale double-blind, 
randomised, placebo-controlled, multicentre trials.  
Previously endometrial secretions obtained from the uterus have been analysed 
for cytokine profiling to assess endometrial receptivity (Boomsma et al., 2009a, 
Boomsma et al., 2009b, Mikolajczyk, Wirstlein & Skrzypczak, 2007). Intrauterine 
flushing of embryo culture media prior to embryo transfer does not adversely 
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affect the outcome as reported by this prospective randomised controlled study 
(Berkkanoglu et al., 2006). Intrauterine injection of hCG with the embryo culture 
media prior to embryo transfer during ART improves the success of ART cycles 
(Mansour et al., 2011, Santibañez et al., 2014). Our study differed from those 
adding hCG to embryo culture media.  We developed an intrauterine flushing 
technique with LMWH as a novel method of administration, to improve 
endometrial preparation for pregnancy. This method resulted in the local 
administration of the drug. Currently, heparin is only licensed for intravenous or 
subcutaneous usage. It is not licensed for intrauterine use.  We therefore needed 
to do a Phase 1 feasibility and patient acceptability study to determine if it is safe 
and acceptable to use this method of administration.  To enable this study to be 
carried out a protocol was written. The study required sponsorship and approval 
by the MHRA UK, NRES and local R&D. Obtaining these approvals was a lengthy 
process. This required individual training (Good Clinical Practice course, Principle 
Investigator course) to undertake this study. This study required multidisciplinary 
collaboration with haematology, R&D, statistician, pharmacy, histopathology, 
gynaecology, reproductive medicine and the manufacturer of LMWH 
(enoxaparin). The study required support from colleagues, administration team, 
healthcare assistants and nursing staff. I wrote all the forms including protocol 
for the study with Professor Quenby and obtained approval from NRES, MHRA 
UK and Local R&D.   Following these approvals recruitment to the study was not 
difficult and achieved within six months. As this was a feasibility study, there 
were 42 participants. Study participants were randomised in to two groups 
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(control and treatment). Both interventions were performed in women during a 
non-conception cycle. Women underwent ART if they wished to after the study. 
Our endometrial flushing technique was based on the HyCoSy technique. An 
endometrial biopsy was obtained 24 hours later. Most women described mild 
pain during endometrial biopsy as expected but found intrauterine flushing 
tolerable.  
Anti-Xa assay levels measured the anticoagulant activity of LMWH. Anti-Xa levels 
were higher in the treatment group when compared to the control group but 
remained in the thromboprophylactic range rather than in the therapeutic range 
for the LMWH. Prior to the study, the research team had previously found that 
uNK cell density could act as a marker of adequate decidualisation (Kuroda et al., 
2013).  Hence the primary outcome of the study was the uNK cell density.  This 
was found not to be different in the two groups.  The women who were in the 
intervention group had a heavier period following flushing than control group 
suggesting a biological effect of enoxaparin. Following the study nine women 
have given birth.  Other secondary outcomes included the measurement of the 
implantation markers PRL, HB-EGF and SGK-1 which will be done in the future. If 
evidence of a positive effect of heparin on decidualisation emerges then a phase 
2 study could be undertaken in the future.  
We have established that endometrial flushing is an acceptable mode of delivery 
of a medication to treat the endometrium. The recruitment to the study was 
successful. Intrauterine flushing is a feasible, well tolerated procedure. No 
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adverse events occurred during the study suggesting intrauterine flushing of 
LMWH is safe. There was pharmacological and biological effects with elevated 
Anti- Xa levels and subsequent heavy periods seen in participants who had 
intrauterine flushing with LMWH compared to those participants who had 
intrauterine flushing with normal saline. The most interesting phenomenon 
witnessed in the study was how quickly the intrauterine flushing fluid was 
absorbed (within 2 minutes of flushing).  Unfortunately, we did not take consent 
for videos in our study so are unable to show this. This could suggest that a luteal 
phase endometrium may be targeted for therapeutic intervention in future.    
I have not obtained evidence that heparin administered this way is beneficial to 
endometrial preparation for pregnancy.  This could be due to heterogeneity of 
the study participants comprised of women with recurrent miscarriages and 
subfertile women. Even subfertile women had only at least one unsuccessful ART 
only. This could have attributed to non-significance between the drug (LMWH) 
and placebo (normal saline) of the primary outcome. Changes in markers of 
decidualistaion does not equate to improvement in live birth rate, so this study 
looked at improving endometrial receptivity for improving implantation. Study 
methodology had only two groups with interventions and both groups had 
intrauterine flushing either with LMWH or placebo. This might have contributed 
to the non-significance of primary outcome. Mechanical disruption of 
endometrium rather than any pharmacological effect could have led to these 
results. We should have another group in the study with no intrauterine flushing 
intervention so to compare with the other two groups. We also could have 
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performed intrauterine flushing one day earlier than we did so that we had 48 
hrs before obtaining endometrial biopsy. This could have given more time to 
detect any effect in the endometrial stroma.   
In future, a multicentre RCT should be undertaken. The RCT (350 participants in 
each group) should compare LMWH with placebo during ART. Subcutaneous 
daily LMWH should be given day after oocyte retrieval until pregnancy test and 
continued until a clinical pregnancy is visualised on ultrasonography. The study 
population for this study should be women with previous unsuccessful ART with 
at least 4 cleavage stage embryos transferred or 2 blastocyst embryos 
transferred).  
In future, intrauterine flushing of LMWH or any other medication (for example 
hCG) should be undertaken in three groups (LMW, placebo and no intervention) 
in a phase 1 study to look at markers of decidualisation. The study population for 
this study should be homogeneous comprised of women with previous 
unsuccessful ART with at least 4 cleavage stage embryos transferred or 2 
blastocyst embryos transferred. There should be at least 48 hrs between 
intrauterine flushing and endometrial biopsy in the study.  
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Appendix 1: Patient Information Sheet 
 
Version 5:  27/10/2012 
 
 
Participant Information Sheet 
 
 
Endometrial Flushing of Low Molecular Weight Heparin Improves 
decidualisation- a prospective randomised control pilot study 
 
Project Reference No:  HEP001QUEN 
Eudra CT Reference No: 2012-003682-18 
ISRCTN78466363 
 
Principal Investigator:  Prof Siobhan Quenby (University of Warwick) 
 
 
You are being invited to take part in a research study. Before you decide whether you 
wish to participate or not, it is important for you to understand why the research is being 
done and what it will involve. Please read the following information carefully and discuss 
it with relatives, friends and your GP, if you wish. If there is anything that is not clear, or if 
you have any further questions, please do not hesitate to ask. Do take time to decide 
whether you would like to take part or not. You may also like to have a copy of a leaflet 
published by Consumers for Ethics in Research (CERES), entitled ‘Medical Research and 
You’, which we can provide on request. This leaflet gives more information about medical 
research and looks at some questions you may want to ask. 
 
If you do decide to participate, please let us know beforehand if you are currently involved 
in another study.  
 
 
What is the purpose of the study? 
Every year in England and Wales there are 700,000 births and thus hundreds of 
thousands of delighted parents. However, many couples are not so fortunate, in the same 
period of time: 15% of couples experience subfertility; 25% (500,000) of conceptions fail 
to implant; 15% (300,000) of pregnancies end in early miscarriage; 2% of couples suffer 
recurrent miscarriages (three or more losses). We have shown previously that failure of 
the lining of the womb (endometrium) to prepare adequately for pregnancy, a process 
known as decidualisation, is an underlying factor in these clinical problems. During 
decidualisation, the womb lining prepares to accept the embryo.  
 
The blood thinning agent, Heparin, has been used in attempts to improve reproductive 
success. Heparin is currently given by daily subcutaneous injections and when given by 
this route causes bruising, pain and occasional bleeding.  
As well as thinning blood, Heparin also has the potential to improve decidualisation by 
acting on factors in the lining of the womb in a way that could improve pregnancy 
outcome. 
We would like to study the effect of flushing heparin directly into the womb prior to 
pregnancy, as this new method of administration should enhance its beneficial effects 
and minimise its adverse effects.  
 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  You need to read this 
information sheet in detail and ask any further questions to the research team.  You are 
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still free to withdraw at any time, without giving a reason.  A decision to withdraw or a 
decision not to take part will not affect the standard of care you receive.  You may find it 
helpful to discuss your decision with someone else. 
 
 
What will happen to me if I take part? 
Your treatment will be the same, whether or not you decide to take part.  You do not need 
to do anything differently.  You will be asked to sign a consent form. 
 
You will be required to have the results of vaginal swabs prior to the study. If any infection 
is found on the vaginal swabs appropriate treatment will be commenced prior to any 
intervention. 
 
If you are eligible and voluntarily agree to participate in the study, you will be asked: 
 To use barrier methods of contraception for the month in which the study 
occurs.  
 To email Principal Investigator Prof Quenby (s.quenby@warwick.ac.uk) or phone 
02476967528 once you have detected ovulation (as assessed by home 
ovulation kit).  
 To attend the implantation clinic 5 to 7 days after ovulation (as assessed by a 
home ovulation kit).  
o At the clinic, you will be randomly allocated to either flushing of your 
womb with low molecular weight heparin OR saline.  
o You will be asked to have a blood test 4 hours after the flushing to 
assess any heparin activity in your blood.  
 To fill in a questionnaire and side effect diary at home.  
 To re-attend clinic 24 hours later for an endometrial biopsy (sampling of lining of 
the womb) together with further blood tests.  
 To take part in a telephone consultation 14 days later to ask about period 
heaviness and duration.  
 To return a questionnaire and side effects diaries in a prepaid envelope back to 
principal investigator. 
 
The lining of the womb, which has been in contact with heparin during the flushing, will be 
shed when you will have your next period. Once the treatment cycle is complete, you do 
not need to use contraception any more.  This study does not restrict your lifestyle and 
you can carry on with all your normal activities. 
 
 
What interventions will take place during flushing and sampling of lining of the 
womb during the study? 
The study will have two groups. You will not be aware that which group you are allocated 
to. 
A small plastic tube (Hycosy catheter) will be passed into the neck of your womb. Four 
mls of normal saline will be gently flushed into the womb cavity for less than two minutes 
with minimal pressure under ultrasound guidance. The ultrasound will enable us to see if 
the infusion has been given slowly and is contained in the womb. 
In the intervention group: The saline will contain the blood thinning agent (low molecular 
weight heparin- Enoxaparin 20 mg/0.2mls)  
In the control group: Saline alone will be used 
 
Do I require pain relief for these visits? 
You do not have to take pain relief but if you wish, you could take Paracetamol 1g orally 
alone or with Codeine Phosphate 30 mg orally, 1 hour prior to the endometrial flushing or 
sampling appointments. 
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What happens to the womb sample you obtained during the study? 
We will analyse your endometrial sample in order to study markers of decidualisation (the 
lining of the womb’s preparation for pregnancy). The decidualisation tests will be done in 
laboratories at the University of Warwick. The researchers working on the samples will 
not know your identity, because the samples will have been coded. 
 
Who would be able take part in this study? 
You will be able to participate if: 
You are 18 years or older but younger than 45 years 
You are able to give informed consent 
You had previous unsuccessful IVF treatment (no live birth after transfer of two good 
quality embryos) or had recurrent miscarriages (3 or more miscarriages) in the past 
 
 
Who would not be able take part in this study?  
You will not be able to participate if: 
You have had unprotected sexual intercourse during the month when the study is taking 
place.   
You have an untreated vaginal infection.  
You are pregnant or Breast feeding  
Your body weight is below 45 kg 
You have any bleeding disorders or you are taking any other blood thinning agents 
(injections or tablets e.g. warfarin) 
You have high blood pressure, stroke, stomach ulcers, diabetes, kidney or liver disease 
You are taking steroid tablets, systemic salicylates, acetylsalicylic acid, NSAIDS including 
Ketorolac, dextran and clopidogrel or any immunosuppressant medications 
You had any allergic reaction previously to any blood thinning agents, Pork, Beef or other 
Animal products 
 
Will my taking part in the study be kept confidential?  
All information that is collected about you during the course of the research will be kept 
strictly confidential and accessible only to authorised staff who already have access to 
your medical records in connection with your clinical care. All research information about 
you will have your name removed so that you cannot be recognised by it. We will store all 
information collected about you in locked cabinets or on password protected computers 
(even if you at any time withdraw from the study) for a length of 10 years. We will also ask 
for your consent to inform your GP that you are taking part in the study. 
 
 
What are the possible risks and disadvantages of taking part? 
There is a risk to pregnancy so if it is possible that you are pregnant you should not take 
part in this study. A urine pregnancy test will be taken to check you are not pregnant. 
Flushing and sampling the lining of the womb may be uncomfortable, but leaves no long 
term effects because your womb lining regenerates every month.  
There is a very small risk of bleeding with the use of heparin. For this reason, we will take 
a blood test 4 and 24 hours after administration. We have an antidote against the blood-
thinning agent that will reverse its effect should bleeding occur. 
There is a very small risk of infection. 
 
What are the possible benefits of taking part? 
There is no immediate medical benefit to taking part, however, the information that we 
gain from this study may help us to treat women in the future.  We do not expect any 
commercially significant results to be gained from this research. It is possible that taking 
an endometrial biopsy may improve the chance of a live birth in a future pregnancy 
however, the medical evidence for this is currently limited and there is no guarantee that 
the biopsy may help.   
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Although there are no benefits to you, the research will lead to new knowledge and we 
expect that this may be of benefit to others in future.  This new knew knowledge may help 
us develop new treatments for problems of infertility, recurrent miscarriage and failures in 
in- vitro fertilisation (IVF).   
 
 
Would any kind of treatment be available once this study has finished? 
This is a preliminary or pilot study so no treatment will be available for participants after 
completion of the study. 
 
Expenses and payments 
The study incurs some extra visits but you will be reimbursed for any extra traveling 
expenses for these visits. 
 
Do I need to make any extra hospital visits? 
Yes.  You are expected to make two hospital visits.  You will also receive a follow up 
telephone call. 
 
Do I need to have any extra blood tests or scans? 
Yes. You need to have extra blood tests and pelvic scans. 
 
Where is the study conducted? 
The study will be conducted at University of Warwick. The patients will be seen in 
outpatients at Centre of Reproductive Medicine at University Hospitals Coventry and 
Warwickshire NHS Trust.  
 
 
What if something goes wrong? 
Complaints:  
If you have any concerns or complaints about this research or staff, please contact Ms 
Nicola Owen, Deputy Registrar, University of Warwick, Research support Services, 
University House, Kirby Corner Road, Coventry CV4 8UW  
Telephone: 02476522785  
Fax: 02476524751  
Email: Nicola.Owen@warwick.ac.uk 
 
For general advice and guidance for NHS, non-staff, Participants:  
Patient Advice and Liaison Service, PALS 
Local contact details can be found on http://www.pals.nhs.uk/ 
 
 
Any Concern or Harm:   
We do not anticipate that this study will cause any harm to you.  However, in the event of 
any adverse effects, please contact us immediately. We are available 24 hours a day, 7 
days a week. You can contact us 
On weekdays from 8 am till 5pm  
Either Professor S Quenby on 02476967528  
Or Dr M Akhtar on 02476964000 Bleep 2730.  
If there are any concerns outside these hours, please contact Gynaecology Emergency 
Room at University Hospitals Coventry and Warwickshire NHS Trust at 02476967000. 
 
The University of Warwick, which is the research sponsor for this study, also holds 
vicarious liability insurance and provides professional indemnity insurance for its 
researchers. 
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How long the study is expected to run for? 
The duration of the study will be 12 months starting from the ethics approval and ending 
at collecting samples from patients. A further 12 months will be required to analyse the 
data. 
 
How will I be informed of the results of the study? 
You will be informed of the results by letter and you will be invited to a patient information 
evening at the end of study. 
 
What happens when the research study stops? 
Any tissue samples collected will be kept for use in this project. The data will be analysed 
and results will be published. 
Only the researchers and specific technical staff at the University will be authorised to 
access the tissue.  All the samples will be anonymous and their labels will be coded so 
you would never be identifiable.  Tissue that is no longer needed for research will be 
destroyed through the normal clinical waste procedures of the University.   
 
It is possible that any stored or fixed tissue might turn out to be useful in other research 
projects, not currently envisaged.  If you agree, any such tissue could be kept for use in 
such future projects. The tissue would only be used in future projects if permission had 
been granted by a Research Ethics Committee and the future use of samples will be 
limited to research in this field of medicine only. Please indicate on your consent form if 
you agree to this.  Occasionally samples may be moved between different universities or 
research sites to enable new research to be undertaken in collaboration with experts in 
different disciplines.  Ethics Committee approval would be required before any such move 
was undertaken.     
 
What will happen to the results of the research study? 
This is an academic study and we expect to publish the results. They may be published in 
a medical or scientific journal. However, please be reassured that you will not be 
identified in any such publication. 
We will also need to submit results for scrutiny by grant giving bodies, ethics committees 
and other experts, for example, at conferences.  Please be reassured that you will not be 
identified in any report or publication. 
 
Who is organising and funding the research? 
This work is funded by Biomedical Research Unit, University Hospitals Coventry and 
Warwickshire NHS Trust. No member of staff, including researchers, doctors or nursing 
staff is being paid for including you in this study. The research is organised and will be 
conducted according to the legal framework for use of human tissues in research 
embodied in the Human Tissue Act.  This trial will adhere to the principles outlined in the 
Medicines for Human use (Clinical Trials) Regulations 2004 (SI 2004/1031), amended 
regulations (SI 2006/1928) and the international conference on Harmonisation Good 
Clinical Practice (ICH GCP) guidelines; it will be conducted in compliance with the 
protocol, the Data Protection Act and other regulatory requirements as appropriate.  
 
Who has approved the study? 
This study has been approved by NRES-West Midlands Edgbaston, Ethics Committee, 
Medicines and Healthcare Products Regulatory Agency (MHRA), University Hospitals of 
Coventry and Warwickshire NHS Trust’s Research and Development department.  
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Contact Details: 
If you would like further information or have any concerns about the study, please contact  
 
Professor Siobhan Quenby B. Sc., MBBS, MD, FRCOG 
Professor in Obstetrics, Division of Reproductive Health 
Clinical Sciences Research Laboratory 
Warwick Medical School, University of Warwick 
Coventry CV2 2DX 
Tel: 02476967528 
E-mail: s.quenby@warwick.ac.uk 
 
 
 
Thank you for taking the time to read this information sheet. 
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Appendix 2: Consent form 
                                                                                                                               
Hospital Number: 
Patient Code Number for this project:  
 
Study number: HEP001QUEN                     Consent form version 5: 27 October 2012   
 
CONSENT FORM 
Title of Project: Endometrial flushing of low molecular weight heparin improves 
decidualisation- a prospective randomised control pilot study 
Name of Researchers:  Professor Siobhan Quenby, Professor Jan J 
Brosens, Dr Muhammad Akhtar  
Please 
initial 
box 
I confirm that I have read and understand the information sheet dated 27 October 
2012 (Version 5) for the above study; I have been given the opportunity to ask 
questions and discuss this study. I have received satisfactory answers to all my 
questions 
               
 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, and without my medical care or legal rights being 
affected. 
               
 
 
I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from University of Warwick, from regulatory 
authorities or from University Hospitals Coventry and Warwickshire NHS Trust, where 
it is relevant to my taking part in this research.  I give permission for these individuals 
to have access to my records.                                   
 
 
               
 
 
I agree to material collected and stored in this study being used in future studies 
limited to research in this field, subject to Ethics Committee approval.   
               
 
 
I agree to take part in the above study voluntarily and I have received enough 
information about the study. 
               
 
 
I agree to material collected and stored in this study being used in future studies 
limited to research in this field, subject to Ethics Committee approval. 
               
 
          
Signed.................................................................................Date................................ 
 
(NAME IN BLOCK CAPITALS)........................................... 
 
 
The study has been explained to me by: 
 
Investigator’s signature....................................................…Date: .............................. 
 
(NAME IN BLOCK CAPITALS)........................................... 
 
When completed, 1 for patient;  1 for researcher site file;  1 (original) to be kept in medical 
notes 
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Appendix 3: Participant Invitation Letter  
 
Letter of Invitation to participants 
Version 5: Dated 27/10/12 
 
Prof Siobhan Quenby 
Professor of Obstetrics 
University of Warwick 
 Department of Obstetrics and Gynaecology 
University Hospitals of Coventry and Warwickshire 
Clifford Bridge Road 
Coventry CV2 2DX 
Email: s.quenby@warwick.ac.uk 
                                                                                                                     Telephone: 02476968657 
 
 
Dear 
 
Title: Endometrial Flushing of Low Molecular Weight Heparin Improves 
decidualisation- a prospective randomised control pilot study  
(Study number: HEP001QUEN) 
 
We are inviting you to take part in the above-mentioned study at University of Warwick 
and Centre of Reproductive Medicine, University Hospitals Coventry and Warwickshire 
NHS Trust. We are aiming to find out whether flushing a blood-thinning agent (Heparin) 
directly into the inside of a womb has a beneficial effect on the womb lining.  
 
This project involves two visits one 5-7 days after ovulation to have your womb flushed 
with either heparin or saline and one the following day to have your womb lining sampled. 
We will also test your blood to ensure that the heparin has no side effects. 
 
It is important that you are not pregnant when we do this.   
 
 We hope that information from this study will enable us to design new treatments 
to increase the chance of a live birth in women with fertility problems. 
 I enclose the patient Information Sheet. Please read carefully before making your 
decision. 
 You have the right to agree or not to take part in the study.  
 Your care will remain entirely unchanged whatever decision you make. 
 
Yours sincerely, 
 
 
 
Professor S Quenby, 
Principal Investigator 
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Appendix 4: GP Letter  
                                                  
Version 4: Dated 09/09/12 
 
 
                                                                                             Prof Siobhan Quenby 
Professor of Obstetrics 
University of Warwick 
 Department of Obstetrics and Gynaecology 
University Hospitals of Coventry and Warwickshire 
Clifford Bridge Road 
Coventry CV2 2DX 
Email: s.quenby@warwick.ac.uk 
                                                                                                    Telephone: 02476968657 
 
 
 
 
Dear Doctor 
 
Subject: Endometrial Flushing of Low Molecular Weight Heparin Improves 
decidualisation- a prospective randomised control pilot study 
 
As you know, the above-named patient is currently being seen at the Centre for 
Reproductive Medicine at University Hospitals Coventry and Warwickshire NHS Trust for 
investigation of sub-fertility or miscarriages. 
 
I am writing to inform you that she has agreed to participate in a research study which is 
being conducted at University of Warwick and University Hospitals Coventry and 
Warwickshire NHS Trust. 
 
We are aiming to test the effects of endometrial flushing with low molecular weight 
heparin in a non-conception menstrual cycle upon markers of decidualisation during the 
potential implantation window. In future this will enable us to improve implantation for 
patients experiencing problems with fertility or miscarriages.  
 
Her care will otherwise be entirely unchanged, and we will keep you posted with her 
progress.  
 
I enclose the Information Sheet that we have given her.  
 
Yours sincerely, 
 
 
Professor S Quenby 
Principal Investigator 
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Appendix 5: Stability data of Clexane-Enoxaparin (Sanofi-Aventis) 
Reference: 0014-7546  
 
14
th
 August 2012  
Dr Muhammad Akhtar 
Walsgrave General Hospital 
Clifford Bridge Road 
Coventry 
United Kingdom 
 
Dear Dr Akhtar,  
Thank you for your enquiry requesting the following information on Clexane - enoxaparin, 
received via my colleague Deborah Woods: 
Clexane - Dilution 
As you are aware from the Summary of Product Characteristics (SPC) for Clexane: 
Subcutaneous Injection: 
Clexane should not be mixed with any other injections or infusions. 
Intravenous (Bolus) Injection for acute STEMI indication only: Enoxaparin: sodium may 
be safely administered with normal saline solution (0.9%) or 5% dextrose in water. 
Having carried out a search of the literature, I have located the following studies which 
have investigated the stability of enoxaparin when diluted. 
Patel et al 
1
 investigated the stability of enoxaparin (100 mg/mL) diluted with sterile water 
or 4% glucose to a concentration of 20 mg/mL over a 31-day period under different 
temperature storage conditions. A pooled batch of enoxaparin (100 mg/mL) was used to 
make up a solution diluted with preservative free sterile water for injection, and another 
solution diluted with sterile 4% glucose solution. An undiluted sample served as a control. 
The samples were stored for up to 31 days at 3 different temperatures (4°C, –12°C, or –
80°C). The control solution lost a significant percentage of its AFXa activity when stored 
at –12°C and –80°C (p<0.05). The solution diluted with 4% glucose, however, retained 
>99.0% of its original activity when stored for 31 days at 4°C. This solution lost some 
activity when frozen at –12°C after 31 days. The authors concluded that the results 
indicated that the inclusion of glucose prevented the loss of AFXa activity of diluted 
enoxaparin when stored at 4°C or –12°C for up to 31 days.  
In a similar study, Dager et al
2
 found that the storage of enoxaparin diluted with sterile 
water (end concentration 20mg/ml), in either 1ml plastic tuberculin syringes or a glass vial 
at room temperature or under refrigeration did not result in a significant loss of anti-Xa 
activity over a 4 week period. Those diluted samples stored in the glass vials, both at 
room temperature and in the fridge had trending decreases in loss of anti-Xa activity at 
weeks 3 and 4. Overall, the decreases in activity did not reach significance.  
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In a third study, Mewborn and colleagues 
3
 conducted a study to evaluate the stability of 
enoxaparin when diluted in 0.9% sodium chloride solution (final concentration 1.2mg/ml) 
and stored in polyvinyl chloride containers for up to 48 hours at 20-22°C. Samples from 
the solutions were assessed for physical compatibility and anti-Xa activity at the time of 
preparation (t0) and then at 0.25, 0.5, 0.75, 1, 4, 12, 16, 24 and 48 hours. The enoxaparin 
was found to be compatible with the 0.9% sodium chloride solution (no colour change or 
precipitation) and the pharmacologic activity at 48 hours was >94% of the activity 
measured at t0.  
 
Marketing Authorisation 
I can confirm, from the current SPC for clexane, the following: 
MARKETING AUTHORISATION HOLDER 
Sanofi-aventis 
One Onslow Street 
Guildford 
Surrey, GU1 4YS 
UK 
MARKETING AUTHORISATION NUMBER(S) 
PL 04425/0187 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
Date of first authorisation: 22 October 1990 
Date of latest renewal: 8 August 2002 
Unfortunately we are unable to provide you with an Investigational Medicinal Product 
Dossier (IMPD) for Clexane as this is a strictly confidential document. If you are wishing 
to obtain this IMPD in order to set a clinical trial application within licence to the MHRA or 
IMB, the SPC is enough to do this.  
If you have any more queries regarding the clinical trial you wish to pursue, please 
contact our scientific advisor Debbie Woods who may be able to help you further as the 
only documentation Medical information could supply you with is the SPC. Please find 
this attached for your reference. 
If you have any further enquiries regarding Clexane - enoxaparin then please contact us. 
 
Yours sincerely 
  
Damilola Surakatu BSc 
Medical Information Officer 
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Appendix 6: Sample Drug Labels 
Sample trial drug Label Enoxaparin 
 
 
 
 
 
For Clinical Trials Use Only 
Endometrial Flushing of Low Molecular weight Heparin study 
EudraCT Number: 2012-003682-18 
Enoxaparin 20mg/0.2 mls Pre-Filled Syringe 
For Intrauterine use but to be given as directed in the study 
protocol 
Keep out of reach of children. Do not store above 25◦C. Do not 
refrigerate or Freeze. 
Batch Number: …………… 
Expiry: MM/YYYY 
Patient Name: 
Patient Hospital Number: 
Patient Trial Number: 
Study Sponsor: University of Warwick, Coventry CV4 8UW 
Tel: +44(0)2476523716 
Principal Investigator: Prof S Quenby, University Hospitals Coventry 
and Warwickshire NHS Trust 
Tel: +44(0)2476967528 
Trial Site: 
University Hospitals Coventry and Warwickshire NHS Trust, UK 
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Sample trial drug Label for Sodium Chloride 0.9%  
 
 
 
 
 
 
For Clinical Trials Use Only 
Endometrial Flushing of Low Molecular weight Heparin study 
EudraCT Number: 2012-003682-18 
Sodium Chloride 0.9% in 10 ml ampoule 
For Intrauterine use but to be given as directed in the study 
protocol 
Keep out of reach of children.  Do not refrigerate or Freeze. 
Batch Number: …………… 
Expiry: MM/YYYY 
Patient Name: 
Patient Hospital Number: 
Patient Trial Number: 
Study Sponsor: University of Warwick, Coventry CV4 8UW 
Tel: +44(0)2476523716 
Principal Investigator: Prof S Quenby, University Hospitals Coventry 
and Warwickshire NHS Trust 
Tel: +44(0)2476967528 
Trial Site: 
University Hospitals Coventry and Warwickshire NHS Trust, UK 
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Appendix 7: Serious Adverse Event Form (HEP001QUEN) 
 
PATIENT IDENTIFICATION   
Consultant:   ________________________  
Hospital:       ________________________  
Study Number 
 
Patient in Intervention group:  Yes / No                   Patient in Control group:  Yes/ No               
Date of endometrial flushing:  DD / MM/ YYYY       Date of Endometrial Biopsy:   DD / MM/ YYYY                          
SAE TYPE 
Is this an initial or follow-up report? 
 
Initial Report                Follow-up report    
Is this the final report Yes           No   
    
REASON FOR REPORTING                                             Yes     No 
Death?   Date of death:                              
Life-threatening event?    
In-patient hospitalisation or prolongation of existing 
hospitalisation? 
  If yes, no of days? 
Persistent or significant disability/ incapacity?    
Congenital anomaly/ birth defect?    
Other pertinent medical reason for reporting?    
If other, please specify:  ________________________________________________________________  
SAE DESCRIPTION 
Date Event Started:  DD / MM / YYYY                   Date Event Ceased:  DD / MM / YYYY                            
Details of Adverse Event (please attach copies of relevant reports):  
 
_________________________________________________________________________________________ 
 
_________________________________________________________________________________________ 
TRIAL TREATMENT           This section must be completed by a clinician 
                                                                                                                                                                                                                                                                                                                                
Date last dose 
administered 
 
Causality Assessment 
(Please assume the mother was prescribed levothyroxine) 
1 Probably unrelated to treatment 
2 Possibly related to treatment 
3 Probably related to treatment 
4 Definitely related to treatment 
Action taken due to SAE 
 
1 None 
2 Treatment stopped 
3 Treatment delayed 
   DD / MM / YYYY                               
Please give reasons if you consider the event to be treatment related:  
 
_________________________________________________________________________________________ 
 
Participant’s Full Name:  ____________________ 
Hospital Number:                                                                                                                                                                                                                                                  
Date of birth: DD / MM / YYYY                 
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Was the SAE unexpected, i.e. of a type or severity which is NOT consistent with the up-to-date SPC of low 
molecular weight Heparin This section must be completed by a clinician 
 Unexpected                          Expected 
 
Please give reasons if you consider the event to be unexpected:  
 
_________________________________________________________________________________________ 
 
CONCOMITANT MEDICATION 
Has the patient taken any other medication within the last week?       Yes           No           
 If yes, please complete below: 
Drug Start date Tick if continuing or specify 
stop date 
Dose (mg) Indication 
_________________ DD / MM / YYYYY                                                                DD / MM / YYYY                        
_________________ DD / MM / YYYY                                             DD / MM/ YYYY                               
_________________ DD / MM / YYYY                                     DD / MM / YYYY                               
_________________ DD / MM / YYYY                                      DD / MM / YYYY                               
_________________  DD / MM / YYYY                                  DD / MM / YYYY                               
 
OUTCOME OF SAE 
 
Outcome:      Fatal                       Recovered     Continuing 
Please describe final outcome if event continuing at time of faxing initial report: 
 
_________________________________________________________________________________________ 
_________________________________________________________________________________________ 
Signature of Person Reporting:  ___________________________     Date: DD / MM / YYYY                                
              
You must have signed the Site Delegation Log 
 
Name:  ___________________________                    Position:  ___________________________ 
 
Telephone No:  ___________________________  
 
Signature of Investigator:  ___________________________               Date: DD / MM / YYYY                                          
                                                                   If not completed by Investigator 
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SUSAR Reporting – Warwick University R&D USE ONLY 
SAE reference number:  
 
Date reported to WU?    DD / MMM / YYYY     
 
Date reported to CI?          DD / MM / YYYY            Date reply received from CI?  DD / MM / YYYY                                
 
Is this event a SUSAR?  Yes                    If yes:         7 day report              OR 15 day report 
 
                                        No            If NO, is this an SAE?     Yes                             No 
PI comments:______________________________________________________________________________ 
 
_________________________________________________________________________________________ 
  
 
PI Signature:_____________________________________    PRINT Name:____________________________       
 
Date due to be reported to MHRA and MREC:     DD / MM / YYYY 
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Appendix 8: Trial Prescription  
University Hospitals Coventry and Warwickshire NHS Trust Clinical Trial 
Prescription 
 
CLINICAL TRIAL PRESCRIPTION Clinical Area  
Patient LABEL: Consultant  
  
Endometrial Flushing of LMWH 
A randomised pilot trial evaluating to assess the effects of 
Enoxaparin on endometrial  
decidualisation in a non-conception menstrual cycle. 
 
Sponsor Study Number: HEP001QUEN 
 EudraCT Number: 2012-003682-18 
Patient Trial No: 
Sponsor: University of Warwick 
 
 
 
Treatment Prescription  
Treatment Group:Enoxaparin 20 mg in 4 mls of Sodium Chloride 0.9% 
 
Control Group (placebo): 4 mls of Sodium Chloride 0.9% only     
 
 
CHECK LIST 
1. Patient has read and understood the participant information leaflet. 
2. Patient has signed the consent form to participate in the study. 
3. Patient has been randomised and allocated to either treatment or control group. 
4. Negative pregnancy test for all participants in this study group. 
5. She has used barrier methods of contraception during this month of intervention. 
 
6. Patient fulfils the inclusion criterion which includes women who had previous one unsuccessful IVF treatment (defined 
as failure to achieve live birth after transfer of two good quality embryos) or women with recurrent miscarriages 
(defined as 3 or more unexplained miscarriages), aged 18 years of age or older but younger than 45 years old 
who are able and willing to give informed consent 
 
7. Patient fulfils the exclusion criterion which includes Women who had unprotected sexual intercourse during the month 
when endometrial flushing is planned, Women having a vaginal infection which is not treated, Women who are 
pregnant or Breastfeeding, Women with weight of < 45 kg (due to higher risk of bleeding), Women with 
bleeding disorders, severe hypertension, Diabetes Mellitus, Peptic Ulcers, Renal or Liver Diseases and  who 
had recent stroke, Women taking Warfarin for any medical condition  or taking systemic steroids, systemic 
salicylates, acetylsalicylic acid, NSAIDS including Ketorolac, dextran and clopidogrel or any 
immunosuppressant medications, Women with hypersensitivity to Heparin, Pork, Beef or other Animal 
products and if she is undergoing Tubal Patency testing, Hysteroscopy or Laparoscopy at the time when 
endometrial flushing is planned 
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Patient Group 
 
Prescribed By: Date: 
Treatment or Control (please 
delete as necessary) 
Signature of Prescriber:  
Results/date 
BP 
(<150/100) 
 Pregnancy 
Test 
 
HVS 
Other Pelvic 
Swabs  
Height 
(cm) 
Weight 
(kg) 
BMI 
 
 
 
       
 
LMP 
 
 
 
Allergies 
 
 
 
 
 DRUG ACTUAL DOSE 
Administration 
ROUTE 
Time given Given by Checked by 
DATE Enoxaparin 20 mg Intrauterine    
………… 
Sodium 
Chloride 0.9% 
4 mls Intrauterine    
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Appendix 9: Participant Questionnaire (Non Validated) 
                                                                                    
 
Version 4:   09/09/2012 
 
STUDY:  Endometrial Flushing of Low Molecular Weight Heparin Improves 
decidualisation- a prospective randomised control pilot study 
Project Reference No:  HEP001QUEN 
Name of researcher Prof S Quenby, Prof J Brosens, Dr M Akhtar 
 
PATIENT NAME: 
Date of completion of the questionnaire: DD / MM/ YYYY        
Date of Intervention: DD / MM/ YYYY        
We would like to know your opinions of this study and we also need to find out about any 
problems that might arise.   
This questionnaire has to be completed once you have finished your first period after the 
procedure of flushing and sampling of the lining of your womb during the above 
mentioned study.  
Please send your completed questionnaire back to us using the prepaid addressed 
envelope provided. Thank you very much for your participation in the study and your time 
and effort in completing this form.   
 
1. How did you find out about the study?  
 
 
2. Was the information provided helpful?  Was there anything else that you would 
have liked to know?  
 
 
3. Please tell us your experience of the study? 
 
 
4. What could we do better to improve it? 
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5. Did you encounter any unpleasant situation during the study?  If so, please tell us 
about it.   
 
 
6. Was the member of staff helpful during the study? 
 
 
7. Did you encounter any side effects or complications during the study? 
a. Bleeding Yes/ No, If yes where was the bleeding? …………. 
b. Infection Yes/ No, If yes where was the infection? …………. 
c. Bruising of skin Yes/ No 
d. Allergic reaction Yes/No 
e. Pain Yes/No  
If yes when did you experience pain?  Can you describe the pain?   
 
 
f. Any other ………………………………………. 
g. Next period after intervention Normal/ Heavy/ Light 
h. Duration of next period after intervention Normal/ Prolong/ Short 
(Please specify duration in days………….) 
 
 
8. Are there any other comments that you wish to make?   
 
 
 
9. If you would like us to reply to your comments, please give us your contact details 
below.   
 
 
 
 
 
Much Appreciated. 
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Other Appendices: 
 
 
 
SUMMARY OF PRODUCT CHARACTERISTICS 
 
1 NAME OF THE MEDICINAL PRODUCT 
 
Clexane® Syringes 
  
2 QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Pre-filled syringes: 
20 mg Injection Enoxaparin sodium 20 mg (equivalent to 2,000 IU anti-
Xa activity) in 0.2 mL Water for Injections 
40 mg Injection Enoxaparin sodium 40 mg (equivalent to 4,000 IU anti-
Xa activity) in 0.4 mL Water for Injections 
60 mg Injection Enoxaparin sodium 60 mg (equivalent to 6,000 IU anti-
Xa activity) in 0.6 mL Water for Injections 
80 mg Injection Enoxaparin sodium 80 mg (equivalent to 8,000 IU anti-
Xa activity) in 0.8 mL Water for Injections 
100 mg Injection Enoxaparin sodium 100mg (equivalent to 10,000 IU 
anti-Xa activity) in 1.0 mL Water for Injections 
 
 For full list of excipients, see section 6.1 
 
3 PHARMACEUTICAL FORM 
 
Solution for injection. 
Clear, colourless to pale yellow solution. 
 
4 CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
The prophylaxis of thromboembolic disorders of venous origin, in particular 
those which may be associated with orthopaedic or general surgery. 
 
The prophylaxis of venous thromboembolism in medical patients bedridden 
due to acute illness.  
 
The treatment of venous thromboembolic disease presenting with deep vein 
thrombosis, pulmonary embolism or both.  
 
The treatment of unstable angina and non-Q-wave myocardial infarction, 
administered concurrently with aspirin. 
 
Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) 
including patients to be managed medically or with subsequent Percutaneous 
Coronary Intervention (PCI) in conjunction with thrombolytic drugs (fibrin or 
non-fibrin specific).  
 
The prevention of thrombus formation in the extracorporeal circulation during 
haemodialysis. 
 
4.2 Posology and method of administration 
 
Adults: 
 
Prophylaxis of venous thromboembolism: 
In patients with a low to moderate risk of venous thromboembolism the 
recommended dosage is 20 mg (2,000 IU) once daily by subcutaneous 
injection for 7 to 10 days, or until the risk of thromboembolism has 
diminished.  In patients undergoing surgery, the initial dose should be given 
approximately 2 hours pre-operatively. In patients with a higher risk, such as 
in orthopaedic surgery, the dosage should be 40 mg (4,000 IU) daily by 
subcutaneous injection with the initial dose administered approximately 12 
hours before surgery. 
 
Prophylaxis of venous thromboembolism in medical patients: 
The recommended dose of enoxaparin sodium is 40 mg (4,000 IU) once daily 
by subcutaneous injection.  Treatment with enoxaparin sodium is prescribed 
for a minimum of 6 days and continued until the return to full ambulation, for 
a maximum of 14 days. 
 
Treatment of venous thromboembolism: 
Clexane should be administered subcutaneously as a single daily injection of 
1.5 mg/kg (150 IU/kg).  Clexane treatment is usually prescribed for at least 5 
days and until adequate oral anticoagulation is established. 
 
Dosage chart for 1.5mg/kg SC treatment of DVT, PE or both 
Patient weight Kg Syringe label Dose 
(mg) 
Injection 
volume 
(ml) 
100mg/ml 
Solution for Injection 
CLEXANE syringes 
40 60mg / 0.6ml 60 od 0.60 
45 
50 
80mg / 0.8ml 
80mg / 0.8ml 
67.5 od 
75 od 
0.675 
0.75 
55 
60 
65 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
82.5 od 
90 od 
97.5 od 
0.825 
0.90 
0.975 
150mg/ml 
Solution for Injection 
CLEXANE Forte 
syringes 
70 
75 
80 
120mg / 0.8ml 
120mg / 0.8ml 
120mg / 0.8ml 
105 od 
112.5 od 
120 od 
0.70 
0.76 
0.80 
85 
90 
95 
100 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
127.5 od 
135 od 
142.5 od 
150 od 
0.86 
0.90 
0.96 
1.00 
Please be aware that in some cases it is not possible to achieve an exact dose 
due to the graduations on the syringe and so some of the volumes 
recommended in this table have been rounded up to the nearest graduation. 
 
 
 
 
Treatment of unstable angina and non-Q-wave myocardial infarction 
The recommended dose is 1 mg/kg Clexane every 12 hours by subcutaneous 
injection, administered concurrently with oral aspirin (100 to 325mg once 
daily). 
 
Treatment with Clexane in these patients should be prescribed for a minimum 
of 2 days and continued until clinical stabilisation.  The usual duration of 
treatment is 2 to 8 days. 
 
Dosage chart for 1mg/kg SC treatment of UA or NSTEMI 
Patient weight Kg Syringe label Dose 
(mg) 
Injection 
volume 
(ml) 
100mg/ml 
Solution for Injection 
CLEXANE syringes 
40 40mg / 0.4ml 40 bd 0.40 
45 
50 
55 
60 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
45 bd 
50 bd 
55 bd 
60 bd 
0.45 
0.50 
0.55 
0.60 
65 
70 
75 
80 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
65 bd 
70 bd 
75 bd 
80 bd 
0.65 
0.70 
0.75 
0.80 
85 
90 
95 
100 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
85 bd 
90 bd 
95 bd 
100 bd 
0.85 
0.90 
0.95 
1.00 
150mg/ml 
Solution for Injection 
CLEXANE Forte 
syringes 
105 
110 
115 
120 
120mg / 0.8ml 
120mg / 0.8ml 
120mg / 0.8ml 
120mg / 0.8ml 
105 bd 
110 bd 
115 bd 
120 bd 
0.70 
0.74 
0.78 
0.80 
125 
130 
135 
140 
145 
150 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
150mg / 1ml 
125 bd 
130 bd 
135 bd 
140 bd 
145 bd 
150 bd 
0.84 
0.88 
0.90 
0.94 
0.98 
1.00 
Please be aware that in some cases it is not possible to achieve an exact dose 
due to the graduations on the syringe and so some of the volumes 
recommended in this table have been rounded up to the nearest graduation. 
 
Treatment of acute ST-segment Elevation Myocardial Infarction 
The recommended dose of enoxaparin sodium is a single IV bolus of 30mg  
plus a 1mg/kg SC dose followed by 1mg/kg administered SC every 12 hours 
(max 100mg for the first two doses only, followed by 1mg/kg dosing for the 
remaining doses). For dosage in patients ≥75 years of age, see section 4.2 
Posology and method of administration: Elderly. 
 
 
 
 
Dosage chart for 1mg/kg SC treatment of STEMI 
Patient weight Kg Syringe label Dose (mg) Injection 
volume 
(ml) 
100mg/ml  
Solution for Injection 
CLEXANE syringes 
40 40mg / 0.4ml  40 bd 0.40 
45 
50 
55 
60 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
45 bd 
50 bd 
55 bd 
60 bd 
0.45 
0.50 
0.55 
0.60 
65 
70 
75 
80 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
65 bd 
70 bd 
75 bd 
80 bd 
0.65 
0.70 
0.75 
0.80 
85 
90 
95 
100 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
85 bd 
90 bd 
95 bd 
100 bd 
0.85 
0.90 
0.95 
1.00 
150mg/ml  
Solution for Injection 
CLEXANE Forte 
syringes 
105 
110 
115 
120 
120mg / 0.8ml (1) 
120mg / 0.8ml (1) 
120mg / 0.8ml (1) 
120mg / 0.8ml (1) 
105 bd (1) 
110 bd (1) 
115 bd (1) 
120 bd (1) 
0.70 (1) 
0.74 (1) 
0.78 (1) 
0.80 (1) 
125 
130 
135 
140 
145 
150 
150mg / 1ml (1) 
150mg / 1ml (1) 
150mg / 1ml (1) 
150mg / 1ml (1) 
150mg / 1ml (1) 
150mg / 1ml (1) 
125 bd (1) 
130 bd (1) 
135 bd (1) 
140 bd (1) 
145 bd (1) 
150 bd (1) 
0.84 (1) 
0.88 (1) 
0.90 (1) 
0.94 (1) 
0.98 (1) 
1.00 (1) 
(1) Not to be given for the first two doses - (maximum 100mg for the first two 
doses only, followed by 1mg/kg dosing for the remaining doses) 
Please be aware that in some cases it is not possible to achieve an exact dose 
due to the graduations on the syringe and so some of the volumes 
recommended in this table have been rounded up to the nearest graduation. 
 
When administered in conjunction with a thrombolytic (fibrin specific or non-
fibrin specific) enoxaparin sodium should be given between 15 minutes before 
and 30 minutes after the start of fibrinolytic therapy. All patients should 
receive acetylsalicylic acid (ASA) as soon as they are identified as having 
STEMI and maintained under (75 to 325mg once daily) unless 
contraindicated. 
 
The recommended duration of enoxaparin sodium treatment is 8 days or until 
hospital discharge, whichever comes first. 
 
For patients managed with Percutaneous Coronary Intervention (PCI): If the 
last enoxaparin sodium SC administration was given less than 8 hours before 
balloon inflation, no additional dosing is needed. If the last SC administration 
was given more than 8 hours before balloon inflation, an IV bolus of 0.3mg/kg 
of enoxaparin sodium should be administered.  
 
 
Prevention of extracorporeal thrombus formation during haemodialysis: 
A dose equivalent to 1 mg/kg (100 IU/kg) introduced into the arterial line at 
the beginning of a dialysis session is usually sufficient for a 4 hour session.  If 
fibrin rings are found, such as after a longer than normal session, a further 
dose of  0.5 to 1mg/kg (50 to 100 IU/kg) may be given.  For patients at a high 
risk of haemorrhage the dose should be reduced to 0.5 mg/kg (50 IU/kg) for 
double vascular access or 0.75 mg/kg (75 IU/kg) for single vascular access. 
 
Elderly: 
For treatment of acute ST-segment Elevation Myocardial Infarction in elderly 
patients ≥75 years of age, do not use an initial IV bolus. Initiate dosing with 
0.75mg/kg SC every 12 hours (maximum 75mg for the first two doses only, 
followed by 0.75mg/kg dosing for the remaining doses). 
 
For other indications, no dosage adjustments are necessary in the elderly, 
unless kidney function is impaired (see also section 4.2 Posology and method 
of administration: Renal impairment; section 4.4 Special warnings and 
precautions for use: Haemorrhage in the elderly; Renal impairment, and 
Monitoring; section 5.2 Pharmacokinetic properties). 
 
Dosage chart for 0.75mg/kg SC treatment of STEMI 
(elderly patients aged ≥75 years only) 
Patient weight Kg Syringe label 0.75mg/kg 
Dose (mg) 
Adjusted 
dosing (mg) 
Injection 
volume (ml) 
100mg/ml 
Solution for 
Injection 
CLEXANE 
syringes 
40 
45 
50 
55 
60 
65 
70 
75 
80 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
60mg / 0.6ml 
30 bd 
33.75 bd 
37.5 bd 
41.25 bd 
45 bd 
48.75 bd 
52.5 bd 
56.25 bd 
60 bd 
30 bd 
35 bd 
37.5 bd 
42.5 bd 
45 bd 
50 bd 
52.5 bd 
57.5 bd 
60 bd 
0.30 
0.35 
0.375 
0.425 
0.45 
0.5 
0.525 
0.575 
0.60 
85 
90 
95 
100 
105 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
80mg / 0.8ml 
63.75 bd 
67.5 bd 
71.25 bd 
75 bd 
78.75 bd (1) 
65 bd 
67.5 bd 
72.5 bd 
75 bd 
80 bd (1) 
0.65 
0.675 
0.725 
0.75 
0.80 (1) 
110 
115 
120 
125 
130 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
100mg / 1ml 
82.5 bd (1) 
86.25 bd (1) 
90 bd (1) 
93.75 bd (1) 
97.5 bd (1) 
82.5 bd (1) 
87.5 bd (1) 
90 bd (1) 
95 bd (1) 
97.5 bd (1) 
0.825 (1) 
0.875 (1) 
0.90 (1) 
0.95 (1) 
0.975 (1) 
150mg/ml  
Solution for 
Injection 
CLEXANE 
Forte syringes 
135 
140 
145 
150 
120mg / 0.8ml 
120mg / 0.8ml 
120mg / 0.8ml 
120mg / 0.8ml 
101.25 bd (1) 
105 bd (1) 
108.75 bd (1) 
112.5 bd (1) 
102 bd (1) 
105 bd (1) 
111 bd (1) 
114 bd (1) 
0.68 (1) 
0.7 (1) 
0.74 (1) 
0.76 (1) 
(1) not to be given for the first two doses - (maximum 75mg for the first two doses 
only, followed by 0.75mg/kg dosing for the remaining doses) 
Please be aware that in some cases it is not possible to achieve an exact dose 
due to the graduations on the syringe and so some of the volumes 
recommended in this table have been rounded up to the nearest graduation. 
 
Children: Not recommended, as dosage not established. 
 
Renal impairment: (See also section 4.4 Special warnings and precautions for 
use: Renal impairment and Monitoring; section 5.2 Pharmacokinetic 
properties). 
 
Severe renal impairment: 
A dosage adjustment is required for patients with severe renal impairment 
(creatinine clearance < 30 ml/min), according to the following tables, since 
enoxaparin sodium exposure is significantly increased in this patient 
population: 
 
Dosage adjustments for therapeutic dosage ranges 
 Standard dosing Severe renal impairment  
 1 mg/kg SC twice daily 1 mg/kg SC once daily  
 1.5 mg/kg SC once daily 1 mg/kg SC once daily  
For treatment of acute STEMI in patients <75 years of age 
 30mg-single IV bolus plus a 
1mg/kg SC dose followed by 
1mg/kg twice daily. 
(Max 100mg for each of the 
first two SC doses) 
30mg-single IV bolus plus a 
1mg/kg SC dose followed 
by 1mg/kg once daily. 
(Max 100mg for first SC 
dose only) 
 
For treatment of acute STEMI in elderly patients ≥75 years of age 
 0.75mg/kg SC twice daily 
without initial bolus. 
(Max 75mg for each of the 
first two SC doses) 
1mg/kg SC once daily 
without initial bolus. 
(Max 100mg for first SC 
dose only) 
 
 
Dosage adjustments for prophylactic dosage ranges 
 Standard dosing Severe renal impairment  
 40 mg SC once daily 20 mg SC once daily  
 20 mg SC once daily 20 mg SC once daily  
The recommended dosage adjustments do not apply to the haemodialysis 
indication. 
 
Moderate and mild renal impairment: 
Although no dosage adjustments are recommended in patients with moderate 
renal impairment (creatinine clearance 30-50 ml/min) or mild renal 
impairment (creatinine clearance 50-80 ml/min), careful clinical monitoring is 
advised. 
 
Hepatic impairment: In the absence of clinical studies, caution should be 
exercised. 
 
 
 
Body weight: 
No dosage adjustments are recommended in obesity or low body weight (see 
also section 4.4 Special warnings and precautions for use: Low body weight 
and Monitoring; section 5.2 Pharmacokinetic properties). 
 
Clexane is administered by subcutaneous injection for the prevention of 
venous thromboembolic disease, treatment of deep vein thrombosis or for the 
treatment of unstable angina, non-Q-wave myocardial infarction and acute ST 
elevation myocardial infarction (STEMI); through the arterial line of a dialysis 
circuit for the prevention of thrombus formation in the extra-corporeal 
circulation during haemodialysis; and via intravenous (bolus) injection through 
an intravenous line only for the initial dose of acute STEMI indication and 
before PCI when needed. It must not be administered by the intramuscular 
route. 
 
To avoid accidental needle stick after injection, the prefilled syringes are fitted 
with an automatic safety device 
 
Subcutaneous injection technique 
The prefilled disposable syringe is ready for immediate use. Clexane should be 
administered when the patient is lying down by deep subcutaneous injection. 
The administration should be alternated between the left and right anterolateral 
or posterolateral abdominal wall. The whole length of the needle should be 
introduced vertically into a skin fold held between the thumb and index finger. 
The skin fold should not be released until the injection is complete.  
Once the plunger is fully pressed down the safety device is activated 
automatically. This protects the used needle. 
Note: The plunger has to be pressed down all the way for the safety device to 
be activated. 
Do not rub the injection site after administration.  
 
Intravenous (Bolus) Injection Technique (for acute STEMI indication only): 
For intravenous injection, either the Multidose Vial or 60mg, 80mg or 100mg 
prefilled syringes can be used. Enoxaparin sodium should be administered 
through an intravenous line. It should not be mixed or co-administered with 
other medications. To avoid the possible mixture of enoxaparin sodium with 
all other drugs, the intravenous access chosen should be flushed with a 
sufficient amount of saline or dextrose solution prior to and following the 
intravenous bolus administration of enoxaparin sodium to clear the port of 
drug. Enoxaparin sodium may be safely administered with normal saline 
solution (0.9%) or 5% dextrose in water. 
 
• Initial 30mg bolus 
For the initial 30mg bolus, using an enoxaparin sodium graduated prefilled 
syringe (60, 80 or 100mg), expel the excessive volume to retain only 30mg 
(0.3ml) in the syringe. The 30mg dose can then be directly injected into an 
injection site in the intravenous line.  
 
• Additional bolus for PCI when last SC administration was given more 
than 8 hours before balloon insertion 
For patients being managed with Percutaneous Coronary Intervention (PCI), 
an additional IV bolus of 0.3mg/kg is to be administered if last SC 
administration was given more than 8 hours before balloon inflation (see 
section 4.2 Posology and method of administration: Treatment of acute ST-
segment Elevation Myocardial Infarction). 
 
In order to assure the accuracy of the small volume to be injected, it is 
recommended to dilute the drug to 3mg/ml. 
To obtain a 3mg/ml solution, using a 60mg enoxaparin sodium prefilled 
syringe, it is recommended to use a 50ml infusion bag (i.e. using either normal 
saline solution (0.9%) or 5% dextrose in water) as follows: 
Withdraw 30ml from the infusion bag with a syringe and discard the liquid. 
Inject the complete contents of the 60mg enoxaparin sodium prefilled syringe 
into the 20ml remaining in the bag. Gently mix the contents of the bag. 
Withdraw the required volume of diluted solution with a syringe for 
administration into the intravenous line (using an appropriate injection site or 
port).  
 
After dilution is completed, the volume to be injected can be calculated using 
the following formula [Volume of diluted solution (ml) = Patient weight (kg) x 
0.1] or using the table below. It is recommended to prepare the dilution 
immediately before use and to discard any remaining solution immediately 
after use. 
 
Volume to be injected through intravenous line after dilution is completed 
 
Weight  Required dose  Volume to inject when diluted to a final  
 (0.3 mg/kg)  concentration of 3 mg/ml  
[Kg]  [mg]  [ml]  
45  13.5  4.5  
50  15  5  
55  16.5  5.5  
60  18  6  
65  19.5  6.5  
70  21  7  
75  22.5  7.5  
80  24  8  
85  25.5  8.5  
90  27  9  
95  28.5  9.5  
100  30  10  
105 31.5 10.5 
110 33 11 
115 34.5 11.5 
120 36 12 
125 37.5 12.5 
130 39 13 
135 40.5 13.5 
140 42 14 
145 43.5 14.5 
150 45 15 
 
4.3 Contraindications 
 Contraindicated in patients with acute bacterial endocarditis, active major 
bleeding and conditions with a high risk of uncontrolled haemorrhage, 
including recent haemorrhagic stroke, thrombocytopenia in patients with a 
positive in-vitro aggregation test in the presence of enoxaparin; active gastric 
or duodenal ulceration; hypersensitivity to either enoxaparin sodium, heparin 
or its derivatives including other Low Molecular Weight Heparins; in patients 
receiving heparin for treatment rather than prophylaxis, locoregional 
anaesthesia in elective surgical procedures is contraindicated. 
 
4.4 Special warnings and precautions for use 
Low Molecular Weight Heparins should not be used interchangeably since 
they differ in their manufacturing process, molecular weights, specific anti Xa 
activities, units and dosage. This results in differences in pharmacokinetics and 
associated biological activities (e.g. anti-IIa activity, and platelet interactions). 
Special attention and compliance with the instructions for use specific to each 
proprietary medicinal product are therefore required. 
 
Enoxaparin is to be used with extreme caution in patients with a history of 
heparin-induced thrombocytopenia with or without thrombosis. 
 
As there is a risk of antibody-mediated heparin-induced thrombocytopenia 
also occurring with low molecular weight heparins, regular platelet count 
monitoring should be considered prior to and during therapy with these agents. 
Thrombocytopenia, should it occur, usually appears between the 5th and the 
21st day following the beginning of therapy.  Therefore, it is recommended 
that the platelet counts be measured before the initiation of therapy with 
enoxaparin sodium and then regularly thereafter during the treatment.  In 
practice, if a confirmed significant decrease of the platelet count is observed 
(30 to 50 % of the initial value), enoxaparin sodium treatment must be 
immediately discontinued and the patient switched to another therapy. 
 
Enoxaparin injection, as with any other anticoagulant therapy, should be used 
with caution in conditions with increased potential for bleeding, such as: 
impaired haemostasis, history of peptic ulcer, recent ischaemic stroke, 
uncontrolled severe arterial hypertension, diabetic retinopathy, recent neuro- 
or ophthalmologic surgery.   
As with other anticoagulants, bleeding may occur at any site (see section 4.8 
Undesirable effects). If bleeding occurs, the origin of the haemorrhage should 
be investigated and appropriate treatment instituted. 
 
Heparin can suppress adrenal secretion of aldosterone leading to 
hyperkalaemia, particularly in patients such as those with diabetes mellitus, 
chronic renal failure, pre-existing metabolic acidosis, a raised plasma 
potassium or taking potassium sparing drugs.  The risk of hyperkalaemia 
appears to increase with duration of therapy but is usually reversible.  Plasma 
potassium should be measured in patients at risk before starting heparin 
therapy and monitored regularly thereafter particularly if treatment is 
prolonged beyond about 7 days. 
 
As with other anti-coagulants, there have been cases of intra-spinal 
haematomas reported with the concurrent use of enoxaparin sodium and 
spinal/epidural anaesthesia or spinal puncture resulting in long term or 
permanent paralysis.  These events are rare with enoxaparin sodium dosage 
regimens 40 mg od or lower.  The risk is greater with higher enoxaparin 
sodium dosage regimens, use of post-operative indwelling catheters or the 
concomitant use of additional drugs affecting haemostasis such as NSAIDs 
(see section 4.5 Interaction with other medicinal products and other forms of 
interaction).  The risk also appears to be increased by traumatic or repeated 
neuraxial puncture or in patients with a history of spinal surgery or spinal 
deformity. 
 
To reduce the potential risk of bleeding associated with the concurrent use of 
enoxaparin sodium and epidural anaesthesia/analgesia, the pharmacokinetic 
profile of the drug should be considered (see section 5.2 Pharmacokinetic 
properties).  Placement and removal of the catheter is best performed when the 
anticoagulation effect of enoxaparin is low. 
 
Placement or removal of a catheter should be delayed for 10 - 12 hours after 
administration of DVT prophylactic doses of enoxaparin sodium, whereas 
patients receiving higher doses of enoxaparin sodium (1.5 mg/kg once daily) 
will require longer delays (24 hours).  The subsequent enoxaparin sodium dose 
should be given no sooner than 4 hours after catheter removal. 
 
Should the physician decide to administer anticoagulation in the context of 
epidural/spinal anaesthesia, extreme vigilance and frequent monitoring must 
be exercised to detect any signs and symptoms of neurological impairment 
such as midline back pain, sensory and motor deficits (numbness or weakness 
in lower limbs), bowel and/or bladder dysfunction.  Patients should be 
instructed to inform their nurse or physician immediately if they experience 
any of the above signs or symptoms.  If signs or symptoms of spinal 
haematoma are suspected, urgent diagnosis and treatment including spinal 
cord decompression should be initiated. 
 
Percutaneous coronary revascularisation procedures: 
To minimise the risk of bleeding following vascular instrumentation during the 
treatment of unstable angina, non-Q-wave myocardial infarction and acute ST-
elevation myocardial infarction, adhere precisely to the intervals 
recommended between enoxaparin sodium doses. It is important to achieve 
homeostasis at the puncture site after PCI. If a closure device is used, the 
sheath can be removed immediately. If a manual compression method is used, 
sheath should be removed 6 hours after the last IV/SC enoxaparin sodium 
injection.  If treatment is to be continued, the next scheduled dose should be 
given no sooner than 6 to 8 hours after sheath removal.  The site of the 
procedure should be observed for signs of bleeding or haematoma formation. 
 
For some patients with pulmonary embolism (e.g. those with severe 
haemodynamic instability) alternative treatment such as thrombolysis or 
surgery may be indicated. 
 
Prosthetic Heart Valves 
There have been no adequate studies to assess the safe and effective use of 
enoxaparin sodium in preventing valve thrombosis in patients with prosthetic 
heart valves.  Prophylactic doses of enoxaparin are not sufficient to prevent 
valve thrombosis in patients with prosthetic heart valves.  Confounding 
factors, including underlying diseases and insufficient clinical data, limit the 
evaluation of these cases. Therapeutic failures have been reported in pregnant 
women with prosthetic heart valves on full anti-coagulant doses (see section 
4.6 Pregnancy and lactation). The use of enoxaparin sodium cannot be 
recommended for this purpose. 
 
Haemorrhage in the elderly: No increased bleeding tendency is observed in 
the elderly within the prophylactic dosage ranges.  Elderly patients (especially 
patients aged eighty years and above) may be at an increased risk for bleeding 
complications within the therapeutic dosage ranges.  In the treatment of acute 
ST-segment Elevation Myocardial Infarction (STEMI), an increase in bleeding 
events was observed in patients aged 65-75 years suggesting these patients 
might be at particular risk of bleeding. Careful clinical monitoring is advised 
(see also section 4.2 Posology and method of administration: Elderly; section 
5.2 Pharmacokinetic properties). 
 
Renal impairment: In patients with renal impairment, there is an increase in 
enoxaparin exposure which increases the risk of bleeding.  Since enoxaparin 
exposure is significantly increased in patients with severe renal impairment 
(creatinine clearance < 30 ml/min) dosage adjustments are recommended in 
therapeutic and prophylactic dosage ranges.  Although no dosage adjustments 
are recommended in patients with moderate (creatinine clearance 30-50 
ml/min) and mild (creatinine clearance 50-80 ml/min) renal impairment, 
careful clinical monitoring is advised (see also section 4.2 Posology and 
method of administration: Renal impairment; section 5.2 Pharmacokinetic 
properties). In the treatment of acute ST-segment Elevation Myocardial 
Infarction (STEMI), the data are limited in patients with creatinine levels 
above 220 and 175 µmol/L for males and females respectively. 
 
Low body weight: In low-weight women (< 45 kg) and low-weight men (< 57 
kg), an increase in enoxaparin exposure has been observed within the 
prophylactic dosage ranges (non-weight adjusted), which may lead to a higher 
risk of bleeding.  Therefore, careful clinical monitoring is advised in these 
patients (see also section 5.2 Pharmacokinetic properties). 
 
Monitoring: Risk assessment and clinical monitoring are the best predictors of 
the risk of potential bleeding. Routine anti-Xa activity monitoring is usually 
not required.  However, anti-Xa activity monitoring might be considered in 
those patients treated with LMWH who also have either an increased risk of 
bleeding (such as those with renal impairment, elderly and extremes of weight) 
or are actively bleeding. 
 
Laboratory tests: 
At doses used for prophylaxis of venous thromboembolism, enoxaparin 
sodium does not influence bleeding time and global blood coagulation tests 
significantly, nor does it affect platelet aggregation or binding of fibrinogen to 
platelets.  At higher doses, increases in APTT (activated partial thromboplastin 
time) and ACT (activated clotting time) may occur.  Increases in APTT and 
ACT are not linearly correlated with increasing enoxaparin sodium 
antithrombotic activity and therefore are unsuitable and unreliable for 
monitoring enoxaparin sodium activity. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
It is recommended that agents which affect haemostasis should be 
discontinued prior to enoxaparin therapy unless their use is essential, such as: 
systemic salicylates, acetylsalicylic acid, NSAIDs including ketorolac, 
dextran, and clopidogrel, systemic glucocorticoids, thrombolytics and 
anticoagulants. If the combination cannot be avoided, enoxaparin should be 
used with careful clinical and laboratory monitoring.  
 
4.6 Pregnancy and lactation 
 
Pregnancy: Animal studies have not shown any evidence of foetotoxicity or 
teratogenicity. In the pregnant rat, the transfer of 35S-enoxaparin across the 
maternal placenta to the foetus is minimal. 
 
In humans, there is no evidence that enoxaparin crosses the placental barrier 
during the second trimester of pregnancy.  There is no information available 
concerning the first and the third trimesters. 
 
As there are no adequately powered and well-controlled studies in pregnant 
women and because animal studies are not always predictive of human 
response, this drug should be used during pregnancy only if the physician has 
established a clear need. 
 
Pregnant women with mechanical prosthetic heart valves 
The use of enoxaparin for thromboprophylaxis in pregnant women with 
mechanical prosthetic heart valves has not been adequately studied. In a 
clinical study of pregnant women with mechanical prosthetic heart valves 
given enoxaparin (1 mg/kg bid) to reduce the risk of thromboembolism, 2 of 8 
women developed clots resulting in blockage of the valve and leading to 
maternal and foetal death. There have been isolated postmarketing reports of 
valve thrombosis in pregnant women with mechanical prosthetic heart valves 
while receiving enoxaparin for thromboprophylaxis. Pregnant women with 
mechanical prosthetic heart valves may be at higher risk for 
thromboembolism. Enoxaparin sodium is not recommended for use in 
pregnant women with prosthetic heart valves (see section 4.4 Special warnings 
and precautions for use: Prosthetic heart valves). 
 
Lactation: In lactating rats, the concentration of 35S-enoxaparin or its labelled 
metabolites in milk is very low. 
 
It is not known whether unchanged enoxaparin is excreted in human breast 
milk.  The oral absorption of enoxaparin is unlikely. However, as a precaution, 
lactating mothers receiving enoxaparin should be advised to avoid breast-
feeding.  
 
4.7 Effects on ability to drive and use machines 
 
Enoxaparin has no effect on the ability to drive and operate machines 
 
4.8 Undesirable effects 
 
The adverse reactions observed in clinical studies and reported in post-
marketing experience are detailed below. 
Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 
to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); 
and very rare (< 1/10,000). 
Adverse events which have not been observed in clinical trials, but were 
reported in post-marketing experience are ranked under the frequency “Rare”. 
 
Haemorrhages 
In clinical studies, haemorrhages were the most commonly reported reaction. 
These included major haemorrhages, reported at most in 4.2 % of the patients 
(surgical patients1). Some of these cases have been fatal. 
 
As with other anticoagulants, haemorrhage may occur during enoxaparin 
therapy in the presence of associated risk factors such as: organic lesions liable 
to bleed, invasive procedures or the concomitant use of medications affecting 
haemostasis (see section 4.5 Interaction with other medicinal products and 
other forms of interaction ). The origin of the bleeding should be investigated 
and appropriate treatment instituted. 
 
MedDRA 
system organ 
class 
Prophylaxis 
in 
surgical 
patients 
 
Prophylaxis in 
medical 
patients 
 
Treatment in 
patients with 
DVT 
with or without 
PE 
 
Treatment in 
patients with 
unstable angina 
and non-Q-wave 
MI 
 
Treatment in 
patients with acute 
STEMI 
 
Vascular 
disorders 
 
Very 
common: 
Haemorrhage 
* 
 
Rare: 
Retroperitone
al 
haemorrhage 
 
Common: 
Haemorrhage * 
 
Very common: 
Haemorrhage * 
Uncommon: 
Intracranial 
haemorrhage, 
Retroperitoneal 
haemorrhage 
 
Common: 
Haemorrhage * 
 
Rare: 
Retroperitoneal 
haemorrhage 
 
Common: 
Haemorrhage * 
 
Uncommon: 
Intracranial 
haemorrhage, 
Retroperitoneal 
haemorrhage 
 
 
*: such as haematoma, ecchymosis other than at injection site, wound 
haematoma, haematuria, epistaxis and gastro-intestinal haemorrhage. 
 
In addition, in post marketing experience: 
Rare: Cases of spinal haematoma (or neuraxial haematoma) have been 
reported with the concurrent use of enoxaparin sodium as well as 
spinal/epidural anaesthesia or spinal puncture and post operative indwelling 
catheters. These reactions have resulted in varying degrees of neurologic 
injuries including long-term or permanent paralysis 
(see section 4.4 Special warnings and precautions for use). 
 
1 In surgical patients, haemorrhage complications were considered major: (1) 
if the haemorrhage caused a significant clinical event, or (2) if accompanied 
by an haemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of 
blood products. Retroperitoneal and intracranial haemorrhages were always 
considered 
major. 
 
Thrombocytopenia and thrombocytosis 
 
MedDRA 
system 
organ 
class 
 
Prophylaxis in 
surgical 
patients 
 
Prophylaxis in 
medical 
patients 
 
Treatment in 
patients with 
DVT 
with or without 
PE 
 
Treatment in 
patients with 
unstable angina 
and 
non-Q-wave MI 
 
Treatment in 
patients with acute 
STEMI 
 
Blood 
and 
lymphatic 
system 
disorders 
 
Very common: 
Thrombocytosi
s* 
 
Common: 
Thrombocytop
enia 
 
Uncommon: 
Thrombocytop
enia 
 
Very common: 
Thrombocytosi
s * 
 
Common: 
Thrombocytop
enia 
 
 
Uncommon: 
Thrombocytope
nia 
 
Common: 
Thrombocytosis* 
Thrombocytopenia 
 
Very rare: 
Immuno-allergic 
thrombocytopenia 
 
*: Platelet increased > 400 G/L 
 
In addition, in post marketing experience: 
Rare: Cases of immuno-allergic thrombocytopenia with thrombosis; in some 
of them thrombosis was complicated by organ infarction or limb ischaemia 
(see section 4.4 Special warnings and precautions for use: Monitoring). 
 
Other clinically relevant adverse reactions 
 
These reactions are presented below, whatever the indications, by system 
organ class, frequency grouping and decreasing order of seriousness. 
 
 
 
 
 
 
MedDRA system 
organ class 
 
All indications 
 
Immune system 
disorders 
 
Common: Allergic reaction 
 
Rare: Anaphylactic / anaphylactoid reaction 
 
Hepatobilary 
disorders 
 
Very common: Hepatic enzymes increase (mainly transaminases 
**) 
 
Skin and 
subcutaneous 
tissue 
disorders 
 
Common: Urticaria, pruritus, erythema, 
 
Uncommon: Bullous dermatitis 
 
General disorders 
and 
administration site 
conditions 
 
Common: Injection site haematoma, injection site pain, other 
injection site reaction* 
 
Uncommon: Local irritation; skin necrosis at injection site 
 
Investigations 
 
Rare: Hyperkaliemia 
 
*: such as injection site oedema, haemorrhage, hypersensitivity, inflammation, 
mass, pain, or reaction (NOS) 
**: transaminases levels > 3 times the upper limit of normality 
 
In addition, in post marketing experience: 
• Skin and subcutaneous disorders 
Rare: 
- Cutaneous vasculitis, skin necrosis usually occurring at the injection site 
(these phenomena have been usually preceded by purpura or erythematous 
plaques, infiltrated and painful). Treatment with enoxaparin sodium must be 
discontinued. 
- Injection site nodules (inflammatory nodules, which were not cystic 
enclosure of enoxaparin). They resolve after a few days and should not cause 
treatment discontinuation. 
 
Valve thrombosis in patients with prosthetic heart valves have been reported 
rarely, usually associated with inadequate dosing (see section 4.4 Special 
warnings and precautions for use). 
 
Long term treatment with heparin has been associated with a risk of 
osteoporosis.  Although this has not been observed with enoxaparin the risk of 
osteoporosis cannot be excluded.  
 
Heparin products can cause hypoaldosteronism which may result in an 
increase in plasma potassium.  Rarely, clinically significant hyperkalaemia 
may occur particularly in patients with chronic renal failure and diabetes 
mellitus (see section 4.4 Special warnings and precautions for use). 
 
4.9 Overdose 
 
Orally administered enoxaparin is poorly absorbed and even large oral doses 
should not lead to any serious consequences.  This may be checked by plasma 
assays of anti-Xa and anti-IIa activities.  
 
Accidental overdose following parenteral administration may produce 
haemorrhagic complications.  The anticoagulant effects can be largely 
neutralised by the slow intravenous injection of Protamine, but even with high 
doses of Protamine, the anti-Xa activity of enoxaparin sodium is never 
completely neutralised (maximum about 60%). The initial dose of Protamine 
depends on the dose of enoxaparin given and also consideration of the 
maximum recommended Protamine dose (50mg).  Data on Protamine dosing 
in humans for enoxaparin overdose is extremely limited. The available data 
suggest that in the first 8 hours after enoxaparin administration 1mg Protamine 
should neutralise the effects of 1mg of enoxaparin. Where the dose of 
enoxaparin has exceeded 50mg, an initial dose of 50mg Protamine would be 
appropriate, based on the maximum recommended single protamine dose.  
Decisions regarding the necessity and dose of subsequent Protamine injections 
should be based on clinical response rather than measurement of anti Xa or 
anti XIIa results. The physician should also consider that the amount of 
enoxaparin in the body drops to 50% after 8 hours and 33% or less after 12 
hours. The dose of Protamine should be adjusted depending on the length of 
time since enoxaparin was administered.   
 
5 PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
 
 Pharmacotherapeutic group: Antithrombotic agent, heparin group.  ATC code 
B01A B05 
 
Enoxaparin is a low molecular weight heparin with a mean molecular weight 
of approximately 4,500 daltons.  The drug substance is the sodium salt. The 
molecular weight distribution is:  
<2000 daltons ≤20%  
2000 to 8000 daltons ≥68%  
>8000 daltons ≤18%  
 
Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl 
ester derived from porcine intestinal mucosa. Its structure is characterized by a 
2-O-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-
O-disulfo-D-glucosamine at the reducing end of the chain. About 20% 
(ranging between 15% and 25%) of the enoxaparin structure contains an 1,6 
anhydro derivative on the reducing end of the polysaccharide chain.  
 
Enoxaparin sodium is characterised by a higher ratio of antithrombotic activity 
to anticoagulant activity than unfractionated heparin.  At recommended doses, 
it does not significantly influence platelet aggregation, binding of fibrinogen to 
platelets or global blood clotting tests such as APTT and prothrombin time. 
Enoxaparin binds to anti-thrombin III leading to inhibition of coagulation 
factors IIa and Xa. 
 
Enoxaparin has been shown to increase the blood concentration of Tissue 
Factor Pathway Inhibitor in healthy volunteers. 
 
5.2 Pharmacokinetic properties 
 
Enoxaparin is rapidly and completely absorbed following subcutaneous 
injection.  The maximum plasma anti-Xa activity occurs 1 to 4 hours after 
injection with peak activities in the order of 0.16 IU/ml and 0.38 IU/ml after 
doses of 20 mg or 40 mg respectively.  The anti-Xa activity generated is 
localised within the vascular compartments and elimination is characterised by 
a half life of 4 to 5 hours.  Following a 40 mg dose, anti-Xa activity may 
persist in the plasma for 24 hours. 
 
A 30mg IV bolus immediately followed by a 1mg/kg SC every 12 hours 
provided initial peak anti-Factor Xa levels of 1.16IU/ml (n=16) and average 
exposure corresponding to 88% of steady state levels.  
 
A linear relationship between anti-Xa plasma clearance and creatinine 
clearance at steady-state has been observed, which indicates decreased 
clearance of enoxaparin sodium in patients with reduced renal function.   In 
patients with severe renal impairment (creatinine clearance < 30 ml/min), the 
AUC at steady state is significantly increased by an average of 65% after 
repeated, once daily subcutaneous doses of 40mg. 
 
Hepatic metabolism by desulphation and depolymerisation also contributes to 
elimination.  The elimination half life may be prolonged in elderly patients 
although no dosage adjustment is necessary. 
 
A study of repeated, once daily subcutaneous doses of 1.5 mg/kg in healthy 
volunteers suggests that no dosage adjustment is necessary in obese subjects 
(BMI 30-48 kg/m2) compared to non-obese subjects. 
 
Enoxaparin, as detected by anti-Xa activity, does not cross the placental 
barrier during the second trimester of pregnancy. 
 
Low Body Weight 
When non-weight adjusted dosing was administered, it was found after a 
single-subcutaneous 40 mg dose, that anti-Xa exposure is 52% higher in low-
weight women (<45 kg) and 27% higher in low-weight men (<57 kg) when 
compared to normal weight control subjects (see section 4.4 Special warnings 
and precautions for use: Low Body Weight). 
 
Pharmacokinetic interactions 
No pharmacokinetic interactions were observed between enoxaparin and 
thrombolytics when administered concomitantly. 
 
5.3 Preclinical safety data 
 
 No long-term studies in animals have been performed to evaluate the 
carcinogenic potential of enoxaparin. 
 
Enoxaparin was not mutagenic in in vitro tests, including the Ames test, mouse 
lymphoma cell forward mutation test, and human lymphocyte chromosomal 
aberration test, and the in vivo rat bone marrow chromosomal aberration test.  
 
Enoxaparin was found to have no effect on fertility or reproductive 
performance of male and female rats at SC doses up to 20 mg/kg/day. 
Teratology studies have been conducted in pregnant rats and rabbits at SC 
doses of enoxaparin up to 30 mg/kg/day. There was no evidence of teratogenic 
effects or fetotoxicity due to enoxaparin.  
 
Besides the anticoagulant effects of enoxaparin, there was no evidence of 
adverse effects at 15 mg/kg/day in the 13-week subcutaneous toxicity studies 
both in rats and dogs and at 10 mg/kg/day in the 26-week subcutaneous and 
intravenous toxicity studies both in rats and monkeys. 
 
6 PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Water for Injections  
 
6.2 Incompatibilities 
 
 Subcutaneous Injection 
Clexane should not be mixed with any other injections or infusions. 
 
Intravenous (Bolus) Injection for acute STEMI indication only 
Enoxaparin sodium may be safely administered with normal saline solution 
(0.9%) or 5% dextrose in water. 
 
6.3 Shelf life 
 
36 months 
 
6.4 Special precautions for storage 
 
Do not store above 25°C.  Do not refrigerate or freeze. 
Clexane pre-filled syringes are single dose containers - discard any unused 
product 
 
6.5 Nature and contents of container 
 
Solution for injection in Type I glass pre-filled syringes fitted with injection 
needle and an automatic safety device in packs of 10. 
 
6.6 Special precautions for disposal 
 
See section 4.2 Posology and method of administration. 
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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the risks and benefits of periconceptual heparin in women undergoing an ART cycle.
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B A C K G R O U N D
Description of the condition
Infertility is the failure of a couple of reproductive age to conceive
after having regular unprotected sexual intercourse for a period of
12 months or more. Primary infertility refers to couples who have
never conceived, and secondary infertility refers to couples who
have previously conceived but are unable to do so again after a
year of trying.
Infertility affects 15% of couples and is becoming increasingly
common. Of these couples, 70% will have primary and 30% sec-
ondary infertility. Assisted reproduction techniques (ART) have
been employed to help some of these couples achieve a pregnancy.
Assisted reproduction has significant physical, social, psychologi-
cal and financial implications. The success of assisted reproductive
treatment is determined by clinical pregnancy and the live birth
of a child. Live birth rates with ART vary from 5% to 60%; hence
various adjuncts have been employed during assisted reproduc-
tion to increase the likelihood of pregnancy and live birth. The
effectiveness of these adjuncts remains to be determined in many
cases. Heparin, given as an adjunct to women with or without a
known thrombophilia, is one such therapy and has been suggested
as being efficacious in improving implantation (attachment of the
fertilised egg to the wall of the uterus) and achieving pregnancy.
This Cochrane review will provide evidence-based knowledge of
the efficacy of heparin given in the periconceptual period (around
the time of conception) to reduce implantation failure in women
who have a history of infertility and are undergoing assisted repro-
duction treatments. In this review we will not be assessing the ef-
ficacy of heparin as an antithrombophilic agent (preventing blood
clots) later in pregnancy or in women with a history of recurrent
miscarriage.
Heparan sulphates have an important role in conception and early
pregnancy events. The role of heparin (a structural analogue of
Heparan) in assisted conception is, however, not clear. Heparin is
a linear polydisperse polysaccharide consisting of 1-4 linked pyra-
nosyluronic acid and 2-amino-deoxyglucopyranose (glucosamine)
residues (Comper 1981). Owing to their highly anionic nature,
heparin and heparan sulphate have high binding affinity to an-
tithrombin, growth factors, growth factor receptors, viral envelope
proteins and extracellular matrix molecules.
Heparan sulphate proteoglycans (HSPGs) are expressed through-
out the reproductive tract and are involved in the regulation of en-
dometrial cycling (Potter et al 1992; Kelly et al 1995, San Martin
et al 2004; Germeyer et al 2007; Lai et al 2007; Xu et al 2007).
Description of the intervention
When heparin is used as an adjunct treatment during assisted
reproduction, there is no consensus regarding the optimum type
of heparin, either unfractionated heparin or low molecular weight
heparin, or the dose. This is an area which will be considered in
the review.
Low molecular weight heparins (LMWH) are derived from hep-
arin by enzymatic (for example tinzaparin) or chemical (for exam-
ple dalteparin, nadroparin and enoxaparin) depolymerization of
unfractionated heparin (UFH), which in itself cannot be synthe-
sized in vitro.
UFH and LMWHs facilitate the anticoagulant effect of an-
tithrombin (Bick et al 2005) but, compared with UFH, LMWH
has reduced antifactor IIa activity leading to inefficient inhibi-
tion of thrombin by antithrombin. However, the smaller LMWH
fragments inactivate factor Xa with equal efficacy. LMWH has a
longer half-life, a more predictable antithrombotic response, and
a substantially lower risk of heparin-induced thrombocytopenia
(HIT) (Warkentin et al 1995; Warkentin and Greinacher et al
2004) and osteoporosis (Murray et al 1995), which has obvious
clinical benefits.
LMWHs have a mean molecular weight of 4300 to 5000 kDa
(range 1000 to 10 000 kDa), compared to 15,000 kDa for UFH
(Nelson and Greer et al 2008).
How the intervention might work
Implantation is a complex, dynamic processwhich involves coordi-
nationof various interactions at an intra and intercellular level. The
interaction between the developing embryo and the endometrium
is still not fully understood; however heparin can potentially mod-
ulate many of the known mechanisms that underlie the successful
implantation of the developing embryo.
Traditionally, the role of heparin in early pregnancy was believed
to be in the prevention of blood clotting during implantation and
placentation in women with inherited and acquired thrombophil-
ias. However, more recent work suggests a possible therapeutic
role for heparin in other mechanisms fundamental to implanta-
tion. UFH as well as LMWH are able to modulate the process
of decidualisation, whereby the cells in the lining of the womb
prepare for pregnancy. This positive effect on decidualisation is a
potential mechanism by which heparin improves implantation in
ART (Corvinus et al 2003, Poehlmann et al 2005, Fluhr H et al
2010).
Heparin also has the ability to bind with and modulate a wide
variety of proteins, which can alter a number of physiological pro-
cesses that are involved in implantation and trophoblastic devel-
opment. These processes include adhesion of the blastocyst to the
endometrial surface (Wang et al 2002), trophoblastic differen-
tiation and invasion (Erden et al 2006, Quenby et al 2004, Di
Simone et al 2007a, Leach et al 2004, Arai et al 1994,; Moller et
al 2006, Weigert et al 2001, Nelson and Greer et al 2008, d’Souza
et al 2007)
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Why it is important to do this review
Heparin is often offered to couples as an adjunct in an attempt
to improve live birth rates, its presumed effect being to improve
implantation. Clinicians may be using heparin as an adjunct based
on biological plausibility rather than evidence of efficacy.
A systematic review is required to determine the efficacy of heparin
to increase pregnancy and live birth rates and reduce adverse peri-
natal outcomes for all women undergoing assisted reproduction.
O B J E C T I V E S
To evaluate the risks and benefits of periconceptual heparin in
women undergoing an ART cycle.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Truly randomised controlled trials (RCTs).
Only trials that are either clearly randomised or claim to be ran-
domised and do not have evidence of inadequate sequence gener-
ation such as date of birth or hospital number will be included.
Types of participants
All women undergoing assisted reproduction treatment (ART)
with a history of infertility. Women undergoing stimulated or
unstimulated intrauterine insemination (IUI)will not be included.
Women with a previously known thrombophilia will not be ex-
cluded.
Types of interventions
1. Heparin versus no treatment
2. Heparin versus placebo
3. Heparin versus aspirin
4. Heparin versus heparin and aspirin
5. Unfractionated heparin (UFH) versus low molecular weight
heparin (LMWH)
Studies will be included if heparin was administered in the peri-
conceptual period (from the day of egg collection or embryo trans-
fer to 14 days later).
Types of outcome measures
Primary outcomes
1. Live birth rate per woman
- Number of live births divided by the number of randomised
women (live birth is defined as delivery of one ormore live infants)
2. Adverse effects of heparin e.g. any bleeding, bruising, heparin-
induced thrombocytopenia (HIT), anaphylaxis and any other un-
expected side effects
Secondary outcomes
1. Clinical pregnancy rate per woman
- Number of clinical pregnancies divided by the number of ran-
domised women
The presence of a gestational sacwith fetal heart beat onultrasound
scan defines a clinical pregnancy.
2. Pregnancy rate per woman
Number of women achieving a pregnancy divided by the number
of randomised women
3. On-going pregnancy rate per woman
- Number of women achieving an on-going pregnancy divided by
the number of randomised women (pregnancies going beyond 12
weeks duration)
4. Multiple pregnancy rate per woman
- Incidence of multiple pregnancy per randomised women
The demonstration of more than one sac with a fetal pole on
ultrasound scan defines multiple pregnancies.
5. Maternal pregnancy complications including first trimester
miscarriage, second trimester miscarriage, preterm delivery, pre-
eclampsia, pregnancy-induced hypertension, any maternal bleed-
ing
6. Fetal complications during pregnancy including intrauterine
growth restriction, placenta previa, placental abruption
Additional outcomes not appropriate for statistical
pooling
Data per cycle, per pregnancy or per embryo transfer (ET) are not
appropriate for pooling because ofwhat statisticians refer to as ’unit
of analysis errors’. Simple group comparison tests for categorical
data require that observations are statistically independent. The
use ofmultiple observations per woman leads to unpredictable bias
in the estimate of treatment difference (Vail et al 2003). However,
due to the frequency with which this form of data is reported in
subfertility research itwill be entered into the ’table of comparisons’
for the following outcomes:
• implantation rate, the number of fetal sacs divided by the number
of embryos transferred;
• incidence of miscarriage per total number of pregnancies;
• incidence of multiple pregnancies per total number of pregnan-
cies.
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Search methods for identification of studies
A comprehensive and exhaustive search strategy has been devel-
oped in consultation with the Trials Search Coordinator of the
Cochrane Menstrual Disorders and Subfertility Group. The strat-
egywill be used in an attempt to identify all relevant studies regard-
less of language or publication status (published, unpublished, in
press, and in progress). Relevant trials will be identified from both
electronic databases and other resources.
Completion of the review is expected within one year of publi-
cation of the protocol on The Cochrane Library. It is also the in-
tention of the review authors that a new search for RCTs will be
performed every two years.When an important study is published
we will update the review accordingly.
Electronic searches
We will search the following electronic databases, from inception
to the present with the Cochrane highly sensitive search strategy
for identifying randomised trials, which appears in the Cochrane
Handbook for Systematic Reviews of Interventions (version 5.1.0;
chapter 6, 6.4.11) (Higgins 2011).
1. The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library latest issue) (see Appendix 1).
2. English language electronic databases: MEDLINE, EMBASE
and PsycINFO (see Appendix 2, Appendix 3, Appendix 4).
3. The Cochrane Library (www.cochrane.org/index.htm) for
DARE, the Database of Abstracts of Reviews of Effects (reference
lists from non-Cochrane reviews on similar topics).
4. Current Controlled Trials (www.controlled-trials.com).
5. The World Health Organization International Trials Registry
Platform search portal (www.who.int/trialsearch/Default.aspx).
Searching other resources
We will search the references lists of all included studies and rele-
vant reviews to identify further relevant articles.
If required, we will contact authors and experts in the relevant
field for potential studies.
We will do a search for grey literature.
Data collection and analysis
Wewill perform statistical analysis in accordancewith theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Review Manager 5.1 will be used for input of data.
Selection of studies
The title, abstract, and keywords of every record retrieved will
be scrutinized independently by two review authors to determine
which studies require further assessment. The full text will be re-
trieved when the information given in the titles, abstracts, and
keywords suggest that the randomised controlled study interven-
tion is heparin as an adjunct to assisted reproduction therapy.
If there are any doubts regarding these criteria, from scanning the
titles and abstracts, the full article will be retrieved for clarification.
Disagreements will be resolved by discussion with a third review
author (Professor S Quenby), if necessary. The authors of trials
will be contacted to provide missing data, if required.
Data extraction and management
The following information will be extracted from the studies in-
cluded in the review. It will be presented in the table ’Character-
istics of included studies’.
Trial characteristics
These will include:
1. method of generating randomisation sequence;
2. allocation concealment;
3. trial design;
4. number of women screened for eligibility then randomised,
excluded, and finally analysed;
5. duration, timing, and location of the trial;
6. source of funding.
Baseline characteristics of the studied groups
1. Age of the women
2. Duration of infertility
3. Type of ART
4. Previous fertility treatments
Intervention
1. Type of intervention and control group
2. Dose regimen and timing
Outcomes
1. Outcomes
2. How outcomes were defined
3. How outcomes were measured
4. Timing of outcome measurement
All data will be extracted independently by two review authors us-
ing forms designed according to Cochrane guidelines. Additional
information will be sought from the authors on trial methodology
and trial data for trials that appear to meet the eligibility criteria
but have aspects of methodology that are unclear or data in an
unsuitable form for meta-analysis.
Differences of opinion are to be noted and resolved by consensus.
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Assessment of risk of bias in included studies
Assessment of risk of bias in the included studies will be indepen-
dently performed by two review authors; disagreements will be
noted and resolved by a third review author.
The risk of bias table will be included in the table ’Characteristics
of included studies’.
The following risk of bias domains will be assessed according to
modificationof the quality criteria specified by theCochrane Hand-
book for Systematic Reviews of Interventions 5.1.0.
1. Random sequence generationmethod (e.g. computer generated,
random number tables, or drawing lots)
2. Allocation concealment: adequate (e.g. third party, sealed en-
velopes); inadequate (e.g. open list of allocation codes); not clear
(e.g. not stated).
3. Blinding of participants, personnel, and outcome assessors.
4. Whether an intention-to-treat analysis was performed or not.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Any other sources of bias not included in this protocol.
Measures of treatment effect
All outcomes are expected to be dichotomous. We will use the
numbers of events in the control and intervention groups of each
study to calculate odds ratios (OR) with 95% confidence intervals
(CI).
Unit of analysis issues
The primary analysis will be per woman randomised. Reported
data that do not allow valid analysis (for example, ’per cycle’ rather
than ’per woman’, where women contribute more than one cycle)
will be briefly summarised in an additional table and will not be
used in meta-analysis. Multiple live births (for example, twins or
triplets) will be counted as one live birth event.
In cross-over trials, only first cycle data will be included in the
analysis.
Dealing with missing data
We will contact the authors of the RCTs to source any missing
data or to resolve any queries that may arise.
If requiredwewill extract data to allow an intention-to-treat analy-
sis (this analysis will include all the participants in the original ran-
domly assigned groups). If the participant numbers randomised
and the numbers analysed are inconsistent then the percentage
loss to follow up will be calculated and reported in an additional
table.
Assessment of heterogeneity
The review authors will check to see if the participants, interven-
tions, and outcomes in the included studies are similar enough to
consider pooling in a meta-analysis.
Tests for statistical heterogeneity in pooled data will be carried out
using the Chi2 test, with significance set at P < 0.1. The I2 statistic
will be used to estimate the total variation across studies that is
due to heterogeneity, where < 25% is considered as low-level, 25%
to 50% as moderate-level, and > 50% as high-level heterogeneity.
If high levels of heterogeneity (I2 > 50%) are seen for primary
outcomes, we will explore possible sources of heterogeneity using
sensitivity and subgroup analyses described below.
Assessment of reporting biases
Potential publication bias will be assessed using a funnel plot, or
other corrective analytical methods, depending on the number of
included studies (Egger et al 1997).
Data synthesis
Meta-analyses will be performed, as appropriate, where data are
available from multiple studies investigating the same treatment,
and where the outcome has been measured in a standard way
between the studies. A fixed-effect model will be used. We will
undertake this meta-analysis according to methods recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). An increase in the odds of a particular outcome,
which may be beneficial (for example, live birth) or detrimental
(for example, adverse effects), will be displayed graphically in the
meta-analyses to the right of the centre-line and a decrease in the
odds of an outcome to the left of the centre-line.
Subgroup analysis and investigation of heterogeneity
Where data are available, we will conduct subgroup analyses to
investigate the following.
1. Efficacy of heparin with different ART excluding IUI.
2. Efficacy of adjunct therapy of heparin with or without throm-
bophilia for women undergoing ART.
3.Duration, dose, timing and type of heparin therapy duringART.
4. Any other adjunct therapy used in addition with heparin during
ART.
5. Efficacy of heparin during ART according to age.
6. Efficacy of heparin during ART according to number of im-
plantation failures.
7. Efficacy of heparin with fresh versus frozen embryo transfer.
Factors such as length of follow-up and use of adjusted or unad-
justed analysis will be considered in interpretation of any hetero-
geneity.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size:
1. Publication status of studies (published or unpublished)
2. Study quality, such as allocation concealment, blinding, and
numbers lost to follow up (considered separately).
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Appendix 1. CENTRAL search strategy
Menstrual Disorders and Subfertility Group Specialised Register (inception to present)
Ovid the Cochrane Central Register of Controlled Trials (CENTRAL) (inception to present)
There is no language restriction in these search.
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
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13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24 (8324)
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1950 to
present)
TheMEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomized trials which
appears in the Cochrane Handbook of Systematic Reviews of Interventions (version 5.0.2; chapter 6, 6.4.11)
There is no language restriction in this search
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
8Heparin for assisted reproduction (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
40 randomized controlled trial.pt.
41 controlled clinical trial.pt.
42 randomized.ab.
43 placebo.tw.
44 clinical trials as topic.sh.
45 randomly.ab.
46 trial.ti.
47 (crossover or cross-over or cross over).tw.
48 or/40-47
49 exp animals/ not humans.sh.
50 48 not 49
51 39 and 50
Appendix 3. EMBASE search strategy
Ovid EMBASE (01.01.10 to present)
EMBASE is only searched one year back as the UKCC has hand searched EMBASE to this point and these trials are already in
CENTRAL.
The EMBASE search is combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) http:/
/www.sign.ac.uk/mehodology/filters.html#random
There is no language restriction in this search
1 exp embryo transfer/ or exp female infertility/ or exp fertilization in vitro/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
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10 exp artificial insemination/
11 artificial$ inseminat$.tw.
12 reproductive technique$.tw.
13 reproduct$ technolog$.tw.
14 exp nidation/
15 (implant$ adj2 fail$).tw.
16 reproduct$ technique$.tw.
17 ((Female$ or women) adj2 infertil$).tw.
18 ((Female$ or women) adj2 subfertil$).tw.
19 exp recurrent abortion/
20 recurrent miscarriage.tw.
21 iui.tw.
22 intrauterine insemination.tw.
23 nidation.tw.
24 exp intracytoplasmic sperm injection/
25 or/1-24
26 exp HEPARIN/ or exp LOW MOLECULAR WEIGHT HEPARIN/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
40 Clinical Trial/
41 Randomized Controlled Trial/
42 exp randomization/
43 Single Blind Procedure/
44 Double Blind Procedure/
45 Crossover Procedure/
46 Placebo/
47 Randomi?ed controlled trial$.tw.
48 Rct.tw.
49 random allocation.tw.
50 randomly allocated.tw.
51 allocated randomly.tw.
52 (allocated adj2 random).tw.
53 Single blind$.tw.
54 Double blind$.tw.
55 ((treble or triple) adj blind$).tw.
56 placebo$.tw.
57 prospective study/
58 or/40-57
59 case study/
60 case report.tw.
61 abstract report/ or letter/
62 or/59-61
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63 58 not 62
64 39 and 63
65 (2010$ or 2011$).em.
66 64 and 65
Appendix 4. PsycINFO search strategy
Ovid PsycINFO (1806 to present)
There is no language restriction in this search
1 exp Reproductive Technology/
2 exp Infertility/
3 exp Embryo/
4 embryo transfer$.tw.
5 in vitro fertili?ation.tw.
6 ivf-et.tw.
7 (ivf or et).tw.
8 icsi.tw.
9 intracytoplasmic sperm injection$.tw.
10 (blastocyst adj2 transfer$).tw.
11 (assist$ adj2 reproducti$).tw.
12 artificial$ inseminat$.tw.
13 iui.tw.
14 intrauterine insemination.tw.
15 nidation.tw.
16 reproductive technique$.tw.
17 reproduct$ technolog$.tw.
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 ((Female$ or women) adj2 infertil$).tw.
21 ((Female$ or women) adj2 subfertil$).tw.
22 exp Spontaneous Abortion/
23 recurrent miscarriage$.tw.
24 or/1-23
25 exp Heparin/
26 heparin$.tw.
27 LMWH$.tw.
28 liquemin.tw.
29 enoxaparin.tw.
30 heparinic acid.tw.
31 dalteparin.tw.
32 tinzaparin.tw.
33 clexane.tw.
34 lovenox.tw.
35 indenox.tw.
36 xaparin.tw.
37 or/25-36
38 24 and 37
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A B S T R A C T
Background
Heparin as an adjunct in assisted reproduction (peri-implantation heparin) is given at or after egg collection or at embryo transfer during
assisted reproduction. Heparin has been advocated to improve embryo implantation and clinical outcomes. It has been proposed that
heparin enhances the intra-uterine environment by improving decidualisation with an associated activation of growth factors and a
cytokine expression profile in the endometrium that is favourable to pregnancy.
Objectives
To investigate whether the administration of heparin around the time of implantation (peri-implantation heparin) improves clinical
outcomes in subfertile women undergoing assisted reproduction.
Search methods
A comprehensive and exhaustive search strategy was developed in consultation with the Trials Search Co-ordinator of the Cochrane
Menstrual Disorders and Subfertility Group (MDSG). The strategy was used in an attempt to identify all relevant studies regardless of
language or publication status (published, unpublished, in press, and in progress). Relevant trials were identified from both electronic
databases and other resources (last search 6 May 2013).
Selection criteria
All randomised controlled trials (RCTs) were included where peri-implantation heparin was given during assisted reproduction. Peri-
implantation low molecular weight heparin (LMWH) during IVF/ICSI was given at or after egg collection or at embryo transfer in
the included studies. Live birth rate was the primary outcome.
Data collection and analysis
Two review authors independently assessed the eligibility and quality of trials and extracted relevant data. The quality of the evidence
was evaluated using GRADE methods.
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Main results
Three RCTs (involving 386 women) were included in the review.
Peri-implantation LMWH administration during assisted reproduction was associated with a significant improvement in live birth rate
compared with placebo or no LMWH (odds ratio (OR) 1.77, 95% confidence interval (CI) 1.07 to 2.90, three studies, 386 women,
I2 = 51%, very low quality evidence with high heterogeneity). There was also a significant improvement in the clinical pregnancy
rate with use of LMWH (OR 1.61, 95% CI 1.03 to 2.53, three studies, 386 women, I2 = 29%, very low quality evidence with low
heterogeneity).
However these findings should be interpreted with extreme caution as they were dependent upon the choice of statistical method: they
were no longer statistically significant when a random-effects model was used.
Adverse events were poorly reported in all included studies, with no comparative data available. However, LMWH did cause adverse
effects including bruising, ecchymosis, bleeding, thrombocytopenia and allergic reactions. It appeared that these adverse effects were
increased if heparin therapy was used over a longer duration.
Authors’ conclusions
The results of this Cochrane review of three randomised controlled trials with a total of 386 women suggested that peri-implantation
LMWH in assisted reproduction treatment (ART) cycles may improve the live birth rate in women undergoing assisted reproduction.
However, these results were dependent on small low quality studies with substantial heterogeneity, and were sensitive to the choice of
statistical model. There were side effects reported with use of heparin, including bruising and bleeding, and no reliable data on long-
term effects. The results do not justify this use of heparin outside well-conducted research trials.
These findings need to be further investigated with well-designed, adequately powered, double-blind, randomised, placebo-controlled,
multicentre trials. Further investigations could also focus on the effects of the local (uterine) and not systemic application of heparin
during ART.
P L A I N L A N G U A G E S U M M A R Y
Heparin for assisted reproduction
Review Question
Researchers in The Cochrane Collaboration reviewed the evidence about the effect of administration of heparin around the time of
implantation, compared with placebo or no treatment, on clinical outcomes in subfertile women undergoing assisted reproduction.They
found three randomised controlled trials.
Background
Heparin is a class of blood thinning drugs that are used in the prevention and treatment of blood clots. It had been suggested that
heparin could improve the intrauterine environment by increasing growth factors to improve attachment of the embryo to the lining
of the womb. The result could be an improvement in pregnancy rates during assisted reproduction.
Study Characteristics
Three studies with 386 participants were included in the review. All studies included subfertile women undergoing assisted reproduction.
The characteristics of the participants differed across studies. One study included women having their first IVF cycle, with no blood
clotting disorder. Another study included women with at least one blood clotting disorder. The third study included women with at
least two previous unsuccessful assisted reproduction treatment cycles. Low molecular weight heparin (as daily injections) was given to
women from the time of egg collection or embryo transfer during assisted reproduction in all three studies. There were no issues with
source of funding in any of the studies. The evidence is current to May 2013.
Key Results
The results of this Cochrane review found evidence suggesting that heparin may increase live births and clinical pregnancies. However,
these findings should be interpreted with extreme caution as the findings were no longer statistically significant when the review authors
checked the effect of using an alternative method of analysis. Moreover, the quality of the trial evidence was poor, heparin had side
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effects such as bruising and bleeding, and its long-term safety has not been established. The evidence does not justify heparin use
outside well-designed clinical research trials. Such trials are a priority.
Quality of Evidence
The evidence was of very low quality due to small studies with different populations of subfertile women, and inconsistency when using
different statistical tests and analyses. So we suggest that further well-designed randomised controlled studies are needed to clarify the
possible role of heparin in assisted reproduction.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin for assisted reproduction
Population: Subfertile women
Settings: Assisted reproduction treatment (ART)
Intervention: Heparin versus placebo or no heparin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Heparin
Live birth rate per
woman
173 per 1000 271 per 1000
(183 to 378)
OR 1.77
(1.07 to 2.9)
386
(3 studies)
⊕©©©
very low1
Clinical pregnancy rate
per woman
250 per 1000 349 per 1000
(256 to 458)
OR 1.61
(1.03 to 2.53)
386
(3 studies)
⊕©©©
very low1
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Selection Bias found in one study. High Heterogeneity. Results sensitive to choice of statistical model
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B A C K G R O U N D
Description of the condition
Infertility is the failure of a couple of reproductive age to conceive
after having regular unprotected sexual intercourse for a period of
12 months or more. Primary infertility refers to couples who have
never conceived, and secondary infertility refers to couples who
have previously conceived but are unable to do so again after a
year of trying.
Infertility affects 15% of couples and is becoming increasingly
common. Of these couples, 70% will have primary and 30% sec-
ondary infertility. Assisted reproduction techniques (ART) have
been employed to help some of these couples achieve a pregnancy.
Assisted reproduction has significant physical, social, psychologi-
cal and financial implications. The success of ART can be defined
as the live birth of a child. Live birth rates with ART vary from
30% to 50%; hence various adjuncts have been employed during
assisted reproduction to increase the likelihood of pregnancy and
live birth. The effectiveness of these adjuncts remains to be de-
termined in many cases. Heparin, given as an adjunct to women
with or without a known thrombophilia, is one such therapy and
has been suggested as being efficacious in improving implantation
(attachment of the fertilised egg to the wall of the uterus) and
achieving pregnancy.
Description of the intervention
Heparan sulphates have an important role in conception and early
pregnancy events. However the role of heparin (a structural ana-
logue of heparan) in assisted conception is not clear. Heparin is a
linear polydisperse polysaccharide consisting of 1-4 linked pyra-
nosyluronic acid and 2-amino-deoxyglucopyranose (glucosamine)
residues (Comper 1981). Owing to their highly anionic nature,
heparin and heparan sulphate have high binding affinity to an-
tithrombin, growth factors, growth factor receptors, viral envelope
proteins and extracellular matrix molecules.
Heparan sulphate proteoglycans (HSPGs) are expressed through-
out the reproductive tract and are involved in the regulation of
endometrial cycling (Potter 1992; Kelly 1995, San Martin 2004;
Germeyer 2007; Lai 2007; Xu 2007).
Low molecular weight heparins (LMWH) are derived from hep-
arin by enzymatic (for example tinzaparin) or chemical (for exam-
ple dalteparin, nadroparin and enoxaparin) depolymerisation of
unfractionated heparin (UFH), which in itself cannot be synthe-
sised in vitro.
Unfractionated heparin and LMWH facilitate the anticoagulant
effect of antithrombin (Bick 2005) but, compared with unfrac-
tionated heparin, LMWH has reduced antifactor IIa activity lead-
ing to inefficient inhibition of thrombin by antithrombin. How-
ever, the smallerweight LMWHinactivates factorXawith equal ef-
ficacy. Low molecular weight heparin has a longer half-life, a more
predictable antithrombotic response, and a substantially lower risk
of heparin-induced thrombocytopenia (HIT) (Warkentin 1995;
Warkentin 2004) and osteoporosis (Murray 1995), thus having
obvious clinical benefits. So in practice, LMWH is used routinely
with daily self-administered subcutaneous injections, not requir-
ing close monitoring and with lower risk of side effects.
Low molecular weight heparins have a mean molecular weight of
4300 to 5000 kDa (range 1000 to 10,000 kDa), compared to
15,000 kDa for unfractionated heparin (Nelson 2008).
How the intervention might work
Implantation is a complex, dynamic process which involves co-
ordination of various interactions at an intra- and intercellular
level. The interaction between the developing embryo and the en-
dometrium is still not fully understood; however heparin can po-
tentially modulate many of the known mechanisms that underlie
the successful implantation of the developing embryo.
Traditionally the role of heparin in early pregnancy was believed to
be in the preventionof blood clotting during implantation andpla-
centation in women with inherited and acquired thrombophilia.
However, more recent work suggests a possible therapeutic role
for heparin in other mechanisms fundamental to implantation.
Unfractionated heparin as well as LMWH are able to modulate
the process of decidualisation, whereby the cells in the lining of
the womb prepare for pregnancy. This positive effect on decid-
ualisation is a potential mechanism by which heparin improves
implantation in ART (Corvinus 2003, Poehlmann 2005, Fluhr H
2010).
Heparin also has the ability to bind with and modulate a wide
variety of proteins, which can influence a number of physiologi-
cal processes involved in implantation and trophoblastic develop-
ment. These processes include adhesion of the blastocyst to the
endometrial surface (Wang 2002) and trophoblastic differentia-
tion and invasion (Arai 1994;Weigert 2001; Leach 2004; Quenby
2004; Erden 2006; Moller 2006; Di Simone 2007; d’Souza 2007;
Nelson 2008).
Why it is important to do this review
Heparin is often offered to couples as an adjunct in an attempt
to improve live birth rates, its presumed effect being to improve
implantation. Clinicians may be using heparin as an adjunct based
on biological plausibility rather than evidence of efficacy. A sys-
tematic review is required to determine the efficacy of heparin to
increase pregnancy and live birth rates and reduce adverse perina-
tal outcomes for all women undergoing assisted reproduction.
When heparin is used as an adjunct treatment during assisted
reproduction, there has been no consensus regarding the optimum
type of heparin (unfractionated heparin or LMWH) timing or the
dose. This is an area which we considered in the review.
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This Cochrane review aims to provide evidence about the efficacy
of heparin given in the peri-implantation period (around the time
of conception) to reduce implantation failure in women who have
a history of infertility and are undergoing assisted reproduction
treatments. In this review we do not assess the efficacy of heparin
as an anti-thrombophilic agent (preventing blood clots) later in
pregnancy or in women with a history of recurrent miscarriage.
O B J E C T I V E S
To investigate whether the administration of heparin around the
time of implantation improves clinical outcomes in subfertile
women undergoing assisted reproduction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included trials of women undergoing assisted reproduction
treatment (ART) with a history of infertility. Trials of women with
a previously known thrombophilia were included.
Trials involving women undergoing stimulated or unstimulated
intrauterine insemination (IUI) were not included.
Types of interventions
1. Heparin versus no treatment.
2. Heparin versus placebo.
3. Heparin versus aspirin.
4. Heparin versus heparin and aspirin.
5. Unfractionated heparin (UFH) versus low molecular weight
heparin (LMWH).
Studies were included if heparin was administered in the peri-
implantation period (from the day of egg collection or embryo
transfer (ET) to 14 days later).
Types of outcome measures
Primary outcomes
1. Live birth rate per woman. Number of live births divided
by the number of randomised women (live birth is defined as
delivery of one or more live infants).
2. Adverse effects of heparin e.g. any bleeding, bruising,
heparin-induced thrombocytopenia (HIT), anaphylaxis and any
other unexpected side effects.
Secondary outcomes
1. Clinical pregnancy rate per randomised woman. The
presence of at least one gestational sac with fetal heart beat on
ultrasound scan defines a clinical pregnancy.
2. Multiple pregnancy rate per randomised woman. The
demonstration of more than one sac with a fetal pole on
ultrasound scan defines multiple pregnancies.
3. Maternal pregnancy complications including first trimester
miscarriage, second trimester miscarriage, preterm delivery, pre-
eclampsia, pregnancy-induced hypertension, any maternal
bleeding.
4. Fetal complications during pregnancy including
intrauterine growth restriction, placenta previa, placental
abruption.
Additional outcomes not appropriate for statistical pooling
Data per cycle, per pregnancy or per ET are not appropriate for
pooling because of what statisticians refer to as ’unit of analysis
errors’. Simple group comparison tests for categorical data require
that observations are statistically independent. The use of multiple
observations per woman leads to unpredictable bias in the estimate
of treatment difference Vail 2003. However, due to the frequency
with which this form of data are reported in subfertility research,
we planned to report the following outcomes in narrative form:
• implantation rate, the number of fetal sacs divided by the
number of embryos transferred;
• incidence of miscarriage per total number of pregnancies;
• incidence of multiple pregnancies per total number of
pregnancies.
Search methods for identification of studies
A comprehensive search strategy was developed in consultation
with the Trials Search Co-ordinator of the Cochrane Menstrual
Disorders and Subfertility Group (MDSG). The strategy was used
in an attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress). Relevant trials were identified from both electronic
databases and other resources.
This review will be updated every two years.
Electronic searches
We searched the following electronic databases, from inception to
6 May 2013 with the Cochrane highly sensitive search strategy
for identifying randomised trials, which appears in the Cochrane
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Handbook for Systematic Reviews of Interventions (version 5.1.0;
chapter 6, 6.4.11) (Higgins 2011):
1. The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library latest issue) (see Appendix
1).
2. English language electronic databases: MEDLINE,
EMBASE and PsycINFO (see Appendix 2, Appendix 3,
Appendix 4).
3. The Cochrane Library (www.cochrane.org/index.htm) for
DARE, the Database of Abstracts of Reviews of Effects (reference
lists from non-Cochrane reviews on similar topics).
4. Current Controlled Trials (www.controlled-trials.com).
5. The World Health Organization International Trials
Registry Platform search portal (www.who.int/trialsearch/
Default.aspx).
Searching other resources
We searched the references lists of all included studies and relevant
reviews to identify further relevant articles and when required, we
contacted authors and experts in the relevant field for potential
studies.
We performed a search for grey literature.
Data collection and analysis
We performed statistical analysis in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Review Manager 5.1 was used to input data.
Selection of studies
The title, abstract, and keywords of every record retrieved were
scrutinised independently by two review authors (MA, SS) to de-
termine which studies required further assessment. The full texts
were retrieved when the information given in the titles, abstracts,
and keywords suggested that the randomised controlled study in-
tervention was heparin as an adjunct to assisted reproduction ther-
apy.
If there were any doubts regarding these criteria from scanning the
titles and abstracts, the full articles were retrieved for clarification.
Disagreements were resolved by discussion with a third review au-
thor (Professor S Quenby), if necessary. We contacted the authors
of trials to provide missing data, if required.
Data extraction and management
The following informationwas extracted from the studies included
in the review. It is presented in the table ’Characteristics of included
studies’.
Trial characteristics
This includes the following items.
1. Method of generating randomisation sequence.
2. Allocation concealment.
3. Trial design.
4. Number of women screened for eligibility then
randomised, excluded, and finally analysed.
5. Duration, timing, and location of the trial.
6. Source of funding.
Baseline characteristics of the studied groups
1. Age of the women.
2. Duration of infertility.
3. Type of ART.
4. Previous fertility treatments.
Intervention
1. Type of intervention and control group.
2. Dose regimen and timing.
Outcomes
1. Outcomes.
2. How outcomes were defined.
3. How outcomes were measured.
4. Timing of outcome measurement.
All data were extracted independently by two review authors (MA,
SS) using forms designed according to Cochrane guidelines. Addi-
tional information was sought from the authors on trial method-
ology and trial data for trials that appeared to meet the eligibility
criteria but had aspects of methodology that were unclear or where
data were in an unsuitable form for meta-analysis. We planned to
settle any differences of opinion by discussion between the review
authors, but there were no disagreements.
Assessment of risk of bias in included studies
Assessment of risk of bias in the included studies was indepen-
dently performed by two review authors (MA, SS). Disagreements
were noted and resolved by a third review author (SQ).
The ’Risk of bias’ table was included in the Characteristics of
included studies
The following ’Risk of bias’ domainswere assessed according to the
criteria specified by the Cochrane Handbook for Systematic Reviews
of Interventions 5.1.0.
1. Selection bias: Random sequence generation method (e.g.
computer-generated, random number tables, or drawing lots)
and allocation concealment: adequate(e.g. third party, sealed
envelopes); inadequate (e.g. open list of allocation codes); not
clear (e.g. not stated).
2. Performance bias: Blinding of participants and personnel.
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3. Detection bias: Blinding of outcome assessments.
4. Attrition bias: Incomplete outcome data and intention-to-
treat analysis if used.
5. Reporting bias: selective outcome reporting.
6. Other bias: Any other potential sources of bias not included
in this protocol.
Measures of treatment effect
All outcomes were dichotomous. We used the numbers of events
in the control and intervention groups of each study to calculate
odds ratios (OR) with 95% confidence intervals (CI).
Unit of analysis issues
The primary analysis was per woman randomised. Reported data
that did not allowvalid analysis (for example, ’per cycle’ rather than
’per woman’, where women contribute more than one cycle) were
briefly summarised in an additional table and were not used in
meta-analysis. Multiple live births (for example, twins or triplets)
were counted as one live birth event.
Dealing with missing data
The data were analysed on an intention-to-treat basis as far as
possible and attempts were made to obtain missing data from the
original trialists.Where these were unobtainable, only the available
data were analysed.
Assessment of heterogeneity
The review authors (MA, SS) considered whether the participants,
interventions, and outcomes in the included studies were similar
enough to consider pooling in a meta-analysis.
Tests for statistical heterogeneity in pooled data were carried out
using the Chi2 test, with significance set at P < 0.1. The I2 statistic
was used to estimate the total variation across studies that was due
to heterogeneity, where < 25% was considered as low-level, 25%
to 50% as moderate-level, and > 50% as high-level heterogeneity.
If high levels of heterogeneity (I2 > 50%) were seen for primary
outcomes, we explored possible sources of heterogeneity using
sensitivity and subgroup analyses.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases for primary outcomes, we per-
formed a comprehensive search for eligible studies and were alert
for duplication of data. We planned to use a funnel plot to explore
the possibility of small study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies)
if there were 10 or more studies in the primary analysis (Egger
1997).
Data synthesis
Meta-analyses were performed, as appropriate, where data were
available from multiple studies investigating the same treatment
and where the outcomes had been measured in a standard way.
A fixed-effect model was used. We undertook this meta-analysis
according to methods recommended in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). An increase
in the odds of a particular outcome, which may be beneficial (for
example, live birth) or detrimental (for example, adverse effects),
were displayed graphically in the meta-analyses to the right of the
centre-line and a decrease in the odds of an outcome to the left of
the centre-line.
Subgroup analysis and investigation of heterogeneity
If there were sufficient data, we planned to perform the following
subgroup analyses.
1. Efficacy of heparin with different ART excluding IUI.
2. Efficacy of adjunct therapy of heparin with or without
thrombophilia for women undergoing ART.
3. Duration, dose, timing and type of heparin therapy during
ART.
4. Any other adjunct therapy used in addition with heparin
during ART.
5. Efficacy of heparin during ART according to age.
6. Efficacy of heparin with fresh versus frozen ET.
Sensitivity analysis
We performed sensitivity analyses for the primary outcomes to
determine whether the review conclusions would have differed if:
1. eligibility were restricted to studies without high risk of
bias;
2. a random-effects model had been adopted;
3. the summary effect measure had been risk ratio rather than
odds ratio.
Overall quality of the body of evidence: ’Summary of
findings’ table
A ’Summary of findings’ table was generated using GRADEPRO
software. This table evaluated the overall quality of the body of
evidence for main review outcomes, using GRADE criteria (study
limitations (i.e. risk of bias), consistency of effect, imprecision, in-
directness and publication bias). Judgements about evidence qual-
ity (high, moderate or low) were justified, documented, and in-
corporated into reporting of results for main outcomes.
R E S U L T S
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Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Seven studies were identified that assessed the use of peri-implan-
tation heparin in assisted reproduction. Of these only three stud-
ies were eligible for the review. They compared heparin alone
versus either no heparin or placebo. The results of one study
were not published yet, however, the characteristics of that study
(Mashayekhy 2011) are available in ’Characteristics of studies
awaiting classification (completed but not yet published)’. Full
agreement existed between the two researchers, concerning inclu-
sion or exclusion of trials. Figure 1
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Figure 1. Study Review flow diagram.
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Included studies
Three studies Qublan 2008; Urman 2009; Noci 2011 met the
criteria for inclusion in this review. For details see Characteristics
of included studies
Participants
The total number of trial participants was 386. The upper age
limit was < 40 years in all participants in the included studies.
Interventions
All women were included for a single IVF/ICSI (in vitro fertilisa-
tion/intracytoplasmic sperm injection) cycle only. Low molecular
weight heparin (LMWH) was administered from either oocyte re-
trieval or embryo transfer (ET), so the treatment protocol varied
across studies.
In Qublan 2008, LMWH therapy treatment was started from the
day of ET until results of Beta-hCG were available two weeks
after ET. If Beta-hCG was 425 IU/mL, LMWH was continued
either until delivery or foetal demise was diagnosed. In Noci 2011
LMWH treatment was started on the day of oocyte retrieval until
nineweeks of pregnancywith positive pregnancy results. InUrman
2009 LMWH treatment was started a day after oocyte retrieval
until 12 weeks of pregnancy with positive pregnancy test results.
Control groups in these studies received placebo (Qublan 2008)
or no heparin (Urman 2009; Noci 2011)
Outcomes
All three included studies reported live birth rate per woman as
the primary outcome, adverse effects, clinical pregnancy rate per
woman, multiple pregnancy rate per woman, implantation rate
per woman and miscarriage rate per woman.
Additional outcomes not appropriate for statistical pooling
Data per cycle, per pregnancy or per ET were not appropriate for
pooling. We have reported the following in additional tables:
• implantation rate, the number of fetal sacs divided by the
number of embryos transferred; Table 1
• incidence of miscarriage per total number of pregnancies;
Table 2
• incidence of multiple pregnancies per total number of
pregnancies; Table 3
Excluded studies
Three studies failed to meet the inclusion criteria. Colicchia 2011
was excluded because LMWHwas used in conjunction with pred-
nisolone. Stern 2003 was excluded because unfractionated hep-
arin (UFH) was used in conjunction with low-dose aspirin. Berker
2011 was excluded because it was a quasi-randomised study. De-
tails are provided in Characteristics of excluded studies.
Risk of bias in included studies
The methodological quality of included studies was documented
in the ’Risk of bias’ table for each individual study. The ’Risk of
bias’ summary and ’Risk of bias’ graph are presented as Figure 2
and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
All three studies were rated as at low risk of this bias.
Allocation concealment
Two studies were rated as at low risk of this bias (Noci 2011;
Urman 2009). The third study was rated as at unclear risk, as
concealment of allocation was not described Qublan 2008.
Blinding
All three studies were rated as at high risk of performance bias.
Two studies were rated as at high risk of detection bias (Qublan
2008; Urman 2009); the other as low risk of detection bias (Noci
2011).
Incomplete outcome data
No dropouts of participants were reported in one study (Qublan
2008).
In Urman 2009, 153 women were recruited to the trial. Three
women in the treatment and control groups were lost to follow-
up before completion of initial follow-up (completion of the 20th
gestational week for the latest recruited participant who achieved
an ongoing pregnancy), and another two women in the LMWH
group were lost to follow-up after completion of the 20th ges-
tational week but before delivery or expected completion of the
40th gestational week. Women lost to follow-up during the first
period were considered not to have an ongoing pregnancy, and
women lost to follow-up in the second period were considered not
to have a live birth in the intention-to-treat analysis. The dropout
rate was 5.22%. In the final analysis, 75 women in each group
were considered. The study was rated as at low risk of attrition bias
because trialists compensated for dropouts by imputing a negative
outcome to losses to follow-up.
Noci 2011 enrolled 210 patients presenting all the necessary re-
quirements and subjected to ovarian stimulation for IVF/ICSI.
On the day of oocyte retrieval, 38 patients were excluded: 30 for
the absence of retrieved oocytes or cancelled cycles and eight who
decided to decline their participation. One hundred and seventy-
two women were allocated to intervention and divided into two
groups: 86women in the control group and 86women in the treat-
ment group. The final series for analysis contained 153 women be-
cause 13 women belonging to the treatment group and six women
belonging to the control group had no embryos to transfer, thus
they were immediately excluded from the study. Thus in the final
analysis, 73 women were in treatment group and 80 women were
in the control group. The dropout rate was 8.72% after allocation
to the intervention. The study was rated as at unclear risk of attri-
tion bias.
Selective reporting
Two studies were at low risk of bias related to selective reporting
(Qublan 2008; Urman 2009). There was no evidence to suggest
that the decision by authors of included studies to either publish or
not publish any specific outcomeswas based onperceived statistical
significance. One study (Noci 2011) did not report adverse events
and was rated as at unclear risk of selective reporting bias.
Other potential sources of bias
No other potential sources of bias were found in any of the in-
cluded studies. There were no significant differences noted in the
baseline characteristics of intervention and control groups in any
of the included studies.
Effects of interventions
See: Summary of findings for the main comparison Heparin
for Assisted Reproduction - live birth rate
Primary Outcomes
1. Live birth rate per woman
All three included studies assessed the primary outcome, namely
’live birth rate per woman’.
Results pooled in meta-analysis (fixed-effect model) showed that
there was a significant improvement in live birth rate with the
use of LMWH (odds ratio (OR)1.77, 95% confidence interval
(CI) 1.07, 2.90 P = 0.03, I2 = 51%, three studies, 386 women)
in comparison to placebo or no LMWH (Figure 4). Sensitivity
analysis performedwith a random-effects model showed that there
was a non significant improvement in live birth rate with the use
of LMWH compared to no LMWH (OR1.85, 95%CI 0.80, 4.24
P,=,0.15, I2,=,51%, three studies, 386 women)
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Figure 4. Forest plot of comparison: 1 Heparin versus control, outcome: 1.1 Live Birth Rate per woman.
This finding should be viewed with extreme caution due to high
heterogeneity and sensitivity to choice of statistical model.
The evidence was of very low quality as shown in Summary of
findings for the main comparison.
2. Adverse effects
Direct adverse effects of heparin including bleeding, bruising,
thrombocytopenia or any other side effects were described in all
the included studies.
Qublan 2008 reported that the most frequent complications
encountered in the heparin-treated group were bleeding (3/42,
7.1%) followed by thrombocytopenia (2/42, 4.8%) and allergic
reactions (1/42, 2.4%).
Urman 2009 revealed that platelet counts did not change signif-
icantly in the LMWH group during the study period. None of
the participants experienced any adverse effects other than small
ecchymosis around the LMWH injection sites. None of the par-
ticipants in the LMWHgroup discontinued treatment due to pain
or ecchymosis around the injection site.
Noci 2011 reported no other adverse effects in the study except
minimal bruising at injection site of heparin.
It appeared from the studies that longer duration of heparin ther-
apy increased the number of side effects; however this interpreta-
tion must be looked with caution as there was no available con-
trolled comparative data for duration of therapy.
In Qublan 2008 LMWH therapy was started from the day of ET
until results of Beta-hCG were available two weeks after ET. If
Beta-hCG was 425 IU/mL, LMWH was continued either until
delivery or foetal demise was diagnosed. In Noci 2011, LMWH
treatment was started on the day of oocyte retrieval until nine
weeks of pregnancy with positive pregnancy results. In Urman
2009 LMWH treatment was started a day after oocyte retrieval
until 12 weeks of pregnancy with positive pregnancy test results.
Secondary Outcomes
1. Clinical pregnancy rates per woman
‘Clinical pregnancy rate per woman’ was described in all included
studies.
Results pooled in meta-analysis (fixed-effect model) showed a sig-
nificant improvement in clinical pregnancy rate with the use of
LMWH compared with placebo or no LMWH (OR 1.61 95%
CI 1.03, 2.53 P = 0.04, I2 = 29%, three studies, 368 women)
Figure 5. Sensitivity analysis performed with a random-effects
model showed no significant improvement in clinical pregnancy
rate with the use of LMWH compared to no LMWH (OR 1.66,
95% CI 0.94 to 2.90, I2 = 29%, three studies, 368 women).
Figure 5. Forest plot of comparison: 1 Heparin versus control, outcome: 1.2 Clinical Pregnancy Rate per
woman.
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These results should be viewed with caution due to high hetero-
geneity and sensitivity to choice of statistical model.
The evidence is of very low quality, as shown in Summary of
findings for the main comparison.
2. Multiple pregnancy rates per woman
‘Multiple pregnancy rates per woman’ were not reported in any of
the included studies. “Multiple pregnancy rates per total number
of pregnancies” was reported in all studies but cannot be pooled
for meta-analysis due to unit of analysis errors. Please see Table 3
3. Maternal pregnancy complications
Qublan 2008 reported placental abruption (1/42, 2.4%) in
LMWH group. Two (4.9%) women in the placebo group devel-
oped pre-eclampsia.
Urman 2009 reported that total numbers of preterm deliveries
were nine (34.6%) in LMWH and six (30.0%) in control groups
(P = 0.74). Three women delivered in the 32nd week (one set
of quadruplets, one set of twins and a singleton, all in LMWH
group), one woman (singleton in control group) delivered in the
33rd week, four women delivered in the 34th week (two sets of
twins in LMWHgroup and two sets of twins in the control group),
four women delivered in the 35th week (all twins, three and one
in LMWH and control groups, respectively) and three women
delivered in the 36th week (one singleton in LMWH group and
two sets of twins in the control group).
Noci 2011 did not describe any maternal pregnancy complica-
tions.
4. Fetal complications during pregnancy
Qublan 2008 reported two intrauterine foetal deaths in the hep-
arin-treated group compared to none in the control group. No
further details were provided.
Urman 2009 reported that none of the infants delivered in the
study had any congenital malformations. One boy (from the
LMWH group) had a unilateral undescended testis, and another
infant delivered at the 32nd week (from the LMWH group) un-
derwent surgery due to necrotising enterocolitis.
Noci 2011 did not describe any fetal complications during preg-
nancy.
Other analyses
There were insufficient studies to conduct the planned subgroup
analyses or to construct a funnel plot to assess publication bias.
We considered clinical and methodological differences between
the studies that might account for the high heterogeneity in the
analysis of live birth. Exclusion of the study that was clearly re-
stricted to women with at least one thrombophilic defect (Qublan
2008) eliminated the heterogeneity (I2 = 0%). However, with so
few studies available for analysis it is unclear whether the effects
of the intervention may differ in this population.
D I S C U S S I O N
Summary of main results
The aim of this review was to investigate whether the administra-
tion of heparin during the peri-implantation period improves clin-
ical outcomes in subfertile women undergoing assisted reproduc-
tion. We found evidence suggesting that administration of peri-
implantation low molecular weight heparin (LMWH) may im-
prove live birth and pregnancy rates during assisted reproduction,
however the studies were few and small (three studies, total 386
participating women) with high heterogeneity and sensitivity to
choice of statisticalmodel. Therefore all resultsmust be interpreted
with extreme caution.
Low molecular weight heparin was associated with adverse events,
including bruising, ecchymosis, bleeding, thrombocytopenia and
allergic reactions. It appeared that adverse effects increased if hep-
arin therapy was used over a longer duration. There were no reli-
able data on long-term side effects of heparin at this stage of preg-
nancy.
Overall, this evidence does not justify the present widespread use
of LMWH in this population subgroup (previous failed IVF),
outside well-conducted randomised trials. Such trials should be a
priority.
Overall completeness and applicability of
evidence
There were only three studies that could be included in the review
and the total sample size was small (386 women) so the findings
have to be viewed with caution. Moreover, study characteristics
varied: one was a multicentre study Noci 2011 while the two
others were conducted at a single centre (Qublan 2008; Urman
2009). There was no uniformity of dose, timing or duration of the
intervention. Only one study Qublan 2008 used sodium chloride
as placebo control, the other two included studies had no placebo,
hence the patients were not blinded. Furthermore, none of the
studies described blinding of clinicians.
Wewere unable to adequately assess the effect of heparin inwomen
with or without thrombophilia undergoing assisted reproduction
as only one study (Qublan 2008) included women with throm-
bophilia, Noci 2011 included women without thrombophilia, the
other remaining study(Urman 2009), did not report about the
presence or absence of thrombophilia in including participants.
The small numbers of underpowered trials means that there was
insufficient evidence to change clinical practice until results of large
high quality randomised controlled trials (RCTs) are available.
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Quality of the evidence
The studies were small, low quality, and had high heterogeneity
reflecting different inclusion criteria. Allocation concealment was
not adequately described in one of the three studies, none were
double blinded and placebo was used only in one study, creating a
risk of performance bias. Risk of detection bias (due to failure to
blind of outcome assessment) was also noted in two studies. There
was significant heterogeneity noted in the analyses. The quality
of the evidence for the main findings was rated as very low, using
GRADE criteria (Summary of findings for the main comparison).
Potential biases in the review process
The findings were sensitive to methodological decisions made in
the review process, and are therefore to be regarded very cautiously.
Agreements and disagreements with other
studies or reviews
It has been suggested that heparin could potentially modulate
many of the known mechanisms that underlie successful apposi-
tion, adhesion and penetration of the developing embryo.Heparin
could improve the endometrial environment for implantation of
embryo. Confirmation of the outlined potential of heparin to al-
ter the molecular processes underpinning successful implantation
was urgently required given the potential for clinical translation to
increased pregnancy and live birth rate and a reduction in adverse
perinatal outcomes for all women undergoing assisted reproduc-
tion (Nelson 2008).The following studies showed no efficacy of
heparin in improving outcome.
• In one small non-randomised study, heparin with low-dose
aspirin was given to women with antiphospholipid positive
antibodies undergoing assisted reproduction. There were no
statistically significant differences detected in implantation,
pregnancy and ongoing pregnancy rates between both groups
(Kutteh 1997).
• A double-blind, randomised cross-over trial was conducted
to investigate whether heparin and low-dose aspirin increase the
pregnancy rate in antiphospholipid antibody or antinuclear
antibody-seropositive women with IVF implantation failure.
Unfractionated heparin and low-dose aspirin were given from
day of embryo transfer. It found that there was no significant
difference in pregnancy rates or implantation rates between
treated and placebo cycles. However, a cross-over design is not
appropriate for a pregnancy trial (Stern 2003).
• Heparin was given to women with thrombophilia and
repeated implantation failure undergoing assisted reproduction
in this prospective cohort study. Authors suggested that it
showed improvement in biochemical and clinical pregnancy
rates. However, no precise data were published. This study also
looked at other factors of implantation failure, therefore it
cannot be inferred that this intervention of heparin only
improved the success rate of assisted reproduction (Sharif 2010).
The American Society for Reproductive Medicine (Practice
Committee of ASRM 2008) assessed available data in 2008 and
suggested that assessment of antiphospholipid antibodies was not
indicated among couples undergoing IVF, and heparin therapy
was not justifiable on the basis of existing data to improve preg-
nancy and live birth rates.
In agreement with our review, Ricci 2010 suggested that heparin
should not be used in women undergoing IVF until its efficacy is
demonstrated in carefully designed RCTs.
Three published studies suggested that heparin did improve clin-
ical outcome:
• One single centre non-randomised study found that
heparin with low-dose aspirin given to women undergoing
assisted reproduction with positive antiphospholipid antibodies
showed improvement in live birth rate and clinical pregnancy
rate Sher 1994.
• The same results were shown by a single centre case control
study by the same author Sher 1998. However, these studies are
non-randomised and significant bias was found.
• Lodigiani 2011 presented observational retrospective
analysis of women with previous implantation failure and
screened for thrombophilia undergoing assisted reproduction
who were given LMWH showed significantly higher pregnancy
rates. The results also showed that there was no relation between
inherited thrombophilia and pregnancy rate in patients with
previous IVF implantation failures. This was an observational
retrospective study, which could be influenced by various other
factors.
We found two reviews on this topic which also agree with our
conclusions:
• Nardo 2009 suggested that clinicians should inform
patients of factors including: our current lack of knowledge;
potential adverse effects; and available weak evidence regarding
adjuvant therapy during assisted reproduction. There was need
for good clinical trials in many of the areas surrounding medical
adjuncts in IVF to resolve the empirical/evidence divide.
• Bohlmann 2011 suggested that the available studies on
heparin in assisted reproduction were characterised by
heterogeneous inclusion criteria and a lack of proven
effectiveness in special constellations. In conclusion, the
application of heparin to improve assisted reproduction
treatment (ART) outcome rates was not justified. A large RCT
should be undertaken to answer this.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was insufficient evidence to determine whether routine ad-
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ministration of peri-implantation heparin improved the clinical
outcome in subfertile women undergoing assisted reproduction.
In addition, heparin caused a number of adverse events.
Implications for research
Well-designed RCTs with sufficient power are warranted to assess
the efficacy of peri-implantation heparin in improving assisted re-
production outcomes. These should be large parallel-group RCTs
with populations of subfertile women with unexplained infertil-
ity, recurrent failure of embryo implantation or a positive throm-
bophilia screen. No additional adjunct therapies should be used.
Cross-over designs should always be avoided in trials where preg-
nancy is an intended outcome.
Studies should be done where local (uterine) rather than systemic
heparin is used to see the effects of heparin on decidualisation,
implantation and pregnancy rates in an attempt to avoid adverse
effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Noci 2011
Methods Multicentre
Prospective randomised control pilot study
Participants 172 patients were allocated to intervention and divided into two groups: 86 women in
the control group and 86 women in the treatment group. The final series for analysis
contained 153 patients because 13 women belonging to treatment group and 6 women
belonging to the control group had no embryos to transfer, thus they were immediately
excluded from the study
So in the final analysis 73 women were in treatment group (A) and 80 women were in
the control group (B). Both groups were matched. Every woman was recruited for only
one cycle. Cause infertility: variety of causes
Interventions IVF or ICSI. The treatment group (A) received both luteal phase support with vaginal
progesterone (Prometrium 200 mg twice per day) and a prophylactic dose of dalteparin
sodium (Fragmin, 2500 IU s.c. daily; Pfizer Italia, Latina, Italy) from the afternoon
of the day of oocyte retrieval until the day of pregnancy test. The control group (B)
received luteal phase support with progesterone only until pregnancy test. Platelet count
was performed on days7-8 of dalteparin treatment to evaluate possible adverse effects
of the therapy. If platelet values dropped to below 50% of basal levels or <100,000/
µ L, dalteparin administration was immediately stopped because of the risk of heparin
induced thrombocytopenia
COH: FSH, GNRH analogue. HCG 250 mcg. Luteal support: progesterone 200 mg
pessaries vaginally twice daily until a pregnancy test was performed. If the test was
positive, progesterone treatment was continued up to 12 gestational weeks
Outcomes Live birth rate per woman: LMWH group (A): 21%, Control group (B): 16 %
Adverse effect: Thrombocytopenia was not observed in any of the 73 patients treated
with dalteparin and only a few patients reported the presence of minimal bruising at the
injection point of the drug
Clinical pregnancy rate per woman: LMWH group (A): 26%, Control group (B): 20%
Multiple pregnancy rate per woman: LMWH group (A): 31.57%, Control group (B):
12.5%
Implantation rate/ embryo transferred LMWH group (A): 15%Control group (B): 12%
Spontaneous Miscarriage rate per woman: LMWH group (A): 21%, Control group (B)
: 19%
Notes Study population consisted of women aged < 40years, without congenital or acquired
thrombophilia and undergoing their first IVF cycle
Risk of bias
Bias Authors’ judgement Support for judgement
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Noci 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computerised random sequence genera-
tion method was used
Allocation concealment (selection bias) Low risk Described clearly with sealed and num-
bered envelopes containing the allocation
information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The ultrasonography was performed by a
gynaecologist unaware of the allocation of
the patients
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study had a follow-up rate of 89%
Selective reporting (reporting bias) Unclear risk No adverse effects were reported in the
study
Other bias Unclear risk Not described
Qublan 2008
Methods Single centre
Prospective randomised placebo controlled
Participants Of the 137 women with a history of three or more previous IVF failures and who had
at least one thrombophilic defect, 39 did not meet the inclusion criteria and 15 refused
participation. The remaining 83 women were randomly allocated to each arm of the
study. Randomisation was started on the day of ET
Interventions The treatment group (A) (n = 42) had enoxaparin 40 mg/day subcutaneous injections.
Control Group (B) (n = 41) received placebo (equivalent volume of NaCl 0.9% sub-
cutaneous; Pharmaceutical Solutions Industry Ltd., Jeddah, SA). Treatment was started
from the day of ET until results of Beta-hCG were available 2 weeks after ET. If Beta-
hCG was 425 IU/mL, LMWH was continued either until delivery or foetal demise was
diagnosed
COH: HMG, GNRH antagonist. HCG 10,000 IU. Luteal support: Progesterone pes-
saries (Cyclogest: Alpharma, Barnstaple, UK) were used for luteal phase support in the
two study groups
Outcomes Live birth rate per woman: LMWH group (A): 23.8%, Control group (B): 2.4%
Adverse effect: The frequency of complications did not differ between the two study
groups. Themost frequent complications encountered in the heparin-treated were bleed-
ing (7.1%) followed by thrombocytopenia (4.8%), allergic reactions (2.4%) and placen-
tal abruption (2.4%)
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Qublan 2008 (Continued)
Pregnancy rate per woman: LMWH group (A): 31%, Control group (B): 9.6%
Multiple pregnancy rate per woman: LMWH group (A): 23.1%, Control group (B):
25%
Implantation rate/ embryo transferred LMWH group (A): 19.8% Control group (B): 6.
1%
Spontaneous Miscarriage rate per woman: LMWH group (A): 7.7%, Control group (B)
: 50%
Intrauterine Fetal death rate: LMWH group (A) 15.4%, control group 0%
Notes Study population consisted of women aged 19-35 years with a history of three or more
previous IVF failures, and who had at least one thrombophilic defect
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done by selection from table
of random numbers
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were blinded but not clinicians
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appears that the data are complete
Selective reporting (reporting bias) Low risk It appears that the data are complete
Other bias Unclear risk Not described
Urman 2009
Methods Single centre
Open labelled randomised controlled pilot trial
Participants 150 consecutive couples who met the inclusion criteria and gave informed consent were
recruited to the trial. Each woman was included for one cycle only. 3 women in the
LMWH and control group each were lost to follow-up before completion of the initially
planned follow-upperiod (completionof the 20th gestational week for the latest recruited
participant that achieved an ongoing pregnancy), and another 2 women in the LMWH
group were lost to follow-up after completion of the 20th gestational week but before
delivery or expected completion of the 40th gestational week. 75 women in each arm of
the study
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Urman 2009 (Continued)
Interventions ICSI. The study group was administered LMWH group (A) (Enoxaparin Sodium,
Clexane, Aventis Pharma) at a dose of 1 mg/kg/day starting on the day after oocyte
retrieval. Patients’ weights were rounded to the closest multiple of 10 kg, and 0.1 mL/10
kg/day Clexane was self-administered subcutaneously by the participants. LMWH was
discontinued if the pregnancy test 12 days after ET was negative, but continued up to
the 12th week of pregnancy if the test was positive. The control group (B) received no
medication besides progesterone gel. In the study group the platelet count was done on
the day of oocyte retrieval and 1 week after commencement of LMWH treatment
COH: FSH, GNRH agonist. HCG 10,000 IU. Luteal support: Progesterone pessaries
90 mg vaginal progesterone gel (Crinone 8%, Serono, Serono, Bedfordshire, UK) start-
ing from the day of oocyte collection. LPS was continued until the pregnancy test per-
formed 12 days after ET. Women with a positive pregnancy test continued the vaginal
progesterone gel until the 12th week of gestation
Outcomes Live birth rate per woman: LMWH group (A): 34.7%, Control group (B): 26.7%
Adverse effect: Platelet counts did not change significantly in the LMWH group during
the study period. Small ecchymoses around the LMWH injection sites were noted
Clinical Pregnancy rate per woman: LMWH group (A): 45.3%, Control group (B): 38.
7%
Ongoing Pregnancy rate per woman: LMWH group (A): 37.3%, Control group (B):
26.7%
Multiple pregnancy rate per woman: LMWH group (A): 35.3%, Control group (B): 34.
5%
Implantation rate/ embryo transferred LMWH group (A): 24.5% Control group (B):
19.8%
Numbers of preterm deliveries were (34.6%) in LMWH and (30.0%) in control groups
Notes Study population consisted of women aged < 38 years with a history of two or more
previous IVF failures. Women lost to follow-up during the first period were considered
not to have an ongoing pregnancy, and women lost to follow-up in the second period
were considered not to have a live birth in the intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Women were randomised according to
a computer-generated randomisation list.
Study subjects were randomised in blocks
of 10; i.e. of every 10 women randomised,
five were allocated to the LMWH arm, and
five were allocated to the control arm, in a
random manner
Allocation concealment (selection bias) Low risk Opaque envelopes that were numbered and
sealed containing the allocation informa-
tion were given to the ART centre nurse
coordinator who assigned patients to study
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Urman 2009 (Continued)
arms following recruitment by attending
physicians on the morning of oocyte re-
trieval procedure
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk This study compensated for dropouts by
imputing a negative outcome to losses to
follow-up
Selective reporting (reporting bias) Low risk It appears that the data are complete
Other bias Unclear risk Not described
COH: controlled ovarian hyperstimulation
ET: embryo transfer
FSH: follicle-stimulating hormone
GNRH: gonadotropin-releasing hormone
HCG: human chorionic gonadotropin
ICSI: intracytoplasmic sperm injection
IVF: in vitro fertilisation
IU: international units
LMWH: low molecular weight heparin
LPS: lipopolysaccharide,
NaCl: sodium chloride
s.c.: subcutaneous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berker 2011 Not a True RCT as quasi randomisation was performed for the purposes of this study
Colicchia 2011 Low molecular weight heparin (LMWH) was used in conjunction with prednisolone
Stern 2003 Unfractionated heparin (UFH) was used in conjunction with low-dose aspirin. Cross-over design study
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Mashayekhy 2011
Methods Single centre
Prospective randomised controlled trial
Participants 86 patients with recurrent IVF-ET failure.
Interventions Ovarian stimulation was performed with long protocol. The patients were randomly divided into two groups after
embryo transfer, and one group received unfractionated heparin 5000 IU twice a day plus 100 mg progesterone and
another group only received progesterone
Outcomes There were no significant differences between individual characteristics of two groups. However, implantation rate
and clinical pregnancy were significantly higher in patients who received unfractionated heparin. Thirty-six women
had at least one thrombophilic mutation
Notes Only the abstract has been published in The Iranian Journal of Reproductive Medicine spring 2011;9 (Suppl 2):30-
30
The authors were contacted regarding the details of study results. The study is presently not able to be included in
the review as it has been completed and submitted for publication. The authors were unable to provide me with the
details of results till publication
ET: embryo transfer
IU: international units
IVF: iv vitro fertilisation
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D A T A A N D A N A L Y S E S
Comparison 1. Heparin versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live Birth Rate per woman 3 386 Odds Ratio (M-H, Fixed, 95% CI) 1.77 [1.07, 2.90]
2 Clinical Pregnancy Rate per
woman
3 386 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [1.03, 2.53]
Analysis 1.1. Comparison 1 Heparin versus control, Outcome 1 Live Birth Rate per woman.
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 1 Live Birth Rate per woman
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noci 2011 15/73 13/80 41.6 % 1.33 [ 0.59, 3.03 ]
Qublan 2008 10/42 1/41 3.3 % 12.50 [ 1.52, 102.85 ]
Urman 2009 26/75 20/75 55.1 % 1.46 [ 0.73, 2.93 ]
Total (95% CI) 190 196 100.0 % 1.77 [ 1.07, 2.90 ]
Total events: 51 (Heparin), 34 (Control)
Heterogeneity: Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
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Analysis 1.2. Comparison 1 Heparin versus control, Outcome 2 Clinical Pregnancy Rate per woman.
Review: Heparin for assisted reproduction
Comparison: 1 Heparin versus control
Outcome: 2 Clinical Pregnancy Rate per woman
Study or subgroup Heparin Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noci 2011 19/73 16/80 37.7 % 1.41 [ 0.66, 3.00 ]
Qublan 2008 13/42 4/41 9.3 % 4.15 [ 1.22, 14.07 ]
Urman 2009 34/75 29/75 52.9 % 1.32 [ 0.69, 2.52 ]
Total (95% CI) 190 196 100.0 % 1.61 [ 1.03, 2.53 ]
Total events: 66 (Heparin), 49 (Control)
Heterogeneity: Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Control Favours Heparin
A D D I T I O N A L T A B L E S
Table 1. Table of Comparisons: Implantation rate per embryos transferred
Study ID Heparin group Control group
Noci 2011 15% 12%
Urman 2009 24.5% 19.8%
Qublan 2008 19.8% 6.1%
Table 2. Table of Comparisons: Incidence of miscarriage per total number of pregnancies and per woman
Study ID Heparin group per
pregnancy
Control group per
pregnancy
Heparin group per woman Control group per woman
Noci 2011 4/19 3/16 4/73 3/80
Urman 2009 n/a n/a n/a n/a
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Table 2. Table of Comparisons: Incidence of miscarriage per total number of pregnancies and per woman (Continued)
Qublan 2008 1/13
*IUFD 2/13
2/4
*IUFD 0/4
1/42
*IUFD 2/42
2/41
*IUFD 0/41
IUFD: Intraunterine fetal death
Table 3. Table of Comparisons: Incidence of multiple pregnancies per total number of pregnancies
Study ID Heparin group Control group
Noci 2011 (6/19) 31.5% (2/16) 12.5%
Urman 2009 (12/34) 35.3% (10/29) 34.5%
Qublan 2008 (3/13) 23.1% (1/4) 25%
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Menstrual Disorders and Subfertility Group Specialised Register (inception to 2 July 2012)
Ovid the Cochrane Central Register of Controlled Trials (CENTRAL) (inception to 2 July 2012)
There is no language restriction in these search.
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
29Heparin for assisted reproduction (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24 (8324)
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1950 to
2 July 2012)
TheMEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomized trials which
appears in the Cochrane Handbook of Systematic Reviews of Interventions (version 5.0.2; chapter 6, 6.4.11)
There is no language restriction in this search
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp insemination, artificial/ or exp reproductive techniques, assisted/
11 artificial$ inseminat$.tw.
12 iui.tw.
13 intrauterine insemination.tw.
14 nidation.tw.
15 reproductive technique$.tw.
16 reproduct$ technolog$.tw.
17 exp Embryo Implantation/
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 exp Infertility, Female/
21 ((Female$ or women) adj2 infertil$).tw.
22 ((Female$ or women) adj2 subfertil$).tw.
23 exp Abortion, Habitual/
24 recurrent miscarriage$.tw.
25 or/1-24
26 exp heparin/ or exp heparin, low-molecular-weight/ or exp heparinoids/
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27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
40 randomized controlled trial.pt.
41 controlled clinical trial.pt.
42 randomized.ab.
43 placebo.tw.
44 clinical trials as topic.sh.
45 randomly.ab.
46 trial.ti.
47 (crossover or cross-over or cross over).tw.
48 or/40-47
49 exp animals/ not humans.sh.
50 48 not 49
51 39 and 50
Appendix 3. EMBASE search strategy
Ovid EMBASE (01.01.10 to 2 July 2012)
EMBASE is only searched one year back as the UKCC has hand searched EMBASE to this point and these trials are already in
CENTRAL.
The EMBASE search is combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) http:/
/www.sign.ac.uk/mehodology/filters.html#random
There is no language restriction in this search
1 exp embryo transfer/ or exp female infertility/ or exp fertilization in vitro/
2 embryo transfer$.tw.
3 in vitro fertilisation.tw.
4 ivf-et.tw.
5 (ivf or et).tw.
6 icsi.tw.
7 intracytoplasmic sperm injection$.tw.
8 (blastocyst adj2 transfer$).tw.
9 (assist$ adj2 reproducti$).tw.
10 exp artificial insemination/
11 artificial$ inseminat$.tw.
12 reproductive technique$.tw.
13 reproduct$ technolog$.tw.
14 exp nidation/
15 (implant$ adj2 fail$).tw.
16 reproduct$ technique$.tw.
17 ((Female$ or women) adj2 infertil$).tw.
18 ((Female$ or women) adj2 subfertil$).tw.
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19 exp recurrent abortion/
20 recurrent miscarriage.tw.
21 iui.tw.
22 intrauterine insemination.tw.
23 nidation.tw.
24 exp intracytoplasmic sperm injection/
25 or/1-24
26 exp HEPARIN/ or exp LOW MOLECULAR WEIGHT HEPARIN/
27 heparin$.tw.
28 LMWH$.tw.
29 liquemin.tw.
30 enoxaparin.tw.
31 heparinic acid.tw.
32 dalteparin.tw.
33 tinzaparin.tw.
34 clexane.tw.
35 lovenox.tw.
36 indenox.tw.
37 xaparin.tw.
38 or/26-37
39 25 and 38
40 Clinical Trial/
41 Randomized Controlled Trial/
42 exp randomization/
43 Single Blind Procedure/
44 Double Blind Procedure/
45 Crossover Procedure/
46 Placebo/
47 Randomi?ed controlled trial$.tw.
48 Rct.tw.
49 random allocation.tw.
50 randomly allocated.tw.
51 allocated randomly.tw.
52 (allocated adj2 random).tw.
53 Single blind$.tw.
54 Double blind$.tw.
55 ((treble or triple) adj blind$).tw.
56 placebo$.tw.
57 prospective study/
58 or/40-57
59 case study/
60 case report.tw.
61 abstract report/ or letter/
62 or/59-61
63 58 not 62
64 39 and 63
65 (2010$ or 2011$).em.
66 64 and 65
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Appendix 4. PsycINFO search strategy
Ovid PsycINFO (1806 to 2 July 2012)
There is no language restriction in this search
1 exp Reproductive Technology/
2 exp Infertility/
3 exp Embryo/
4 embryo transfer$.tw.
5 in vitro fertili?ation.tw.
6 ivf-et.tw.
7 (ivf or et).tw.
8 icsi.tw.
9 intracytoplasmic sperm injection$.tw.
10 (blastocyst adj2 transfer$).tw.
11 (assist$ adj2 reproducti$).tw.
12 artificial$ inseminat$.tw.
13 iui.tw.
14 intrauterine insemination.tw.
15 nidation.tw.
16 reproductive technique$.tw.
17 reproduct$ technolog$.tw.
18 (implant$ adj2 fail$).tw.
19 reproduct$ technique$.tw.
20 ((Female$ or women) adj2 infertil$).tw.
21 ((Female$ or women) adj2 subfertil$).tw.
22 exp Spontaneous Abortion/
23 recurrent miscarriage$.tw.
24 or/1-23
25 exp Heparin/
26 heparin$.tw.
27 LMWH$.tw.
28 liquemin.tw.
29 enoxaparin.tw.
30 heparinic acid.tw.
31 dalteparin.tw.
32 tinzaparin.tw.
33 clexane.tw.
34 lovenox.tw.
35 indenox.tw.
36 xaparin.tw.
37 or/25-36
38 24 and 37
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Biological pregnancy rates and ongoing pregnancy rates per woman were included in the protocol but not in the review, as these outcome
measures are not as important from a patient perspective as live birth rates and clinical pregnancy rates. We made these changes on the
advice of the MDSG Co-ordinating Editor.
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It is suggested that heparin may improve
clinical outcomes in women undergoing
assisted reproduction techniques (ART)
by enhancing decidualization and thus
improving the intrauterine environment.
It is given in the peri-implantation
period (at or after egg collection or at
ET). This systematic review evaluates
the use of heparin in subfertile women
undergoing ART.METHODS
We included all randomized controlled
trials (RCTs) of the use of peri-
implantationheparin in subfertilewomen
undergoing ART. Study selection, quality
assessment, and data extraction were
conducted independently by two review
authors. The literature search was con-
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were live birth and adverse effects.
We calculated odds ratios (ORs) and
95% conﬁdence intervals (CIs) and
pooled data using a ﬁxed-effects
model. A sensitivity analysis was
conducted using random effects. Sta-
tistical heterogeneity was assessed
using the I2 statistic. The overall quality
of the evidence was evaluated using
GRADE methods.
Institutional Review Board approval
was not required for this work, as it is
secondary research.RESULTS
We included three RCTs (386 women) in
which low molecular weight heparin
given at ET (one RCT) or egg collection.
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Medicine, Published by Elsevier Inc.(two RCTs) was compared with placebo
or no treatment. Participant character-
istics varied across studies. One study
included women having their ﬁrst IVF
cycle, with no blood clotting disorder;
one included women with at least one
blood clotting disorder; and the third
included women who had undergone
at least two previous unsuccessful
ART cycles.
Our ﬁndings require very cautious
interpretation as they differed according
to choice of statistical model. Use of a
ﬁxed-effects analysis suggested that
peri-implantation heparin may be asso-
ciated with an improvement in live-
birth and pregnancy rates compared
with placebo or no heparin, but there
was high heterogeneity for the outcome
of live birth (I2 ¼ 51%). When a
random-effects model was used there
was no longer a difference between the
groups for either live birth (OR, 1.85;
95% CI, 0.80–4.24, three studies, 386
women, I2 ¼ 51%, very low quality evi-
dence) or clinical pregnancy (OR, 1.66;
95% CI, 0.94–2.90, three studies 386
women, I2¼ 29%, low-quality evidence;
see Fig. 1 and Table 1).
Adverse eventswerepoorly reported
in all the included studies. Events such
as bleeding and thrombocytopenia1
FIGURE 1
Forest plot for live birth: heparin versus no heparin.
Akhtar. Heparin for assisted reproduction. Fertil Steril 2014.
TABLE 1
Summary of ﬁndings table: heparin versus no heparin.
Outcome
Illustrative comparative
risksa (95% CI) Relative effect
(95% CI) using a
random-effects
model
No. of
Participants
(no. of
studies)
Quality of the
evidence
(GRADE) Comments
Assumed risk
control
Corresponding
risk heparin
Live-birth rate per
woman
173 per 1,000 280 per 1,000
(144–471)
OR, 1.85
(0.8–4.24)
386 (3) 4BBB
very lowb,c
Estimate using a ﬁxed
effects model: OR,
1.77; 95% CI, 1.07–2.9
Clinical pregnancy rate
per woman
250 per 1,000 356 per 1,000
(239–492)
OR, 1.66
(0.94–2.9)
386 (3) 44BB
lowc
Estimate using a ﬁxed-
effects model: OR, 1.61;
95% CI, 1.03–2.53
Adverse effects No comparative data available so no conclusions could be drawn. Adverse effects such as bleeding and thrombocytopenia
were reported in the heparin groups and affected 5%–7% of women in one study.
Note: The population was subfertile women. The setting was an ART laboratory. The interventions were heparin versus placebo or no heparin. GRADE Working Group grades of evidence: high
quality means further research is very unlikely to change our conﬁdence in the estimate of effect. Moderate quality means further research is likely to have an important impact on our conﬁdence in
the estimate of effect and may change the estimate. Low quality means further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change
the estimate. Very low quality means we are very uncertain about the estimate.
a The basis for the assumed risk is themedian control group risk across studies. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of
the intervention (and its 95% CI).
b Inconsistency (high heterogeneity: I2 ¼ 51%).
c Imprecision: low overall event rate, conﬁdence intervals compatible with substantial beneﬁt or no appreciable beneﬁt, ﬁndings sensitive to choice of statistical model.
Akhtar. Heparin for assisted reproduction. Fertil Steril 2014.
COCHRANE CONCISEwere reported inwomen receivingheparin and affected5%–7%
of women in the heparin group in one study. However, no
studies reported data suitable for analysis and so no ﬁrm
conclusions could be drawn regarding the safety of heparin.
The evidence was seriously limited by inconsistency,
imprecision, and inadequate reporting of adverse events.CONCLUSIONS
It is unclear whether peri-implantation heparin improves live-
birth and pregnancy rates in subfertile women undergoing2ART, as the evidence is seriously limited by inconsistency
and imprecision. No beneﬁt is apparent when a random-
effects model is used.
Adverse events were inadequately reported, and no
ﬁrm conclusions could be drawn regarding the safety of
heparin.
Our ﬁndings do not justify the use of heparin in this
context except in well-conducted research trials, and
further such studies are recommended. Further investiga-
tions could also focus on the effects of local (uterine)
heparin during ART.VOL.- NO.- /- 2014
